<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomedicines</journal-id><journal-id journal-id-type="iso-abbrev">Biomedicines</journal-id><journal-id journal-id-type="publisher-id">biomedicines</journal-id><journal-title-group><journal-title>Biomedicines</journal-title></journal-title-group><issn pub-type="epub">2227-9059</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7601869</article-id><article-id pub-id-type="pmid">33050619</article-id><article-id pub-id-type="doi">10.3390/biomedicines8100405</article-id><article-id pub-id-type="publisher-id">biomedicines-08-00405</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Tackling Antibiotic Resistance with Compounds of Natural Origin: A Comprehensive Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5275-1282</contrib-id><name><surname>&#x000c1;lvarez-Mart&#x000ed;nez</surname><given-names>Francisco Javier</given-names></name><xref ref-type="aff" rid="af1-biomedicines-08-00405">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8113-0795</contrib-id><name><surname>Barraj&#x000f3;n-Catal&#x000e1;n</surname><given-names>Enrique</given-names></name><xref ref-type="aff" rid="af1-biomedicines-08-00405">1</xref><xref rid="c1-biomedicines-08-00405" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8089-0696</contrib-id><name><surname>Micol</surname><given-names>Vicente</given-names></name><xref ref-type="aff" rid="af1-biomedicines-08-00405">1</xref><xref ref-type="aff" rid="af2-biomedicines-08-00405">2</xref></contrib></contrib-group><aff id="af1-biomedicines-08-00405"><label>1</label>Institute of Research, Development and Innovation in Health Biotechnology of Elche (IDiBE), Universitas Miguel Hern&#x000e1;ndez (UMH), 03202 Elche, Spain; <email>f.alvarez@umh.es</email> (F.J.&#x000c1;.-M.); <email>vmicol@umh.es</email> (V.M.)</aff><aff id="af2-biomedicines-08-00405"><label>2</label>CIBER, Fisiopatolog&#x000ed;a de la Obesidad y la Nutrici&#x000f3;n, CIBERobn, Instituto de Salud Carlos III (CB12/03/30038), 28220 Madrid, Spain</aff><author-notes><corresp id="c1-biomedicines-08-00405"><label>*</label>Correspondence: <email>e.barrajon@umh.es</email>; Tel.: +34-965222586</corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2020</year></pub-date><volume>8</volume><issue>10</issue><elocation-id>405</elocation-id><history><date date-type="received"><day>18</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>09</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Drug-resistant bacteria pose a serious threat to human health worldwide. Current antibiotics are losing efficacy and new antimicrobial agents are urgently needed. Living organisms are an invaluable source of antimicrobial compounds. The antimicrobial activity of the most representative natural products of animal, bacterial, fungal and plant origin are reviewed in this paper. Their activity against drug-resistant bacteria, their mechanisms of action, the possible development of resistance against them, their role in current medicine and their future perspectives are discussed. Electronic databases such as PubMed, Scopus and ScienceDirect were used to search scientific contributions until September 2020, using relevant keywords. Natural compounds of heterogeneous origins have been shown to possess antimicrobial capabilities, including against antibiotic-resistant bacteria. The most commonly found mechanisms of antimicrobial action are related to protein biosynthesis and alteration of cell walls and membranes. Various natural compounds, especially phytochemicals, have shown synergistic capacity with antibiotics. There is little literature on the development of specific resistance mechanisms against natural antimicrobial compounds. New technologies such as -omics, network pharmacology and informatics have the potential to identify and characterize new natural antimicrobial compounds in the future. This knowledge may be useful for the development of future therapeutic strategies.</p></abstract><kwd-group><kwd>natural antimicrobial</kwd><kwd>antimicrobial resistance</kwd><kwd>polyphenols</kwd><kwd>future medicine</kwd><kwd>natural origin</kwd><kwd>antibacterial compound</kwd><kwd>phytochemicals</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-biomedicines-08-00405"><title>1. Introduction</title><p>Antimicrobial resistance (AMR) and the inexorable advance of superbacteria poses a great threat to human health worldwide. If this problem is not tackled, the antibiotics we have used with great success so far could become substances unable to help us against infections caused by bacteria, going back to a worrying pre-antibiotic era. According to data from the United Kingdom government [<xref rid="B1-biomedicines-08-00405" ref-type="bibr">1</xref>], 10 million deaths could happen annually due to antibiotic resistance by 2050, becoming one of the leading causes of death in the world (<xref ref-type="fig" rid="biomedicines-08-00405-f001">Figure 1</xref>).</p><p>This problem is known to scientists and institutions around the world, which are organizing to establish protocols to address the problem of antibiotic-resistant microbes. Proof of this was the 2012 Chennai Declaration of India, in which international experts and representatives of medical entities met to draw up action plans in the face of the inexorable advance of the superbugs [<xref rid="B2-biomedicines-08-00405" ref-type="bibr">2</xref>]. Similar initiatives have been promoted from private and public institutions worldwide.</p><p>Bacteria use their genetic plasticity to resist attack by antibiotics through mutations, acquisition of genetic material, and alteration of the expression of their genome [<xref rid="B3-biomedicines-08-00405" ref-type="bibr">3</xref>]. In this way, bacteria that survive the attack of an antibiotic become the precursors of the next bacterial generations, further aggravating the problem of resistance. Once antibiotic resistance genes are acquired, they can be passed from one bacterium to another through division processes or by horizontal gene transfer [<xref rid="B4-biomedicines-08-00405" ref-type="bibr">4</xref>]. Horizontal gene transfer processes can occur by transformation, transduction or conjugation with other bacteria. These mechanisms can transfer antibiotic resistance to bacteria that have not been subjected to antibiotic selection pressure, creating reservoirs of resistant bacteria in the environment [<xref rid="B5-biomedicines-08-00405" ref-type="bibr">5</xref>]. In addition, the epistasis of the receptor bacteria plays a fundamental role in the process of acquisition of resistance genes, determining whether these bacteria are capable of maintaining, accumulating and propagating the genetic material [<xref rid="B6-biomedicines-08-00405" ref-type="bibr">6</xref>].</p><p>Antibiotic resistance is an example of the enormous capacity for natural evolution and adaptation of bacteria to different environments [<xref rid="B7-biomedicines-08-00405" ref-type="bibr">7</xref>,<xref rid="B8-biomedicines-08-00405" ref-type="bibr">8</xref>]. Although this process seems inevitable, humans have accelerated it through various anthropogenic activities [<xref rid="B9-biomedicines-08-00405" ref-type="bibr">9</xref>,<xref rid="B10-biomedicines-08-00405" ref-type="bibr">10</xref>]. The causes behind the increase in the number of antimicrobial-resistant bacteria in recent years include the misuse of antibiotics in humans and animals, inadequate control of infections in hospitals and clinics or poor hygiene and sanitation [<xref rid="B9-biomedicines-08-00405" ref-type="bibr">9</xref>,<xref rid="B10-biomedicines-08-00405" ref-type="bibr">10</xref>,<xref rid="B11-biomedicines-08-00405" ref-type="bibr">11</xref>]. In addition to the causes mentioned, the problem worsens as there is a drought in the discovery of new antibiotics. The increase in resistance rates in bacteria leads to a decrease in the effectiveness of existing antibiotics, making research in this field unattractive to companies that decide to invest in other types of fields with greater chances of success and benefits [<xref rid="B12-biomedicines-08-00405" ref-type="bibr">12</xref>,<xref rid="B13-biomedicines-08-00405" ref-type="bibr">13</xref>]. This concerning trend can be observed in <xref ref-type="fig" rid="biomedicines-08-00405-f002">Figure 2</xref>.</p><p>In view of this scenario, research on alternative or complementary therapies to traditional antibiotics has emerged strongly. Antimicrobial products of natural origin have been positioned as compounds of great scientific interest due to their enormous chemical variety and intrinsic properties that have promoted their study as a possible therapeutic tool in recent years.</p></sec><sec sec-type="methods" id="sec2-biomedicines-08-00405"><title>2. Methodology</title><p>Electronic databases such as PubMed, Scopus and ScienceDirect were used to search scientific contributions until September 2020, using relevant keywords. Search terms included &#x0201c;natural antimicrobial&#x0201d;, &#x0201c;antimicrobial resistance&#x0201d;, &#x0201c;polyphenols&#x0201d;, &#x0201c;future medicine&#x0201d;, &#x0201c;natural origin&#x0201d;, &#x0201c;antibacterial compound&#x0201d;, &#x0201c;phytochemical&#x0201d; and their combinations. Literature focusing on the antimicrobial activity of natural origin compounds against bacteria focusing on antibiotic-resistant strains were identified and summarized.</p><p>The term &#x0201c;antimicrobial activity&#x0201d; is used throughout this work to refer to the process of killing or inhibiting the growth of microbes. Usually, this activity is expressed as MIC (minimum inhibitory concentration) values for a given agent. The methods to test microbial susceptibility compiled in this work are in accordance with the guidelines of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and The Clinical and Laboratory Standards Institute (CLSI). Following the EUCAST guidelines for the reproducibility and reliability of antimicrobial assays, broth dilution or microdilution methods should be used to test microbial susceptibility [<xref rid="B14-biomedicines-08-00405" ref-type="bibr">14</xref>].</p></sec><sec sec-type="results" id="sec3-biomedicines-08-00405"><title>3. Results</title><sec id="sec3dot1-biomedicines-08-00405"><title>3.1. Use of Natural Products as Antimicrobials</title><p>Natural products (NPs) make up a heterogeneous group of chemical entities that possess diverse biological activities with various uses in fields such as human and veterinary medicine, agriculture and industry. Molecules from the secondary metabolism of animals, vegetables, bacteria and fungi are classified as NPs, which are not crucial for the producer&#x02019;s survival under laboratory conditions, but which give him a clear advantage over his competitors in his native habitat [<xref rid="B15-biomedicines-08-00405" ref-type="bibr">15</xref>]. Since the discovery of penicillin, more than 23,000 new NPs have been characterized, many of which have proven to be valuable tools in the field of pharmacology, herbicides, insecticides and more [<xref rid="B16-biomedicines-08-00405" ref-type="bibr">16</xref>].</p><p>One of the main sources of antimicrobial NPs is plants. Plant organisms make up most of the biosphere on planet Earth, whose biomass accounts for a percentage greater than 80% of the total biomass [<xref rid="B17-biomedicines-08-00405" ref-type="bibr">17</xref>]. Since their appearance, plants have survived, evolved and adapted to all types of ecosystems and adverse conditions. This adaptive process has led them to develop complex and effective defense systems against external aggressions: predators, abiotic stress and, of course, infections. Being sessile organisms that cannot escape their threats, plants have developed a splendid chemical arsenal in the form of secondary metabolites capable of coping with the most dangerous pathogens [<xref rid="B18-biomedicines-08-00405" ref-type="bibr">18</xref>]. Humanity has made use of the medicinal properties of plants for thousands of years. There is evidence that in the year 5000 BC. the Sumerians already used thyme for its beneficial health properties [<xref rid="B19-biomedicines-08-00405" ref-type="bibr">19</xref>]. The Egyptian Ebers Papyrus dating from around 1500 BC already attributed medicinal properties to plants and spices such as aloe vera, castor bean, garlic, hemp, anise or mustard [<xref rid="B20-biomedicines-08-00405" ref-type="bibr">20</xref>,<xref rid="B21-biomedicines-08-00405" ref-type="bibr">21</xref>]. Other texts such as the Atharva Veda, the Rig Veda and the Sushruta Samhita belonging to Indian Ayurveda, also spoke of the pharmacological properties of plant substances such as turmeric or cannabis [<xref rid="B22-biomedicines-08-00405" ref-type="bibr">22</xref>,<xref rid="B23-biomedicines-08-00405" ref-type="bibr">23</xref>]. Current technology allows us to study the bases of this ancestral knowledge and find therapeutic applications adapted to our time, making plants a source of invaluable therapeutic potential.</p><p>Bacteria are another of the main sources of antimicrobial NPs with radical importance during the 20th century. Most of the antibiotics used today in the clinic were discovered thanks to the Waksman platform in the 1940s. Waksman and his students dedicated themselves to growing soil microorganisms to detect and isolate antimicrobial substances. Through this method, they discovered very important antibiotics such as neomycin or streptomycin, for which Waksman received the Nobel Prize in 1952 for Physiology or Medicine [<xref rid="B24-biomedicines-08-00405" ref-type="bibr">24</xref>]. Despite these successes, it should be noted that most existing bacteria are not cultivable in the laboratory using traditional methods. We could find an immense amount of opportunities for the isolation of new antibiotic compounds using a method like Waksman&#x02019;s combined with new technologies not present decades ago. From this idea, the Small World Initiative was born in 2012, a project in which students from all over the world collect soil samples and look for antibiotic-producing microorganisms in them [<xref rid="B25-biomedicines-08-00405" ref-type="bibr">25</xref>].</p><p>Many of the NPs with antibiotic activity have been isolated from bacteria, especially from the genus actinomycetes. In the so-called &#x0201c;Golden Age&#x0201d; of the discovery of new antibiotics, which began in the 40s of the twentieth century, natural products were the star. The isolation of streptomycin from <italic>Streptomyces griseus</italic> in 1944 caused a worldwide surge in which numerous research groups struggled to identify new NPs, especially from samples of soil bacteria. The media were very limited, both in technology and in access to soil samples from remote places. However, another great milestone occurred in 1952, when a sample of soil sent from Borneo allowed <italic>Streptomyces orientalis</italic> to grow, from which vancomycin was extracted. Six years later, vancomycin was used in patients with great success. Unfortunately, this prolific period of discovery of valuable compounds ended the appearance and spread of bacteria resistant to these NPs, such as methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) or glycopeptide-resistant enterococci (GREs), since the compounds that worked in the past stopped working with the desired efficiency [<xref rid="B26-biomedicines-08-00405" ref-type="bibr">26</xref>], as observed in <xref ref-type="fig" rid="biomedicines-08-00405-f002">Figure 2</xref>.</p><p>In the 1990s, the pharmaceutical industry concentrated its efforts on other more sophisticated methods of identifying antimicrobial compounds, such as high-throughput screening of synthetic chemical libraries against specific therapeutic targets, many of them discovered from the Human Genome Project. Currently, there is a renewed interest in the discovery of new NPs of different sources since it has a much more advanced technology than that available during the &#x0201c;Golden Age&#x0201d;. Advances in genomics, bioinformatics and mass spectrometry, among others, have elucidated that many of the sources of classical NPs were surprisingly under-exploited and have an enormous and unknown potential for the discovery of new NPs to be used for the discovery of present and tomorrow&#x02019;s antibiotics [<xref rid="B15-biomedicines-08-00405" ref-type="bibr">15</xref>].</p><p>Given the existing problems in the field of antibiotics, in recent years alternative and complementary therapies have emerged that make use of different strategies to deal with new generations of resistant bacteria. The growing interest in this area is reflected in the ascending number of publications related to natural antimicrobials available in the PubMed search engine over the past recent years (<xref ref-type="fig" rid="biomedicines-08-00405-f003">Figure 3</xref>).</p><p>As abovementioned, the molecules with antimicrobial function present in nature have been molded by thousands of years of evolution to maintain their efficacy and selectivity, since they are a key piece for the development of the life of any organism exposed to bacteria. Thanks to these processes of continuous physicochemical adaptation driven by selective pressure, it has been demonstrated that antimicrobial compounds of natural origin generally have a greater capacity for cell penetration, being able to use active bacterial transporters and, in addition, passively pass through the cell membrane [<xref rid="B27-biomedicines-08-00405" ref-type="bibr">27</xref>]. These and other properties that will be discussed below, make NPs a tool of great potential value for the development of novel and effective antibiotic therapies against AMR bacteria.</p></sec><sec id="sec3dot2-biomedicines-08-00405"><title>3.2. Main Classes of Natural Antimicrobial Products</title><p>NPs are extremely diverse in terms of their chemical structures, properties and mechanisms of action. These agents can be classified according to their original source: animal, bacterial, fungal or vegetal.</p><sec id="sec3dot2dot1-biomedicines-08-00405"><title>3.2.1. Animal Origin</title><p>Animals have colonized virtually the entire planet Earth. For thousands of years, they have lived closely with different kinds of bacteria and have faced not a few pathogenic microorganisms. Evolution has shaped animal defense systems to deal with these microscopic threats. In recent years, attention has been focused on identifying which molecules confer resistance and allow certain animals to live in hostile environments with high pollution and pathogenic load, as is the case with certain insects such as cockroaches.</p><p>Currently, animals, and especially insects, are one of the main sources of antimicrobial proteins or peptides (AMPs). Since the discovery of AMPs in 1974, more than 150 new AMPs have been isolated or identified, the majority being cationic peptides between 20 and 50 residues in length. These molecules mainly have antimicrobial capacity mediated by disruption of the bacterial plasma membrane, most probably by forming pores or ion channels [<xref rid="B28-biomedicines-08-00405" ref-type="bibr">28</xref>]. Some AMPs also have shown antifungal, antiparasitic or antiviral properties [<xref rid="B29-biomedicines-08-00405" ref-type="bibr">29</xref>]. These AMPs can be divided into four subfamilies with different structures and sequences: the &#x003b1;-helical peptides, such as cecropin, which has a broad spectrum of antimicrobial activity against bacteria of both Gram-positive and Gram-negative bacteria; cysteine-rich peptides, such as insect defensins, which are mainly active against Gram-positive bacteria; proline-rich peptides, such as lebocins, which are active against both Gram-positive and Gram-negative bacteria and some fungi; and finally glycine-rich peptides or proteins, such as attacin, which are effective against Gram-negative bacteria and especially against <italic>Escherichia coli</italic>. These AMPs present a promising basis for the development of medical therapies, however, additional work must be developed to make them more powerful and stable [<xref rid="B30-biomedicines-08-00405" ref-type="bibr">30</xref>]. Moreover, the intrinsic antimicrobial capacity of AMPs can be enhanced by a fusion of peptides to create more potent hybrid ones, such as in the case of attacin from <italic>Spodoptera exigua</italic> and a coleoptericin-like protein from <italic>Protaetia brevitarsis seulensis</italic>, which, when fused, exhibited a greater antimicrobial capacity than its two original peptides [<xref rid="B31-biomedicines-08-00405" ref-type="bibr">31</xref>].</p><p>The study of antimicrobial molecules existent in cockroaches (<italic>Periplaneta americana</italic>) has revealed that extracts derived from its brain have a great antimicrobial capacity against MRSA and neuropathogenic <italic>E. coli</italic> K1. Although not all the components of the extract could be accurately identified, a great variety of molecules with known biological activity were found, such as isoquinolines, flavanones, sulfonamides and imidazone among others. A hypothesis about the production of this antimicrobial cocktail in the cockroach brain suggests that there could be a constitutive expression of these antimicrobials to protect the animal&#x02019;s neural system, since it is the central axis of its survival and a key piece to protect when it is lived in an environment of high pollution and exposure to pathogens and even superbugs [<xref rid="B32-biomedicines-08-00405" ref-type="bibr">32</xref>]. Another example of insect producing antimicrobial molecules against resistant bacteria is <italic>Lucilia cuprina</italic> blowfly maggots. The extract obtained from excretions and secretions from maggots showed mild bacterial growth inhibition. However, using subinhibitory concentrations of this extract in combination with the antibiotic ciprofloxacin enhanced its activity, further delaying the appearance of bacteria resistant to it. The properties of this extract, including the presence of defensins and phenylacetaldehyde, make maggot debridement therapy a promising tool in the treatment of MRSA-infected wounds acquired in hospital [<xref rid="B33-biomedicines-08-00405" ref-type="bibr">33</xref>].</p><p>One of the most popular insect-related products worldwide is honey. In addition to its nutritional properties and culinary values, it has antimicrobial capacity against Gram-negative bacteria, such as <italic>E. coli</italic> or <italic>Pseudomonas aeruginosa</italic>, and against Gram-positive bacteria, such as <italic>Bacillus subtilis</italic> or <italic>S. aureus</italic>, including MRSA. The key factors of honey&#x02019;s antimicrobial activity appear to be the presence of H<sub>2</sub>O<sub>2</sub>, bee defensin-1 and methylglyoxal. The diverse molecular composition of the different honey types that depends on the producing species and the raw material used, exerts also different antimicrobial activities and mechanisms [<xref rid="B34-biomedicines-08-00405" ref-type="bibr">34</xref>]. Another substance produced by bees is propolis, a resinous substance produced by honeybees from plant matter, such as buds or sap. This substance has been used since ancient times, up to 3000 years BC in Egypt thanks to its various biological properties. The main components responsible for its activity are flavonoids, terpene derivatives and phenolic acids, although its composition is variable depending on the geographical area where it occurs. Ethanol extract of propolis produced by <italic>Apis mellifera</italic> in Brazil has demonstrated significant antibacterial capacity against <italic>S. aureus</italic>, <italic>E. coli</italic> and <italic>Enterococcus sp</italic>. [<xref rid="B35-biomedicines-08-00405" ref-type="bibr">35</xref>]. Canadian propolis has also been shown to possess antibacterial capacity against <italic>E. coli</italic> and <italic>S. aureus</italic>, being more effective against the latter [<xref rid="B36-biomedicines-08-00405" ref-type="bibr">36</xref>]. Another product with antimicrobial properties derived from honeybees is royal jelly. It is produced from the mandibular salivary and hypopharyngeal glands of bees aged between 5 and 14 days. Its composition is based on a complex mixture of carbohydrates, proteins, lipids, vitamins and minerals that varies with regional conditions, season, bee&#x02019;s genetics and postharvest storage conditions. Royal jelly shows antimicrobial activity against both Gram-positive and Gram-negative bacteria, including MDR bacteria such as MRSA. The compounds isolated from royal jelly with activity against Gram-positive bacteria are the peptide royalisin [<xref rid="B37-biomedicines-08-00405" ref-type="bibr">37</xref>], the peptide family of jelleines and 10-hydroxy-2-decenoic acid (10-HDA), also known as queen bee acid [<xref rid="B38-biomedicines-08-00405" ref-type="bibr">38</xref>]. Melittin, a major component from the venom of <italic>A. mellifera</italic>, has also shown interesting antimicrobial activity, including in in vivo experiments with mice infected with MRSA [<xref rid="B39-biomedicines-08-00405" ref-type="bibr">39</xref>].</p><p>Other animals that can live in contaminated environments and exposed to infections are reptiles, such as snakes that are able to ingest rodents infected with germs and not develop a disease. Results suggest that animals exposed to huge amounts of pathogens can be a valuable source of antimicrobial molecules. However, to further study and identification of the key molecules responsible for the activity, it is necessary to know if they would be candidates for drugs with real applicability in therapies [<xref rid="B40-biomedicines-08-00405" ref-type="bibr">40</xref>]. There are studies in Black cobra (<italic>Naja naja karachiensis</italic>) that show that plasma lysates and certain organs have a potent antimicrobial capacity against <italic>E. coli</italic> K1, MRSA, <italic>P. aeruginosa</italic>, <italic>Streptococcus pneumoniae</italic>, <italic>Acanthamoeba castellanii</italic>, and <italic>Fusarium solani</italic>. Against <italic>E. coli</italic> K1, solutions containing 25% and 50% of plasma from the blood of the Black cobra showed a bactericidal activity of 85% and 93% respectively with respect to the effect of the antibiotic gentamicin. Against MRSA, concentrations of 25% and 50% of plasma showed activity of 90% and 93%, respectively. Lung and gallbladder lysates also showed high antimicrobial capacity against MRSA. Antimicrobial molecules can also be extracted from the venom produced by certain species of snakes, such as cathelicidines or toxins. A cathelicidin-like antimicrobial peptide (cathelicidin-BF) isolated from the venom of <italic>Bungarus fasciatus</italic> has shown high antimicrobial activity, including drug-resistant bacteria [<xref rid="B41-biomedicines-08-00405" ref-type="bibr">41</xref>]. <italic>Crotalus adamanteus</italic> toxin-II (CaTx-II) exerted a strong antimicrobial effect against <italic>S. aureus</italic>, <italic>Burkholderia pseudomallei</italic> and <italic>Enterobacter aerogenes</italic> by causing pores and damaging their membranes. Interestingly, this compound showed no cytotoxicity against lung (MRC-5), skin fibroblast (HEPK) cells or treated mice [<xref rid="B42-biomedicines-08-00405" ref-type="bibr">42</xref>].</p><p>Molecules with great antimicrobial capacity have also been found in crustaceans, coming from their immune system. The anti-lipopolysacchride factor of red claw crayfish <italic>Cherax quadricarinatus</italic> has shown low minimum bactericidal concentrations (MBC) against Gram-negative <italic>Shigella flexneri</italic> (MBC &#x0003c; 6 &#x000b5;M) and Gram-positive <italic>S. aureus</italic> (MBC &#x0003c; 12 &#x000b5;M), meaning a high antimicrobial capacity. Studies showed that the mechanism of action of this compound does not appear to be related to the bacterial plasma membrane alteration, requiring more studies to find its specific mechanism [<xref rid="B43-biomedicines-08-00405" ref-type="bibr">43</xref>].</p><p>The venom of <italic>Vaejovis mexicanus</italic>, a mexican scorpion, has an AMP called vejovine, which presents a high antimicrobial capacity against MDR Gram-negative bacteria with MIC values between 4.4 &#x000b5;M and 50 &#x000b5;M [<xref rid="B44-biomedicines-08-00405" ref-type="bibr">44</xref>].</p></sec><sec id="sec3dot2dot2-biomedicines-08-00405"><title>3.2.2. Bacterial Origin</title><p>Bacteria are the most prolific source of NPs with antimicrobial activity found so far, especially those of the actinomycetes class. Their great diversity, competitiveness and colonization capacity have led them to the development of secondary metabolites capable of giving them great advantages over other bacterial species. As described in previous sections, the detection and isolation of these bacterial antimicrobial NPs propelled medical science vertiginously in the middle of the last century. Some of the most relevant are described below.</p><p>Some of the most important antimicrobial molecules produced by bacteria of the actinomyces class are: vancomycin, baulamycin, fasamycin A and orthoformimycin. Vancomycin is a naturally occurring tricyclic glycopeptide extracted from <italic>Streptococcus orientalis</italic> that has reaped great success as an antibiotic against Gram-positive bacteria, especially against threats that are resistant to other treatments such as MRSA and penicillin-resistant pneumococci among others [<xref rid="B45-biomedicines-08-00405" ref-type="bibr">45</xref>]. Vancomycin forms hydrogen bonds with the terminal dipeptide of the nascent peptidoglycan chain during biosynthesis of the bacterial cell wall. This union prevents the action of penicillin-binding proteins (PBPs), interrupting further wall formation and finally activating autolysin-triggered cell rupture and cell death [<xref rid="B46-biomedicines-08-00405" ref-type="bibr">46</xref>]. Another important bacterial NP is produced by actinomyces is baulamycin, which is an isolated molecule of the marine bacterium <italic>Streptomyces tempisquensis</italic> that can inhibit the biosynthesis of iron-chelating siderophores in <italic>S. aureus</italic> (targeting staphylopherrin B) and <italic>Bacillus anthracis</italic> (targeting petrobactin), helping to treat MRSA and anthrax infections, respectively. In addition, it was also able to inhibit the growth of Gram-negative bacteria such as <italic>S. flexneri</italic> and <italic>E. coli</italic>, turning baulamycin and its derivatives into potential broad-spectrum antibiotics [<xref rid="B47-biomedicines-08-00405" ref-type="bibr">47</xref>]. Fasamycin A is a polyketide isolated from <italic>Streptomyces albus</italic> that shows specific antimicrobial activity against Gram-positive bacteria such as vancomycin-resistant Enterococci (VRE) and MRSA with MIC values of 0.8 and 3.1 &#x000b5;g/mL, respectively. This molecule targets FabF in the initial condensation step of the elongation cycle from the lipidic biosynthetic bacterial metabolism [<xref rid="B48-biomedicines-08-00405" ref-type="bibr">48</xref>]. Orthoformimycin is a molecule produced by <italic>S. griseus</italic> which can inhibit bacterial translation by more than 80% in the case of <italic>E. coli</italic>. Although the mechanism of action is not clear now, one hypothesis is the decoupling of mRNA and aminoacyl-tRNA in the bacterial ribosome [<xref rid="B49-biomedicines-08-00405" ref-type="bibr">49</xref>].</p><p>The actinobacteria class is also prolific in the production of antimicrobial molecules. One example is kibdelomycin, which is a potent inhibitor of DNA synthesis that was isolated from <italic>Kibdelosporangium</italic> sp., MA7385. Its complex structure and its infrequent function as an inhibitor of bacterial DNA gyrase and IV topoisomerase make kibdelomycin the first bacterial type II topoisomerase inhibitor discovered from natural sources in more than 60 years [<xref rid="B50-biomedicines-08-00405" ref-type="bibr">50</xref>]. This molecule has a broad-spectrum antimicrobial activity against aerobic bacteria, including antibiotic-resistant bacteria such as MRSA, with a MIC value of 0.25 &#x000b5;g/mL. In addition, this molecule has a very low resistance development rate due to its structure and way of binding with its target, at levels of other successful antibiotics such as ciprofloxacin [<xref rid="B51-biomedicines-08-00405" ref-type="bibr">51</xref>]. Another example is pyridomycin, a molecule isolated from <italic>Dactylosporangium fulvum</italic> which has a great antimicrobial capacity against mycobacteria, a bacterium that causes tuberculosis. This disease is becoming relevant due to the appearance of bacteria resistant to the main antibiotics used for its treatment such as the InhA inhibitor isoniazid. Pyridomycin acts on the cell wall of <italic>Mycobacterium tuberculosis</italic> by inhibiting the production of mycolic acid by targeting NADH-dependent enoyl- (Acyl-Carrier-Protein) reductase InhA even in strains resistant to isoniazid. Pyridomycin showed minimum bactericidal concentration (MBC) values between 0.62 and 1.25 &#x000b5;g/mL against <italic>M. tuberculosis</italic> [<xref rid="B52-biomedicines-08-00405" ref-type="bibr">52</xref>].</p><p>In addition to the two classes mentioned above, there are other classes of bacteria such as deltaproteobacteria, cyanophyceae or betaproteobacteria from which antimicrobial molecules have also been isolated. Myxovirecin is a macrocyclic secondary metabolite isolated from myxobacteria (deltaproteobacteria class) that possesses broad-spectrum antibacterial capacity. It seems to inhibit the production of type II signal peptidase by blocking Lpp lipoprotein processing. Myxovirecin showed very potent activity against <italic>E. coli</italic> DW37 with a MIC of 0.063 &#x000b5;g/mL [<xref rid="B53-biomedicines-08-00405" ref-type="bibr">53</xref>]. Spirohexenolide A is a natural spirotetronate originally isolated from <italic>Spirulina platensis</italic> of the cyanophyceae class that shows antimicrobial activity against methicillin-resistant <italic>S. aureus</italic> by disrupting the cytoplasmic membrane, collapsing the proton motive force [<xref rid="B54-biomedicines-08-00405" ref-type="bibr">54</xref>]. Teixobactin is a naturally occurring molecule produced by <italic>Eleftheria terrae</italic> of the betaproteobacteria class that possesses antibacterial capacity against antibiotic-resistant pathogens in infection animal models. It acts by binding to the precursors of the bacterial wall teicoic acid, causing the digestion of the cell wall by autolysins [<xref rid="B55-biomedicines-08-00405" ref-type="bibr">55</xref>].</p><p>Lypoglycopeptides isolated from different bacteria show antimicrobial activity by inhibiting signal peptidase type IB (SpsB), which is a membrane-localized serine protease that cleaves the amino-terminal signal peptide from most secreted proteins. One example is actinocarbasin, a molecule isolated from <italic>Actinoplanes ferrugineus</italic> strain MA7383. Moreover, this molecule enhances the activity of &#x003b2;-lactam antibiotics against MRSA, sensitizing it to those drugs. Arylomycin is another lipoglycopeptide with bacterial type I signal peptidase inhibitory capacity which showed antibacterial activity witch MIC values in the range of 4&#x02013;64 &#x000b5;M against Gram-positive and 8&#x02013;64 &#x000b5;M against Gram-negative bacteria. Krisynomycin is also a lypoglycopeptide, isolated from <italic>Streptomyces fradiae</italic> strain MA7310, with the capacity of inhibition of SpsB [<xref rid="B56-biomedicines-08-00405" ref-type="bibr">56</xref>]. </p><p>In addition to the natural bacteria molecules with direct antimicrobial activity, there are also others capable of attacking the virulence factors caused by bacterial infections. Skyllamycins B and C are cyclic depsipeptides isolated from marine bacterial fractions with <italic>P. aeruginosa</italic> biofilm inhibition and dispersal activity. The ability to prevent the formation of biofilms or to disperse those already formed is of great importance since these biofilms are one of the major causes of drug resistance in nosocomial infections. These molecules do not possess a bactericidal capacity per se, but they are effective in combination with antibiotics that are not able to act in the presence of biofilms, causing them to recover their activity as in the case of azithromycin [<xref rid="B57-biomedicines-08-00405" ref-type="bibr">57</xref>].</p></sec><sec id="sec3dot2dot3-biomedicines-08-00405"><title>3.2.3. Fungal Origin</title><p>Fungi are eukaryotic-type living things, such as mushrooms, yeasts, and molds. Currently, the existence of some 120,000 species of fungi has been accepted, however, it is estimated that the number of different species of fungi present on earth could be between 2.2 and 3.8 million [<xref rid="B58-biomedicines-08-00405" ref-type="bibr">58</xref>]. This relatively unexplored kingdom is a source of antimicrobial NPs and has great potential to be studied in the future as new species are discovered and identified.</p><p>Aspergillomarasmine A is a polyaminoacid naturally produced by <italic>Aspergillus versicolor</italic> capable of inhibiting antibiotic resistance enzymes in Gram-negative pathogenic bacteria, such as <italic>Enterobacteriaceae</italic>, <italic>Acinetobacter spp.</italic>, <italic>Pseudomonas spp</italic>. and <italic>Klebsiella pneumoniae</italic>. This compound has been used successfully to reverse resistance in mice infected with meropenem-resistant <italic>K. pneumoniae</italic> thanks to the NDM-I protein, making the bacterium sensitive to the antibiotic and ending the infection [<xref rid="B59-biomedicines-08-00405" ref-type="bibr">59</xref>].</p><p>Mirandamycin is a quinol of fungal origin capable of inhibiting the growth of both Gram-negative and Gram-positive bacteria, being more effective against the latter group, including antibiotic-resistant strains such as MRSA or carbapenemase-producing <italic>K. pneumoniae</italic>. Its mechanism of action consists in the inhibition of the bacterial metabolism of sugars, interfering with their fermentation and transport [<xref rid="B60-biomedicines-08-00405" ref-type="bibr">60</xref>].</p><p>There is evidence of the antibacterial capacity of various fungal species against Gram-positive bacteria. Extracts of <italic>Ganoderma lucidum</italic>, <italic>Ganoderma applanatum</italic>, <italic>Meripilus giganteus</italic>, <italic>Laetiporus sulphureus</italic>, <italic>Flammulina velutipes</italic>, <italic>Coriolus versicolor</italic>, <italic>Pleurotus ostreatus</italic> and <italic>Panus tigrinus</italic> demonstrated antimicrobial activity in Kirby&#x02013;Bauer assays against Gram-positive bacteria, such as <italic>S. auerus</italic> and <italic>B. luteus</italic> [<xref rid="B61-biomedicines-08-00405" ref-type="bibr">61</xref>].</p><p>In recent times, molecules produced by various species of marine fungi have been studied, especially those that cohabit with sponges or corals. Fungal compounds with activity against antibiotic resistant bacteria have been isolated, such as lindgomycin and ascosetin, with MIC values of 5.1 &#x000b5;M and 3.2 &#x000b5;M against MRSA, respectively. These molecules were isolated from the mycelium and the <italic>Lindgomycetae spp</italic> culture broth from sponges found in the Baltic and Antarctic Sea [<xref rid="B62-biomedicines-08-00405" ref-type="bibr">62</xref>]. Another marine fungus capable of producing antimicrobial molecules is <italic>Pestalotiopsis</italic> sp., isolated from the coral <italic>Sarcophyton</italic> sp. This fungus produces (&#x000b1;) -pestalachloride D, a chlorinated benzophenone derivative, which has shown antibacterial capacity against <italic>E. coli</italic>, <italic>Vibrio anguillarum</italic> and <italic>Vibrio parahaemolyticus</italic> with MIC values of 5, 10 and 20 &#x003bc;M, respectively [<xref rid="B63-biomedicines-08-00405" ref-type="bibr">63</xref>]. <italic>Trichoderma sp.</italic> is a sponge-derived fungus from which different aminolipopeptide classes, called trichoderins, have been isolated. These molecules have a potent antimycobacterial capacity showing MIC values between 0.02 and 2.0 &#x000b5;g/mL against <italic>Mycobacterium smegmatis</italic>, <italic>Mycobacterium bovis</italic> BCG, and <italic>M. tuberculosis</italic> H37Rv in different aerobic and hypoxic conditions [<xref rid="B64-biomedicines-08-00405" ref-type="bibr">64</xref>].</p></sec><sec id="sec3dot2dot4-biomedicines-08-00405"><title>3.2.4. Plant Origin</title><p>Plants are a great source of biomolecules with various interesting properties for humans thanks to their enormous diversity and proven safety for human health [<xref rid="B65-biomedicines-08-00405" ref-type="bibr">65</xref>]. Being sessile organisms, evolution has shaped its metabolism to produce certain molecules to cope with external aggressions and infections, since they cannot flee or defend themselves [<xref rid="B66-biomedicines-08-00405" ref-type="bibr">66</xref>]. The Dictionary of Natural Products lists approximately 200,000 secondary plant metabolites, of which 170,000 have unique chemical structures [<xref rid="B67-biomedicines-08-00405" ref-type="bibr">67</xref>]. Some of the families of molecules with antimicrobial capacity produced by plants are alkaloids, terpenoids, and polyphenols [<xref rid="B68-biomedicines-08-00405" ref-type="bibr">68</xref>].</p><p>Plants that have been used in traditional medicine in various countries of the world for thousands of years. They are currently being studied at the molecular and functional level, rediscovering their properties and explaining their mechanisms of action.</p><p>Alkaloids have been shown to possess antimicrobial capacity against various bacterial species. Although studies of the antimicrobial capacity of pure alkaloids are limited, there are several studies on the antimicrobial activity of plant extracts that contain alkaloids as their main components. Different extracts rich in alkaloids obtained from <italic>Papaver rhoeas</italic> have shown activity against <italic>S. aureus</italic>, <italic>Staphylococcus epidermidis</italic> and <italic>K. pneumoniae</italic>, the main active component being roemerine [<xref rid="B69-biomedicines-08-00405" ref-type="bibr">69</xref>]. Raw alkaloid-rich extracts of <italic>Annona squamosa</italic> seeds and <italic>Annona muricata</italic> root have also shown moderate antimicrobial capacity against <italic>E. coli</italic> and <italic>S. aureus</italic> [<xref rid="B70-biomedicines-08-00405" ref-type="bibr">70</xref>].</p><p>Terpenoids, along with other families of compounds, are part of plant essential oils, many of which possess antimicrobial activity. Various in vitro studies affirm that terpenoids do not possess significant antimicrobial activity per se [<xref rid="B71-biomedicines-08-00405" ref-type="bibr">71</xref>]. However, they can contribute to the antimicrobial activity of complete essential oils thanks to their hydrophobic nature and a low molecular weight that allow them to disrupt the cell wall and facilitate the action of the rest of the active components [<xref rid="B72-biomedicines-08-00405" ref-type="bibr">72</xref>].</p><p>Polyphenols are molecules present in plants with a function of defense against stress and have one or more phenolic groups in their chemical structure as a common feature. There is abundant literature on the antimicrobial capacity of polyphenols and extracts of plants rich in them that have bactericidal and bacteriostatic capacity against many pathogens, both Gram-positive and Gram-negative. The potential use of polyphenols as antimicrobials is widely studied to be applied in different areas such as agriculture [<xref rid="B73-biomedicines-08-00405" ref-type="bibr">73</xref>], food preservation [<xref rid="B74-biomedicines-08-00405" ref-type="bibr">74</xref>] and medicine [<xref rid="B75-biomedicines-08-00405" ref-type="bibr">75</xref>].</p><p>There are several subfamilies within the group of polyphenols according to their differentiated chemical structures: flavonoids, hydrolyzable tannins, lignans, phenolic acids and stilbenes. In turn, the flavonoid group can be subdivided into other subfamilies: anthocyanidins, flavanones, flavones, flavonols and isoflavones [<xref rid="B76-biomedicines-08-00405" ref-type="bibr">76</xref>]. Examples of flavonoids with antimicrobial activity are quercetin [<xref rid="B77-biomedicines-08-00405" ref-type="bibr">77</xref>], kaempferol [<xref rid="B78-biomedicines-08-00405" ref-type="bibr">78</xref>], morin [<xref rid="B79-biomedicines-08-00405" ref-type="bibr">79</xref>], myricetin [<xref rid="B80-biomedicines-08-00405" ref-type="bibr">80</xref>] epigallocatechin gallate [<xref rid="B81-biomedicines-08-00405" ref-type="bibr">81</xref>] or galangin [<xref rid="B82-biomedicines-08-00405" ref-type="bibr">82</xref>] among many others [<xref rid="B76-biomedicines-08-00405" ref-type="bibr">76</xref>,<xref rid="B83-biomedicines-08-00405" ref-type="bibr">83</xref>]. Other known polyphenols with good antimicrobial activity are punicalagin, which exerts both antibacterial and antibiofilm effect against <italic>S. aureus</italic> [<xref rid="B80-biomedicines-08-00405" ref-type="bibr">80</xref>,<xref rid="B84-biomedicines-08-00405" ref-type="bibr">84</xref>], and resveratrol, which has antimicrobial activity against a wide range of bacteria [<xref rid="B75-biomedicines-08-00405" ref-type="bibr">75</xref>].</p><p>The growing relevance of the study of polyphenols in the clinical setting is due to their antimicrobial synergy between polyphenols and antibiotics for clinical use. Polyphenols in subinhibitory concentrations enhance the action of an antibiotic against a bacterium that was originally resistant to its effect. For example, kaempferol and quercetin, two flavonols with antimicrobial activity on their own, have also shown to increase the efficacy of the rifampicin antibiotic against rifampicin-resistant MRSA strains by 57.8% and 75.8%, respectively. The study authors blame this increase in the activity to which these polyphenols are able to inhibit the catalytic activity of topoisomerases, inhibiting DNA synthesis, with a mechanism similar to that of the ciprofloxacin antibiotic, with which they have also shown to have a synergistic activity [<xref rid="B85-biomedicines-08-00405" ref-type="bibr">85</xref>]. Epicatechin gallate (ECg), a flavanol, is capable of sensitizing strains of MRSA against &#x003b2;-lactam antibiotics such as penicillin or oxacillin. This polyphenol can bind to the MRSA cytoplasmic membrane and cause large changes in its structure and reducing its fluidity, decoupling the functioning mechanism of the enzyme PBP2a, which is the protein responsible for resistance to &#x003b2;-lactam antibiotics. In addition, ECg can reduce biofilm formation and protein secretion associated with virulence factors [<xref rid="B86-biomedicines-08-00405" ref-type="bibr">86</xref>]. (-)-Epigallocatechin gallate (EGCg) is another flavanol with a great capacity to enhance the effect of antibiotics that acts mainly on the cell wall directly or indirectly and on some virulence factors, such as the production of penicillinases [<xref rid="B87-biomedicines-08-00405" ref-type="bibr">87</xref>]. </p><p>Another example of synergy between polyphenols and antibiotics is the case of the combination of catechin and epicatechin gallate extracted from <italic>Fructus crataegi</italic> and ampicillin, ampicillin/sulbactam, cefazolin, cefepime, and imipenem/cilastatin antibiotics, which are usually ineffective against MRSA. These combinations were effective against MRSA in both in vitro and in vivo assays using mice with an established infection model. The authors stressed that the possible mechanism of action of the combination of these two polyphenols to enhance the effect of antibiotics was the accumulation of antibiotics inside the cell thanks to the inhibition of the efflux pump gene [<xref rid="B88-biomedicines-08-00405" ref-type="bibr">88</xref>]. </p><p>In addition to synergy with antibiotics, there are also studies that point to the synergy between the polyphenols themselves, such as that between EGCg and quercetin against MRSA, attributed to a co-permeabilization process that would facilitate the activity of the compounds inside of the cell [<xref rid="B89-biomedicines-08-00405" ref-type="bibr">89</xref>]. Synergic activity has also been found between the polyphenols quercetin-3-glucoside, punicalagin, ellagic acid and myricetin in different proportions and combinations against <italic>S. aureus</italic> CECT 59 [<xref rid="B80-biomedicines-08-00405" ref-type="bibr">80</xref>].</p><p>Apart from the antimicrobial use of concrete molecules of plant origin, the use of complex extracts made from different parts of plants is common and effective. Plant extracts have a great diversity in their composition, since even from the same plant multiple completely different extracts can be obtained varying the extraction conditions. Time, temperature, solvents, pressure and other parameters such as the use of ultrasound or microwave have a huge impact on the final extract composition [<xref rid="B90-biomedicines-08-00405" ref-type="bibr">90</xref>]. There is numerous evidence of the antimicrobial activity of plant extracts [<xref rid="B76-biomedicines-08-00405" ref-type="bibr">76</xref>,<xref rid="B91-biomedicines-08-00405" ref-type="bibr">91</xref>] and the synergistic effect that exists between different phytochemicals [<xref rid="B80-biomedicines-08-00405" ref-type="bibr">80</xref>] when acting against different bacteria. An example of a plant extract with potent activity against AMR bacteria are extracts from <italic>Lantana camara</italic> leaves against clinical isolates of MRSA, <italic>Streptococcus pyogenes</italic>, VRE, <italic>Acinetobacter baumannii</italic>, <italic>Citrobacter freundii</italic>, <italic>Proteus mirabilis</italic>, <italic>Proteus vulgaris</italic> and <italic>P. aeruginosa</italic> [<xref rid="B92-biomedicines-08-00405" ref-type="bibr">92</xref>]. The ethanolic extracts of <italic>Anthocephalus cadamba</italic>, <italic>Pterocarpus santalinus</italic> and <italic>Butea monosperma</italic> Lam. they have also demonstrated antimicrobial activity against MDR clinical isolates of 10 different microbial species: <italic>S. aureus</italic>, <italic>Acinetobacter sp.</italic>, <italic>C. freundii</italic>, <italic>Chromobacterium violeceum</italic>, <italic>E. coli</italic>, <italic>Klebsiella sp.</italic>, <italic>Proteus sp.</italic>, <italic>P. aeruginosa</italic>, <italic>Salmonella typhi</italic> and <italic>Vibrio cholerae</italic> [<xref rid="B93-biomedicines-08-00405" ref-type="bibr">93</xref>,<xref rid="B94-biomedicines-08-00405" ref-type="bibr">94</xref>]. In the case of <italic>B. monosperma</italic> Lam., antimicrobial activity was also found in the extract made with hot water from leaf.</p></sec><sec id="sec3dot2dot5-biomedicines-08-00405"><title>3.2.5. Summary</title><p>As a summary, <xref rid="biomedicines-08-00405-t001" ref-type="table">Table 1</xref> contains all the NPs mentioned above together with their producing organism, type, target bacteria, mechanism of action, main use and references. <xref ref-type="fig" rid="biomedicines-08-00405-f004">Figure 4</xref> shows the main molecular targets of the most relevant antimicrobial NPs.</p></sec></sec><sec id="sec3dot3-biomedicines-08-00405"><title>3.3. Antibiotics and Plant Compounds Combinations to Get around AMR</title><p>The synergic combination of antibiotics and phytochemicals represents a promising strategy with numerous clinical and developmental benefits. Some plant compounds have direct antimicrobial activity against antibiotic-resistant bacteria, while others can sensitize resistant bacteria against antibiotics, reversing the resistance as mentioned and exemplified in the previous section. Some of these NPs can enhance the effect of antibiotics in different ways, such as facilitating their entry into the cell by destabilizing the cytoplasmic membrane [<xref rid="B153-biomedicines-08-00405" ref-type="bibr">153</xref>,<xref rid="B154-biomedicines-08-00405" ref-type="bibr">154</xref>], inhibiting efflux pumps (EPs) [<xref rid="B155-biomedicines-08-00405" ref-type="bibr">155</xref>] or dispersing biofilms [<xref rid="B156-biomedicines-08-00405" ref-type="bibr">156</xref>] among other mechanisms of action (<xref ref-type="fig" rid="biomedicines-08-00405-f004">Figure 4</xref>). Some of the synergistic interactions between phytochemicals and antibiotics include increased efficiency, lower antibiotic doses, reduced side effects, increased bioavailability and increased stability [<xref rid="B157-biomedicines-08-00405" ref-type="bibr">157</xref>]. The multidimensional and multifactorial activity of phytochemicals studied by network pharmacology is crucial for synergy with clinical antibiotics, opening the door to many different potential combinations. Moreover, the use of molecules that have already passed the relevant clinical controls, as in the case of antibiotics, in combination with innocuous natural compounds facilitates the process of research and development of new potential therapies [<xref rid="B158-biomedicines-08-00405" ref-type="bibr">158</xref>].</p><p>There is clear evidence of NPs capable of inhibiting efflux pumps of AMR bacteria, specifically, phytochemicals. These molecules can inhibit various efflux pumps in different pathogenic bacterial species, both Gram-positive and Gram-negative. As an example, the NorA efflux pump of <italic>S. aureus</italic> SA-1199-B has been effectively inhibited using baicalein plant molecules [<xref rid="B159-biomedicines-08-00405" ref-type="bibr">159</xref>], capsaicin [<xref rid="B160-biomedicines-08-00405" ref-type="bibr">160</xref>], indirubin [<xref rid="B161-biomedicines-08-00405" ref-type="bibr">161</xref>], kaempferol rhamnoside [<xref rid="B162-biomedicines-08-00405" ref-type="bibr">162</xref>] and olympicin A [<xref rid="B163-biomedicines-08-00405" ref-type="bibr">163</xref>]. NorA of <italic>S. aureus</italic> NCTC 8325-4 was inhibited using sarothrin [<xref rid="B164-biomedicines-08-00405" ref-type="bibr">164</xref>]. Cumin demonstrated antimicrobial activity on its own and also resistance modulation properties against MRSA by inhibiting LmrS efflux pump [<xref rid="B155-biomedicines-08-00405" ref-type="bibr">155</xref>]. Plant molecules inhibiting the ethidium bromide efflux pump (EtBr) have also been found: 1&#x02032;-S-1&#x02032;-acetoxyeugenol acetate inhibits it in <italic>Mycobacterium smegmatis</italic> [<xref rid="B165-biomedicines-08-00405" ref-type="bibr">165</xref>], catechol and catharanthine inhibits it in <italic>P. aeruginosa</italic> [<xref rid="B166-biomedicines-08-00405" ref-type="bibr">166</xref>,<xref rid="B167-biomedicines-08-00405" ref-type="bibr">167</xref>] and galotannins inhibit it in MDR uropathogenic <italic>E. coli</italic> [<xref rid="B168-biomedicines-08-00405" ref-type="bibr">168</xref>]. The Yojl efflux pump of MDR <italic>E. coli</italic> has been shown to be inhibited by molecules such as 4-hydroxy&#x02014;tetralone, ursolic acid and its derivatives [<xref rid="B169-biomedicines-08-00405" ref-type="bibr">169</xref>] and lysergol [<xref rid="B170-biomedicines-08-00405" ref-type="bibr">170</xref>]. Berberine and palmatine inhibit MexAB-OprM from clinical isolates of MDR <italic>P. aeruginosa</italic> [<xref rid="B171-biomedicines-08-00405" ref-type="bibr">171</xref>]. There are also complete extracts of plants with EPs inhibitory activity with clear synergistic effects with antibiotics in the treatment of MDR bacterial infections. The extract made from <italic>Rhus coriaria</italic> seeds have shown an obvious synergistic effect with oxytetracycline, penicillin G, cephalexin, sulfadimethoxine and enrofloxacin against MDR clinical isolates of <italic>P. aeruginosa</italic>. This effect is mainly attributed to the inhibitory capacity of EPs of the phytochemicals present in the extract [<xref rid="B172-biomedicines-08-00405" ref-type="bibr">172</xref>]. The activity of these plant molecules as inhibitors of microbial efflux pumps can act as restorers of antimicrobial susceptibility and open the door to combined antibiotic treatments, since these could exert their action more easily by not being expelled from the bacterial interior, allowing relive obsolete or discarded therapies due to this resistance mechanism [<xref rid="B173-biomedicines-08-00405" ref-type="bibr">173</xref>]. A catechin, (-)-epigallocatechin gallate (EGCg), has shown sensitizing activity in <italic>S. aureus</italic> against tetracycline by inhibiting EPs such as Tet (K), increasing intracellular retention of the antibiotic and enhancing its effect [<xref rid="B174-biomedicines-08-00405" ref-type="bibr">174</xref>]. Stilbenes also act as EPs inhibitors against antibiotic-resistant <italic>Arcobacter butzleri</italic>, reducing its resistance. Resveratrol and pinosylvin have also shown activity as resistance modulators being able to even reverse the resistance completely [<xref rid="B175-biomedicines-08-00405" ref-type="bibr">175</xref>].</p><p>There are studies that state that certain polyphenols, such as catechins, can enter deeply into the structure of the lipid bilayer of bacterial membranes, causing significant thermotropic changes. Lipophilic hydrocarbons present in plant extracts are known to destabilize the cellular structure of the cytoplasmic membrane, increase its permeability and interact with hydrophobic portions of proteins [<xref rid="B176-biomedicines-08-00405" ref-type="bibr">176</xref>]. This could explain the potentiation in the effect of certain antibiotics against resistant bacteria, as these compounds could increase antibiotic intake and interact with resistance proteins, hindering their activity. Specifically, (-)-epicatechin gallate (ECg) has a great affinity for the staphylococcal wall and its binding to it produces biophysical changes in it that are capable of dispersing the biosynthetic machinery responsible for resistance to &#x003b2;-lactam antibiotics [<xref rid="B177-biomedicines-08-00405" ref-type="bibr">177</xref>]. This activity would explain the restoration of the sensitivity of bacteria resistant to traditional antibiotics through the use of polyphenolic compounds capable of interacting with bacterial membranes, as in the case of catechins capable of sensitizing MRSA against oxacillin and other &#x003b2;-lactam antibiotics thanks to its ability to integrate and interact with the cell membrane [<xref rid="B178-biomedicines-08-00405" ref-type="bibr">178</xref>,<xref rid="B179-biomedicines-08-00405" ref-type="bibr">179</xref>]. </p><p>Plant extracts are also capable of exert antimicrobial activity against AMR bacteria and synergize with antibiotics. For instance, extracts of <italic>Duabanga grandiflora</italic> can restore MRSA&#x02019;s sensitivity to ampicillin. The mechanism proposed by the researchers is that the components of this extract can decrease the expression of the mecA gene that gives rise to the resistance protein PBP2a [<xref rid="B180-biomedicines-08-00405" ref-type="bibr">180</xref>]. Extracts of <italic>Acacia nilotica</italic>, <italic>Syzygium aromaticum</italic> and <italic>Cinnamum zeylanicum</italic> exhibited antimicrobial capacity against a panel of AMR bacteria including clinical isolates and ATCC strains. Extract of <italic>A. nilotica</italic> showed MIC values as low as 9.75 &#x000b5;g/mL against <italic>K. pneumoniae</italic> ATCC-700803, <italic>Salmonella typhimurium</italic> ATCC-13311 and <italic>E. faecalis</italic> ATCC-29212 [<xref rid="B181-biomedicines-08-00405" ref-type="bibr">181</xref>]. Extracts of <italic>Salvia spp</italic>. and <italic>Matricaria recutita</italic> have shown great synergy with the antibiotic oxacillin [<xref rid="B182-biomedicines-08-00405" ref-type="bibr">182</xref>]. The multifactorial and multi-target character of the compounds that make up plant extracts can hinder the development of resistance by bacteria [<xref rid="B80-biomedicines-08-00405" ref-type="bibr">80</xref>]. The molecular promiscuity of polyphenols, their multarget activity, the possibility of obtaining complex extracts containing multiple different polyphenols, and their synergistic effect in combined use with clinical antibiotics make natural antimicrobial compounds of plant origin ideal tools to be studied from the point of view of network pharmacology in the future. The evidence found in the combination studies between plant extracts and clinical antibiotics shows a synergistic enhancement that may be key to the fight against AMR bacteria. Although the development of new synthetic antibiotics is essential to continue the fight, the sensitization of resistant bacteria by phytochemicals is also crucial to achieving effective and long-lasting therapies [<xref rid="B158-biomedicines-08-00405" ref-type="bibr">158</xref>].</p><p>Infections caused by bacteria forming biofilms are extremely difficult to treat and are much less susceptible to antibiotics [<xref rid="B183-biomedicines-08-00405" ref-type="bibr">183</xref>,<xref rid="B184-biomedicines-08-00405" ref-type="bibr">184</xref>]. One way to enhance the effect of an antimicrobial agent is to disrupt the biofilm that certain resistant bacteria form. Studies on <italic>P. aeruginosa</italic> showed that many natural products can inhibit biofilm formation or disrupt the previously formed biofilm: alginate lyase [<xref rid="B185-biomedicines-08-00405" ref-type="bibr">185</xref>], ursolic acid [<xref rid="B186-biomedicines-08-00405" ref-type="bibr">186</xref>], zingerone [<xref rid="B187-biomedicines-08-00405" ref-type="bibr">187</xref>], cranberry proanthocyanidins [<xref rid="B188-biomedicines-08-00405" ref-type="bibr">188</xref>], casbane diterpene [<xref rid="B189-biomedicines-08-00405" ref-type="bibr">189</xref>], manoalide [<xref rid="B190-biomedicines-08-00405" ref-type="bibr">190</xref>], solenopsin A [<xref rid="B191-biomedicines-08-00405" ref-type="bibr">191</xref>], catechin [<xref rid="B192-biomedicines-08-00405" ref-type="bibr">192</xref>], naringenin [<xref rid="B193-biomedicines-08-00405" ref-type="bibr">193</xref>], ajoene [<xref rid="B194-biomedicines-08-00405" ref-type="bibr">194</xref>], rosmarinic acid [<xref rid="B195-biomedicines-08-00405" ref-type="bibr">195</xref>], eugenol [<xref rid="B196-biomedicines-08-00405" ref-type="bibr">196</xref>], bergamottin [<xref rid="B197-biomedicines-08-00405" ref-type="bibr">197</xref>], emodin [<xref rid="B198-biomedicines-08-00405" ref-type="bibr">198</xref>] and baicalein [<xref rid="B199-biomedicines-08-00405" ref-type="bibr">199</xref>] among others. These natural biofilm disrupting compounds could be a very valuable tool to be incorporated into joint therapies with traditional antibiotics when treating infections caused by AMR bacteria. For example, cranberry proanthocyanidins enhanced the activity of gentamicin in an in vivo model of infection using <italic>Galleria mellonella</italic> [<xref rid="B188-biomedicines-08-00405" ref-type="bibr">188</xref>]. In addition, some of these compounds have intrinsic antimicrobial activity on its own, which could further increase the potency of the treatment.</p></sec><sec id="sec3dot4-biomedicines-08-00405"><title>3.4. Development of Resistance to Natural Products</title><p>Historically, bacteria have managed to develop resistance to a greater or lesser extent against most antimicrobial agents used in medicine. Nevertheless, the ability of bacteria to develop a resistance mechanism against natural products is not well documented [<xref rid="B200-biomedicines-08-00405" ref-type="bibr">200</xref>]. Due to the huge chemical and structural diversity among antimicrobial products of natural origin, it is often stated the difficulty for bacteria to avoid the action of NPs [<xref rid="B201-biomedicines-08-00405" ref-type="bibr">201</xref>,<xref rid="B202-biomedicines-08-00405" ref-type="bibr">202</xref>]. However, there are some recent studies that suggest that bacteria can develop certain levels of resistance against plant compounds, especially enteric bacteria [<xref rid="B203-biomedicines-08-00405" ref-type="bibr">203</xref>]. The mechanisms of resistance behind these observations remain unknown and literature on the subject is scarce.</p><p>There are multiple mechanisms by which a bacterium can get rid of the action of an antimicrobial molecule: target alterations, expulsion or modification of the antibiotic, inactivation, reduced permeability and biofilm formation among others [<xref rid="B204-biomedicines-08-00405" ref-type="bibr">204</xref>]. These resistant mechanisms can be spontaneously developed (mutations) or acquired (by transduction, transfection or conjugation processes) as shown in <xref ref-type="fig" rid="biomedicines-08-00405-f005">Figure 5</xref>. Understanding the mechanism by which bacteria can circumvent the action of antibiotics and how they acquire these capabilities is crucial to developing effective and lasting therapies. </p><p>Depending on their properties, some products are more susceptible than others to the appearance of bacteria resistant to them. Molecules that attack highly conserved targets are less conducive to the appearance of bacteria with mutations in said targets that confer resistance to the antimicrobial in question, since modifying one or more fundamental routes or targets can imply an unbearable fitness cost for the bacteria [<xref rid="B205-biomedicines-08-00405" ref-type="bibr">205</xref>]. </p><p>On the other hand, molecules against less conserved molecular targets are more likely to promote the development of resistance mechanisms against them. Modification of less evolutionarily conserved or non-essential targets is easier for bacteria to assimilate since they have greater flexibility to modify the molecular target or adapt their metabolism without paying a high fitness cost. Although the acquisition of antimicrobial resistance mechanisms is often accompanied by reduced fitness in the absence of a selective environment, this loss of adaptive efficacy can be counteracted by compensatory mutations or modifications in epistasis [<xref rid="B206-biomedicines-08-00405" ref-type="bibr">206</xref>].</p><p>Thanks to the multifactorial nature of the molecular promiscuity of naturally occurring antimicrobial compounds, bacteria experience difficulties in changing several molecular targets simultaneously [<xref rid="B80-biomedicines-08-00405" ref-type="bibr">80</xref>]. Multiple simultaneous molecular changes in a bacterium to overcome the action of a multifactorial antimicrobial agent would very negatively affect its metabolism, that is, it would have a high fitness cost potentially unacceptable for its development. Likewise, mutations that carry a high fitness cost are less likely to persist in bacterial populations once the selective pressure disappears [<xref rid="B207-biomedicines-08-00405" ref-type="bibr">207</xref>]. This cost would be higher if the molecular targets of the antimicrobial were highly evolutionary conserved molecules or routes, since they would be more difficult to change while maintaining the metabolic efficiency necessary for survival and competition with other living beings. Furthermore, there are studies that affirm that many of the natural antimicrobial compounds attack macromolecular structures such as the membrane or the bacterial wall and that this fact could hinder the appearance of resistance, given that they are very difficult targets to vary as a whole [<xref rid="B208-biomedicines-08-00405" ref-type="bibr">208</xref>,<xref rid="B209-biomedicines-08-00405" ref-type="bibr">209</xref>].</p><p>Despite the multiple possible mechanisms for acquiring existing resistances, the use of new technologies in NPs can help prevent their development. Based on new laboratory bacterial culture techniques, it has been possible to identify and isolate interesting natural compounds such as teixobactin. This molecule displays a mechanism of action that is capable of using the bacteria&#x02019;s own machinery to kill itself, in a similar way to how vancomycin, a really successful antibiotic, works. No resistant mutants have been found against teixobactin. Theoretically, the generation of resistant mutants to this compound is difficult, since its target is very conserved among the eubacteria, in addition to being exposed in the outermost part of Gram-positive bacteria. In addition, as teixobactin is produced by a Gram-negative bacterium, the molecule cannot re-enter the cell and exert its action due to the presence of the outer envelope characteristic of Gram-negative bacteria. This fact is crucial in the process of the eventual development of resistance, since the producing microorganism does not use a different metabolic route to avoid the action of the antibiotic it produces. Thus, in the absence of an intrinsic resistance mechanism in the producer, horizontal transfer of resistance genes to other species susceptible to teixobactin cannot occur [<xref rid="B55-biomedicines-08-00405" ref-type="bibr">55</xref>].</p><p>Vancomycin, discovered in 1958, enjoyed a period of 30 years in which no bacterium resistant to its antibiotic action was identified, thanks to its potent and unusual mechanism of action. However, during the last 20 years, <italic>S. aureus</italic> strains resistant to this antibiotic have been detected [<xref rid="B210-biomedicines-08-00405" ref-type="bibr">210</xref>]. One of the resistance mechanisms identified is the incorporation of D-Ala-D-lactate instead of the usual D-Ala-D-Ala at the dipeptide termini of nascent peptidoglycan, considerably reducing its binding affinity and formation disruption capacity of the bacterial wall. Other resistant strains identified have a thicker cell wall with free D-Ala-D-Ala ends that can sequester vancomycin and removing it from the place where the biosynthesis of the wall occurs [<xref rid="B211-biomedicines-08-00405" ref-type="bibr">211</xref>]. Despite the emergence of these and other resistance mechanisms, researchers are currently working on vancomycin derivatives that have promising qualities that allow them to circumvent these resistance mechanisms and exert their antibiotic action. An example of this is the discovery of a new vancomycin resistance mechanism mediated by the activity of Atl amidase. This inhibition produces cellular morphological changes that reduce the action of vancomycin on the main target in the biosynthesis of the wall, increasing the tolerance of the pathogen against the antibiotic without any changes at the genetic level. The discovery of this target opens the door to the design of derivatives of vancomycin with a reduced affinity for Atl, resulting in greater efficacy against MRSA [<xref rid="B46-biomedicines-08-00405" ref-type="bibr">46</xref>]. Another resistance mechanism found in <italic>S. aureus</italic> against vancomycin is based on the thickening of the bacterial wall, which slows the penetration of vancomycin into the bacteria [<xref rid="B212-biomedicines-08-00405" ref-type="bibr">212</xref>].</p><p>A possible strategy to prevent or slow the appearance of antimicrobial-resistant bacteria is the combined use of various agents that act against different molecular targets. In this way, the bacteria will have to adopt different resistance mechanisms, which would imply a greater and less likely adaptive cost. This hypothesis could support the use of plant extracts and essential oils in traditional medicine used for millennia, since these may be composed of dozens of different phytochemicals with different mechanisms of action. The combined activity of these molecules would hinder bacterial adaptation and extend the therapeutic shelf life of antimicrobial plant extracts.</p><p>Although the idea of the difficulty of acquiring resistance against complex plant extracts is widespread, some studies go in the opposite direction. It has been observed that certain antimicrobial extracts used against enterobacteria isolated from geckos from various environments in India have reduced effectiveness. The authors attribute this resistance to the variability and changing environment that has shaped the isolates collected and used in the assay. They suggest that exposure of geckos to medicinal plants may have caused a process of selecting the bacteria present in them, resulting in strains more resistant to plant compounds [<xref rid="B203-biomedicines-08-00405" ref-type="bibr">203</xref>]. Mechanisms of possible resistance are not mentioned.</p></sec><sec id="sec3dot5-biomedicines-08-00405"><title>3.5. New Methodologies to Find Antimicrobial Compounds against AMR Bacteria</title><p>Currently, there are many methodologies capable of having a very positive impact on the discovery of new natural molecules with antimicrobial capacity against AMR bacteria. Some of these methodologies are the use of -omics technologies, network pharmacology, synergy studies and in silico trials.</p><p>Thanks to the -omics technologies, today it is known that genomes of bacteria such as actinomycetes are much more complex than previously thought in the mid-twentieth century and that there are multiple secondary metabolite gene clusters (SMGCs) that could produce new NPs. It is estimated that under the conditions of the classic fermentation studies for NP isolation, less than 10% of the SMGCs are active, which could be activated using genetic techniques and varying the culture conditions to reveal potential new NPs hidden inside of the &#x0201c;biosynthetic dark matter&#x0201d; [<xref rid="B213-biomedicines-08-00405" ref-type="bibr">213</xref>]. By combining the progressive lowering of the massive sequencing of bacterial genomes and the advancement of the analysis and prediction software it will be possible to identify new SMGCs and their products [<xref rid="B214-biomedicines-08-00405" ref-type="bibr">214</xref>,<xref rid="B215-biomedicines-08-00405" ref-type="bibr">215</xref>]. The discovery and deepening of knowledge of NP-producing modular macroenzymes such as non-ribosomal peptide synthetases and polyketyde synthetases open the door to new NPs production strategies based on combinatorial biosynthesis [<xref rid="B15-biomedicines-08-00405" ref-type="bibr">15</xref>]. Scientists now have greater access to soil samples and other potential sources of NPs, which significantly increases the likelihood of finding new compounds. The use of non-laboratory-dependent metagenomic techniques and the heterologous expression of DNA extracted directly from complex samples will allow the identification and production of new NPs hitherto unknown or impossible to produce [<xref rid="B216-biomedicines-08-00405" ref-type="bibr">216</xref>]. </p><p>Other new technologies such as molecular docking or virtual simulations open the door to the effective discovery of new natural antimicrobial compounds unknown so far using computers [<xref rid="B76-biomedicines-08-00405" ref-type="bibr">76</xref>,<xref rid="B217-biomedicines-08-00405" ref-type="bibr">217</xref>]. In silico assays allow hundreds of thousands of molecules to be screened to efficiently select leaders, greatly reducing the cost of new drug development processes. Prediction via molecular docking or virtual simulation makes it possible to predict the interactions of a molecule with its target, obtaining huge amounts of valuable information and allowing the screening of drug libraries in a short time if the necessary computing capacity is available [<xref rid="B218-biomedicines-08-00405" ref-type="bibr">218</xref>,<xref rid="B219-biomedicines-08-00405" ref-type="bibr">219</xref>].</p><p>Emerging studies based on network pharmacology that expand the classic single-ligand-target viewpoint provide excellent opportunities for the development of new antimicrobial compounds. The study of the network pharmacology of phytochemicals based on their molecular promiscuity and multi-target capacity can help to better understand their antimicrobial mechanisms of action and to develop more effective therapies [<xref rid="B220-biomedicines-08-00405" ref-type="bibr">220</xref>]. In turn, this point also has a positive impact on synergy studies between antibiotics and phytochemicals such as those described in the previous sections, and they are currently showing such good results.</p></sec></sec><sec sec-type="conclusions" id="sec4-biomedicines-08-00405"><title>4. Conclusions and Future Perspectives</title><p>In conclusion, most NPs do not have sufficient therapeutic power to perform monotherapies based on them against antibiotic resistant bacteria, however, their joint application in combination therapy with traditional antibiotics could contribute to enhance their effect, reduce their dosage, side effects and improve its pharmacokinetics and pharmacodynamics properties. Natural antimicrobial products offer a promising avenue of study in the field of antibiotic development thanks to their unique properties, natural availability and enormous chemical diversity. The prospects in the discovery of new NPs with antibiotic activity are very positive. There is a tendency to revise the traditional sources of NPs that offered such good results during the &#x0201c;Golden Age&#x0201d; [<xref rid="B221-biomedicines-08-00405" ref-type="bibr">221</xref>]. The use of new technologies and applications of non-existent knowledge during that age opens the door to the second era of massive discovery of molecules with remarkable and novel biological activity against AMR bacteria.</p></sec></body><back><notes><title>Author Contributions</title><p>Conceptualization, F.J.&#x000c1;.-M., E.B.-C. and V.M.; methodology, F.J.&#x000c1;.-M.; investigation, F.J.&#x000c1;.-M.; data curation, F.J.&#x000c1;.-M., E.B.-C. and V.M.; writing&#x02014;original draft preparation, F.J.&#x000c1;.-M.; writing&#x02014;review and editing, F.J.&#x000c1;.-M., E.B.-C. and V.M.; visualization, F.J.&#x000c1;.-M., E.B.-C. and V.M.; supervision, E.B.-C. and V.M.; project administration, E.B.-C. and V.M.; funding acquisition, E.B.-C. and V.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>We thank grants RTI2018-096724-B-C21 from the Spanish Ministry of Economy and Competitiveness (MINECO); PROMETEO/2016/006, from Generalitat Valenciana; CIBER (CB12/03/30038, Fisiopatologia de la Obesidad y la Nutricion, CIBERobn, Instituto de Salud Carlos III) and the &#x0201c;Aid for the support to the training of research staff&#x0201d; of the Miguel Hern&#x000e1;ndez University of Elche (resolution 0236/17).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-biomedicines-08-00405"><label>1.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>IHME</collab><collab>GBD</collab></person-group><article-title>The Review on Antimicrobial Resistance</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://amr-review.org/">https://amr-review.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-20">(accessed on 20 May 2020)</date-in-citation></element-citation></ref><ref id="B2-biomedicines-08-00405"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goossens</surname><given-names>H.</given-names></name></person-group><article-title>The chennai declaration on antimicrobial resistance in india</article-title><source>Lancet Infect. Dis.</source><year>2013</year><volume>13</volume><fpage>105</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(12)70346-8</pub-id><pub-id pub-id-type="pmid">23347623</pub-id></element-citation></ref><ref id="B3-biomedicines-08-00405"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sultan</surname><given-names>I.</given-names></name><name><surname>Rahman</surname><given-names>S.</given-names></name><name><surname>Jan</surname><given-names>A.T.</given-names></name><name><surname>Siddiqui</surname><given-names>M.T.</given-names></name><name><surname>Mondal</surname><given-names>A.H.</given-names></name><name><surname>Haq</surname><given-names>Q.M.R.</given-names></name></person-group><article-title>Antibiotics, resistome and resistance mechanisms: A bacterial perspective</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2066</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02066</pub-id><?supplied-pmid 30298054?><pub-id pub-id-type="pmid">30298054</pub-id></element-citation></ref><ref id="B4-biomedicines-08-00405"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daubin</surname><given-names>V.</given-names></name><name><surname>Szollosi</surname><given-names>G.J.</given-names></name></person-group><article-title>Horizontal gene transfer and the history of life</article-title><source>Cold Spring Harb Perspect. Biol.</source><year>2016</year><volume>8</volume><fpage>a018036</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a018036</pub-id><?supplied-pmid 26801681?><pub-id pub-id-type="pmid">26801681</pub-id></element-citation></ref><ref id="B5-biomedicines-08-00405"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munita</surname><given-names>J.M.</given-names></name><name><surname>Arias</surname><given-names>C.A.</given-names></name></person-group><article-title>Mechanisms of antibiotic resistance</article-title><source>Microbiol. Spectr.</source><year>2016</year><volume>4</volume><fpage>481</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.VMBF-0016-2015</pub-id></element-citation></ref><ref id="B6-biomedicines-08-00405"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>A.</given-names></name></person-group><article-title>Epistasis and the evolution of antimicrobial resistance</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>246</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.00246</pub-id><pub-id pub-id-type="pmid">28261193</pub-id></element-citation></ref><ref id="B7-biomedicines-08-00405"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>L.</given-names></name><name><surname>Pelin</surname><given-names>A.</given-names></name><name><surname>Phan</surname><given-names>M.</given-names></name><name><surname>Wong</surname><given-names>A.</given-names></name></person-group><article-title>The effect of environmental heterogeneity on the fitness of antibiotic resistance mutations in <italic>Escherichia coli</italic></article-title><source>Evol. Ecol.</source><year>2020</year><volume>34</volume><fpage>379</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1007/s10682-019-10027-y</pub-id></element-citation></ref><ref id="B8-biomedicines-08-00405"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>J.</given-names></name><name><surname>Davies</surname><given-names>D.</given-names></name></person-group><article-title>Origins and evolution of antibiotic resistance</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2010</year><volume>74</volume><fpage>417</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00016-10</pub-id><pub-id pub-id-type="pmid">20805405</pub-id></element-citation></ref><ref id="B9-biomedicines-08-00405"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiltunen</surname><given-names>T.</given-names></name><name><surname>Virta</surname><given-names>M.</given-names></name><name><surname>Laine</surname><given-names>A.L.</given-names></name></person-group><article-title>Antibiotic resistance in the wild: An eco-evolutionary perspective</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><year>2017</year><volume>372</volume><fpage>20160039</fpage><pub-id pub-id-type="doi">10.1098/rstb.2016.0039</pub-id></element-citation></ref><ref id="B10-biomedicines-08-00405"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>A.</given-names></name></person-group><article-title>Unknown risk on the farm: Does agricultural use of ionophores contribute to the burden of antimicrobial resistance?</article-title><source>mSphere</source><year>2019</year><volume>4</volume><fpage>e00433-19</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00433-19</pub-id><pub-id pub-id-type="pmid">31554722</pub-id></element-citation></ref><ref id="B11-biomedicines-08-00405"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machowska</surname><given-names>A.</given-names></name><name><surname>Stalsby Lundborg</surname><given-names>C.</given-names></name></person-group><article-title>Drivers of irrational use of antibiotics in Europe</article-title><source>Int. J. Environ. Res. Public Health</source><year>2018</year><volume>16</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph16010027</pub-id></element-citation></ref><ref id="B12-biomedicines-08-00405"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Towse</surname><given-names>A.</given-names></name><name><surname>Hoyle</surname><given-names>C.K.</given-names></name><name><surname>Goodall</surname><given-names>J.</given-names></name><name><surname>Hirsch</surname><given-names>M.</given-names></name><name><surname>Mestre-Ferrandiz</surname><given-names>J.</given-names></name><name><surname>Rex</surname><given-names>J.H.</given-names></name></person-group><article-title>Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation</article-title><source>Health Policy</source><year>2017</year><volume>121</volume><fpage>1025</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.healthpol.2017.07.011</pub-id><?supplied-pmid 28888660?><pub-id pub-id-type="pmid">28888660</pub-id></element-citation></ref><ref id="B13-biomedicines-08-00405"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabtu</surname><given-names>N.</given-names></name><name><surname>Enoch</surname><given-names>D.A.</given-names></name><name><surname>Brown</surname><given-names>N.M.</given-names></name></person-group><article-title>Antibiotic resistance: What, why, where, when and how?</article-title><source>Br. Med. Bull.</source><year>2015</year><volume>116</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1093/bmb/ldv041</pub-id><?supplied-pmid 26491083?><pub-id pub-id-type="pmid">26491083</pub-id></element-citation></ref><ref id="B14-biomedicines-08-00405"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>EUCAST</collab></person-group><article-title>Determination of minimum inhibitory concentrations (mics) of antibacterial agents by broth dilution</article-title><source>Clin. Microbiol. Infect.</source><year>2003</year><volume>9</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12691538</pub-id></element-citation></ref><ref id="B15-biomedicines-08-00405"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>L.</given-names></name><name><surname>Baltz</surname><given-names>R.H.</given-names></name></person-group><article-title>Natural product discovery: Past, present, and future</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2016</year><volume>43</volume><fpage>155</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1007/s10295-015-1723-5</pub-id><?supplied-pmid 26739136?><pub-id pub-id-type="pmid">26739136</pub-id></element-citation></ref><ref id="B16-biomedicines-08-00405"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berdy</surname><given-names>J.</given-names></name></person-group><article-title>Thoughts and facts about antibiotics: Where we are now and where we are heading</article-title><source>J. Antibiot.</source><year>2012</year><volume>65</volume><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1038/ja.2012.27</pub-id><?supplied-pmid 22511224?><pub-id pub-id-type="pmid">22511224</pub-id></element-citation></ref><ref id="B17-biomedicines-08-00405"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-On</surname><given-names>Y.M.</given-names></name><name><surname>Phillips</surname><given-names>R.</given-names></name><name><surname>Milo</surname><given-names>R.</given-names></name></person-group><article-title>The biomass distribution on earth</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>6506</fpage><lpage>6511</lpage><pub-id pub-id-type="doi">10.1073/pnas.1711842115</pub-id><pub-id pub-id-type="pmid">29784790</pub-id></element-citation></ref><ref id="B18-biomedicines-08-00405"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthamilarasan</surname><given-names>M.</given-names></name><name><surname>Prasad</surname><given-names>M.</given-names></name></person-group><article-title>Plant innate immunity: An updated insight into defense mechanism</article-title><source>J. Biosci.</source><year>2013</year><volume>38</volume><fpage>433</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1007/s12038-013-9302-2</pub-id><pub-id pub-id-type="pmid">23660678</pub-id></element-citation></ref><ref id="B19-biomedicines-08-00405"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tapsell</surname><given-names>C.L.</given-names></name><name><surname>Hemphill</surname><given-names>I.</given-names></name><name><surname>Cobiac</surname><given-names>L.</given-names></name></person-group><article-title>Health benefits of herbs and spices: The past, the present, the future</article-title><source>MJA</source><year>2006</year><volume>185</volume><fpage>S1</fpage><lpage>S24</lpage><pub-id pub-id-type="doi">10.5694/j.1326-5377.2006.tb00548.x</pub-id><pub-id pub-id-type="pmid">17022438</pub-id></element-citation></ref><ref id="B20-biomedicines-08-00405"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leja</surname><given-names>K.B.</given-names></name><name><surname>Czaczyk</surname><given-names>K.</given-names></name></person-group><article-title>The industrial potential of herbs and spices&#x02014;A mini review</article-title><source>Acta Sci. Pol. Technol. Aliment.</source><year>2016</year><volume>15</volume><fpage>353</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.17306/J.AFS.2016.4.34</pub-id><pub-id pub-id-type="pmid">28071013</pub-id></element-citation></ref><ref id="B21-biomedicines-08-00405"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>H.</given-names></name><name><surname>Scholl</surname><given-names>R.</given-names></name><name><surname>Aigner</surname><given-names>A.</given-names></name></person-group><article-title>Ricin and ricinus communis in pharmacology and toxicology-from ancient use and &#x0201c;papyrus ebers&#x0201d; to modern perspectives and &#x0201c;poisonous plant of the year 2018&#x0201d;</article-title><source>Naunyn Schmiedebergs Arch. Pharm.</source><year>2019</year><volume>392</volume><fpage>1181</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1007/s00210-019-01691-6</pub-id></element-citation></ref><ref id="B22-biomedicines-08-00405"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwivedi</surname><given-names>G.</given-names></name><name><surname>Shridhar</surname><given-names>D.</given-names></name></person-group><article-title>Sushruta&#x02014;The clinician&#x02014;Teacher par excellence</article-title><source>Indian J. Chest Dis. Allied Sci.</source><year>2007</year><volume>49</volume><fpage>243</fpage><lpage>244</lpage></element-citation></ref><ref id="B23-biomedicines-08-00405"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name><name><surname>Sundaram</surname><given-names>C.</given-names></name><name><surname>Malani</surname><given-names>N.</given-names></name><name><surname>Ichikawa</surname><given-names>H.</given-names></name></person-group><article-title>Curcumin: The indian solid gold</article-title><source>The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease</source><person-group person-group-type="editor"><name><surname>Aggarwal</surname><given-names>B.B.</given-names></name><name><surname>Surh</surname><given-names>Y.-J.</given-names></name><name><surname>Shishodia</surname><given-names>S.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>Boston, MA, USA</publisher-loc><year>2007</year><volume>Volume 595</volume></element-citation></ref><ref id="B24-biomedicines-08-00405"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodruff</surname><given-names>H.B.</given-names></name></person-group><article-title>Selman A. Waksman, winner of the 1952 nobel prize for physiology or medicine</article-title><source>Appl. Environ. Microbiol.</source><year>2014</year><volume>80</volume><fpage>2</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1128/AEM.01143-13</pub-id><?supplied-pmid 24162573?><pub-id pub-id-type="pmid">24162573</pub-id></element-citation></ref><ref id="B25-biomedicines-08-00405"><label>25.</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Kurt</surname><given-names>E.L.</given-names></name></person-group><article-title>Small World Initiative</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.smallworldinitiative.org/">http://www.smallworldinitiative.org/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-08-05">(accessed on 5 August 2020)</date-in-citation></element-citation></ref><ref id="B26-biomedicines-08-00405"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>K.</given-names></name></person-group><article-title>Antibiotics: From prehistory to the present day</article-title><source>J. Antimicrob. Chemother.</source><year>2016</year><volume>71</volume><fpage>572</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv484</pub-id><?supplied-pmid 26851273?><pub-id pub-id-type="pmid">26851273</pub-id></element-citation></ref><ref id="B27-biomedicines-08-00405"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>L.</given-names></name></person-group><article-title>Natural products as a source of drug leads to overcome drug resistance</article-title><source>Future Microbiol.</source><year>2015</year><volume>10</volume><fpage>1711</fpage><lpage>1718</lpage><pub-id pub-id-type="doi">10.2217/fmb.15.67</pub-id><?supplied-pmid 26517443?><pub-id pub-id-type="pmid">26517443</pub-id></element-citation></ref><ref id="B28-biomedicines-08-00405"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrajon-Catalan</surname><given-names>E.</given-names></name><name><surname>Menendez-Gutierrez</surname><given-names>M.P.</given-names></name><name><surname>Falco</surname><given-names>A.</given-names></name><name><surname>Carrato</surname><given-names>A.</given-names></name><name><surname>Saceda</surname><given-names>M.</given-names></name><name><surname>Micol</surname><given-names>V.</given-names></name></person-group><article-title>Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their her2 expression level</article-title><source>Cancer Lett.</source><year>2010</year><volume>290</volume><fpage>192</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2009.09.010</pub-id><?supplied-pmid 19896266?><pub-id pub-id-type="pmid">19896266</pub-id></element-citation></ref><ref id="B29-biomedicines-08-00405"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falco</surname><given-names>A.</given-names></name><name><surname>Barraj&#x000f3;n-Catal&#x000e1;n</surname><given-names>E.</given-names></name><name><surname>Men&#x000e9;ndez-Guti&#x000e9;rrez</surname><given-names>M.P.</given-names></name><name><surname>Coll</surname><given-names>J.</given-names></name><name><surname>Micol</surname><given-names>V.</given-names></name><name><surname>Estepa</surname><given-names>A.</given-names></name></person-group><article-title>Melittin-loaded immunoliposomes against viral surface proteins, a new approach to antiviral therapy</article-title><source>Antivir. Res.</source><year>2013</year><volume>97</volume><fpage>218</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.12.004</pub-id><?supplied-pmid 23261846?><pub-id pub-id-type="pmid">23261846</pub-id></element-citation></ref><ref id="B30-biomedicines-08-00405"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>H.Y.</given-names></name><name><surname>Chowdhury</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>Y.D.</given-names></name><name><surname>Yu</surname><given-names>X.Q.</given-names></name></person-group><article-title>Insect antimicrobial peptides and their applications</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2014</year><volume>98</volume><fpage>5807</fpage><lpage>5822</lpage><pub-id pub-id-type="doi">10.1007/s00253-014-5792-6</pub-id><pub-id pub-id-type="pmid">24811407</pub-id></element-citation></ref><ref id="B31-biomedicines-08-00405"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Bang</surname><given-names>K.</given-names></name><name><surname>Kwon</surname><given-names>H.</given-names></name><name><surname>Cho</surname><given-names>S.</given-names></name></person-group><article-title>Enhanced antibacterial activity of an attacin-coleoptericin hybrid protein fused with a helical linker</article-title><source>Mol. Biol. Rep.</source><year>2013</year><volume>40</volume><fpage>3953</fpage><lpage>3960</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-2472-4</pub-id><pub-id pub-id-type="pmid">23271135</pub-id></element-citation></ref><ref id="B32-biomedicines-08-00405"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>S.M.</given-names></name><name><surname>Siddiqui</surname><given-names>R.</given-names></name><name><surname>Ong</surname><given-names>S.K.</given-names></name><name><surname>Shah</surname><given-names>M.R.</given-names></name><name><surname>Anwar</surname><given-names>A.</given-names></name><name><surname>Heard</surname><given-names>P.J.</given-names></name><name><surname>Khan</surname><given-names>N.A.</given-names></name></person-group><article-title>Identification and characterization of antibacterial compound(s) of cockroaches (<italic>Periplaneta americana</italic>)</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2017</year><volume>101</volume><fpage>253</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/s00253-016-7872-2</pub-id><pub-id pub-id-type="pmid">27743045</pub-id></element-citation></ref><ref id="B33-biomedicines-08-00405"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>S.</given-names></name><name><surname>Baptista</surname><given-names>C.</given-names></name><name><surname>Lim</surname><given-names>C.S.</given-names></name></person-group><article-title>Maggot metabolites and their combinatory effects with antibiotic on <italic>Staphylococcus aureus</italic></article-title><source>Ann. Clin. Microbiol. Antimicrob.</source><year>2011</year><volume>10</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1476-0711-10-6</pub-id><pub-id pub-id-type="pmid">21299858</pub-id></element-citation></ref><ref id="B34-biomedicines-08-00405"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwakman</surname><given-names>P.H.</given-names></name><name><surname>Te Velde</surname><given-names>A.A.</given-names></name><name><surname>de Boer</surname><given-names>L.</given-names></name><name><surname>Vandenbroucke-Grauls</surname><given-names>C.M.</given-names></name><name><surname>Zaat</surname><given-names>S.A.</given-names></name></person-group><article-title>Two major medicinal honeys have different mechanisms of bactericidal activity</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e17709</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017709</pub-id><?supplied-pmid 21394213?><pub-id pub-id-type="pmid">21394213</pub-id></element-citation></ref><ref id="B35-biomedicines-08-00405"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zabaiou</surname><given-names>N.</given-names></name><name><surname>Fouache</surname><given-names>A.</given-names></name><name><surname>Trousson</surname><given-names>A.</given-names></name><name><surname>Baron</surname><given-names>S.</given-names></name><name><surname>Zellagui</surname><given-names>A.</given-names></name><name><surname>Lahouel</surname><given-names>M.</given-names></name><name><surname>Lobaccaro</surname><given-names>J.A.</given-names></name></person-group><article-title>Biological properties of propolis extracts: Something new from an ancient product</article-title><source>Chem. Phys. Lipids</source><year>2017</year><volume>207</volume><fpage>214</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.chemphyslip.2017.04.005</pub-id><?supplied-pmid 28411017?><pub-id pub-id-type="pmid">28411017</pub-id></element-citation></ref><ref id="B36-biomedicines-08-00405"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>M.M.</given-names></name><name><surname>Richardson</surname><given-names>A.</given-names></name><name><surname>Sofian-Azirun</surname><given-names>M.</given-names></name></person-group><article-title>Antibacterial activity of propolis and honey against <italic>Staphylococcus aureus</italic> and <italic>Escherichia coli</italic></article-title><source>Afr. J. Microbiol. Res.</source><year>2010</year><volume>4</volume><fpage>1872</fpage><lpage>1878</lpage></element-citation></ref><ref id="B37-biomedicines-08-00405"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilikova</surname><given-names>K.</given-names></name><name><surname>Huang</surname><given-names>S.C.</given-names></name><name><surname>Lin</surname><given-names>I.P.</given-names></name><name><surname>Simuth</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>C.C.</given-names></name></person-group><article-title>Structure and antimicrobial activity relationship of royalisin, an antimicrobial peptide from royal jelly of <italic>Apis mellifera</italic></article-title><source>Peptides</source><year>2015</year><volume>68</volume><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2015.03.001</pub-id><pub-id pub-id-type="pmid">25784287</pub-id></element-citation></ref><ref id="B38-biomedicines-08-00405"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fratini</surname><given-names>F.</given-names></name><name><surname>Cilia</surname><given-names>G.</given-names></name><name><surname>Mancini</surname><given-names>S.</given-names></name><name><surname>Felicioli</surname><given-names>A.</given-names></name></person-group><article-title>Royal jelly: An ancient remedy with remarkable antibacterial properties</article-title><source>Microbiol. Res.</source><year>2016</year><volume>192</volume><fpage>130</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2016.06.007</pub-id><pub-id pub-id-type="pmid">27664731</pub-id></element-citation></ref><ref id="B39-biomedicines-08-00405"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memariani</surname><given-names>H.</given-names></name><name><surname>Memariani</surname><given-names>M.</given-names></name><name><surname>Shahidi-Dadras</surname><given-names>M.</given-names></name><name><surname>Nasiri</surname><given-names>S.</given-names></name><name><surname>Akhavan</surname><given-names>M.M.</given-names></name><name><surname>Moravvej</surname><given-names>H.</given-names></name></person-group><article-title>Melittin: From honeybees to superbugs</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2019</year><volume>103</volume><fpage>3265</fpage><lpage>3276</lpage><pub-id pub-id-type="doi">10.1007/s00253-019-09698-y</pub-id><pub-id pub-id-type="pmid">30824944</pub-id></element-citation></ref><ref id="B40-biomedicines-08-00405"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagheer</surname><given-names>M.</given-names></name><name><surname>Siddiqui</surname><given-names>R.</given-names></name><name><surname>Iqbal</surname><given-names>J.</given-names></name><name><surname>Khan</surname><given-names>N.A.</given-names></name></person-group><article-title>Black cobra (<italic>Naja naja karachiensis</italic>) lysates exhibit broad-spectrum antimicrobial activities</article-title><source>Pathog. Glob. Health</source><year>2014</year><volume>108</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1179/2047773214Y.0000000132</pub-id><pub-id pub-id-type="pmid">24625321</pub-id></element-citation></ref><ref id="B41-biomedicines-08-00405"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Hong</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>A.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Lai</surname><given-names>R.</given-names></name></person-group><article-title>Snake cathelicidin from <italic>Bungarus fasciatus</italic> is a potent peptide antibiotics</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e3217</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0003217</pub-id><pub-id pub-id-type="pmid">18795096</pub-id></element-citation></ref><ref id="B42-biomedicines-08-00405"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samy</surname><given-names>R.P.</given-names></name><name><surname>Kandasamy</surname><given-names>M.</given-names></name><name><surname>Gopalakrishnakone</surname><given-names>P.</given-names></name><name><surname>Stiles</surname><given-names>B.G.</given-names></name><name><surname>Rowan</surname><given-names>E.G.</given-names></name><name><surname>Becker</surname><given-names>D.</given-names></name><name><surname>Shanmugam</surname><given-names>M.K.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name><name><surname>Chow</surname><given-names>V.T.</given-names></name></person-group><article-title>Wound healing activity and mechanisms of action of an antibacterial protein from the venom of the eastern diamondback rattlesnake (<italic>Crotalus adamanteus</italic>)</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e80199</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0080199</pub-id><pub-id pub-id-type="pmid">24551028</pub-id></element-citation></ref><ref id="B43-biomedicines-08-00405"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>F.Y.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Q.X.</given-names></name><name><surname>Zeng</surname><given-names>C.L.</given-names></name><name><surname>Liu</surname><given-names>H.P.</given-names></name></person-group><article-title>Identification of an anti-lipopolysacchride factor possessing both antiviral and antibacterial activity from the red claw crayfish cherax quadricarinatus</article-title><source>Fish Shellfish Immunol.</source><year>2016</year><volume>57</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2016.08.037</pub-id><pub-id pub-id-type="pmid">27544268</pub-id></element-citation></ref><ref id="B44-biomedicines-08-00405"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Aponte</surname><given-names>C.A.</given-names></name><name><surname>Silva-Sanchez</surname><given-names>J.</given-names></name><name><surname>Quintero-Hernandez</surname><given-names>V.</given-names></name><name><surname>Rodriguez-Romero</surname><given-names>A.</given-names></name><name><surname>Balderas</surname><given-names>C.</given-names></name><name><surname>Possani</surname><given-names>L.D.</given-names></name><name><surname>Gurrola</surname><given-names>G.B.</given-names></name></person-group><article-title>Vejovine, a new antibiotic from the scorpion venom of vaejovis mexicanus</article-title><source>Toxicon</source><year>2011</year><volume>57</volume><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2010.10.008</pub-id><?supplied-pmid 20969885?><pub-id pub-id-type="pmid">20969885</pub-id></element-citation></ref><ref id="B45-biomedicines-08-00405"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruniera</surname><given-names>F.R.</given-names></name><name><surname>Ferreira</surname><given-names>F.M.</given-names></name><name><surname>Saviolli</surname><given-names>L.R.M.</given-names></name><name><surname>Bacci</surname><given-names>M.R.</given-names></name><name><surname>Feder</surname><given-names>D.</given-names></name><name><surname>Pedreira</surname><given-names>M.</given-names></name><name><surname>Peterlini</surname><given-names>M.A.</given-names></name><name><surname>Azzalis</surname><given-names>L.A.</given-names></name><name><surname>Junqueira</surname><given-names>V.B.</given-names></name><name><surname>Fonseca</surname><given-names>F.L.A.</given-names></name></person-group><article-title>The use of vancomycin with its therapeutic and adverse effects: A review</article-title><source>Eur. Rev. Med. Pharm. Sci.</source><year>2015</year><volume>19</volume><fpage>694</fpage><lpage>700</lpage></element-citation></ref><ref id="B46-biomedicines-08-00405"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eirich</surname><given-names>J.</given-names></name><name><surname>Orth</surname><given-names>R.</given-names></name><name><surname>Sieber</surname><given-names>S.A.</given-names></name></person-group><article-title>Unraveling the protein targets of vancomycin in living <italic>S. aureus</italic> and <italic>E. faecalis</italic> cells</article-title><source>J. Am. Chem. Soc.</source><year>2011</year><volume>133</volume><fpage>12144</fpage><lpage>12153</lpage><pub-id pub-id-type="doi">10.1021/ja2039979</pub-id><?supplied-pmid 21736328?><pub-id pub-id-type="pmid">21736328</pub-id></element-citation></ref><ref id="B47-biomedicines-08-00405"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>A.</given-names></name><name><surname>Schofield</surname><given-names>M.M.</given-names></name><name><surname>Chlipala</surname><given-names>G.E.</given-names></name><name><surname>Schultz</surname><given-names>P.J.</given-names></name><name><surname>Yim</surname><given-names>I.</given-names></name><name><surname>Newmister</surname><given-names>S.A.</given-names></name><name><surname>Nusca</surname><given-names>T.D.</given-names></name><name><surname>Scaglione</surname><given-names>J.B.</given-names></name><name><surname>Hanna</surname><given-names>P.C.</given-names></name><name><surname>Tamayo-Castillo</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Baulamycins a and b, broad-spectrum antibiotics identified as inhibitors of siderophore biosynthesis in <italic>Staphylococcus aureus</italic> and <italic>Bacillus anthracis</italic></article-title><source>J. Am. Chem. Soc.</source><year>2014</year><volume>136</volume><fpage>1579</fpage><lpage>1586</lpage><pub-id pub-id-type="doi">10.1021/ja4115924</pub-id><?supplied-pmid 24401083?><pub-id pub-id-type="pmid">24401083</pub-id></element-citation></ref><ref id="B48-biomedicines-08-00405"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Chakraborty</surname><given-names>D.</given-names></name><name><surname>Dewell</surname><given-names>S.B.</given-names></name><name><surname>Reddy</surname><given-names>B.V.</given-names></name><name><surname>Brady</surname><given-names>S.F.</given-names></name></person-group><article-title>Environmental DNA-encoded antibiotics fasamycins a and b inhibit fabf in type ii fatty acid biosynthesis</article-title><source>J. Am. Chem. Soc.</source><year>2012</year><volume>134</volume><fpage>2981</fpage><lpage>2987</lpage><pub-id pub-id-type="doi">10.1021/ja207662w</pub-id><pub-id pub-id-type="pmid">22224500</pub-id></element-citation></ref><ref id="B49-biomedicines-08-00405"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maffioli</surname><given-names>S.I.</given-names></name><name><surname>Fabbretti</surname><given-names>A.</given-names></name><name><surname>Brandi</surname><given-names>L.</given-names></name><name><surname>Savelsbergh</surname><given-names>A.</given-names></name><name><surname>Monciardini</surname><given-names>P.</given-names></name><name><surname>Abbondi</surname><given-names>M.</given-names></name><name><surname>Rossi</surname><given-names>R.</given-names></name><name><surname>Donadio</surname><given-names>S.</given-names></name><name><surname>Gualerzi</surname><given-names>C.O.</given-names></name></person-group><article-title>Orthoformimycin, a selective inhibitor of bacterial translation elongation from streptomyces containing an unusual orthoformate</article-title><source>ACS Chem. Biol.</source><year>2013</year><volume>8</volume><fpage>1939</fpage><lpage>1946</lpage><pub-id pub-id-type="doi">10.1021/cb4004095</pub-id><pub-id pub-id-type="pmid">23895646</pub-id></element-citation></ref><ref id="B50-biomedicines-08-00405"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>J.W.</given-names></name><name><surname>Goetz</surname><given-names>M.A.</given-names></name><name><surname>Smith</surname><given-names>S.K.</given-names></name><name><surname>Zink</surname><given-names>D.L.</given-names></name><name><surname>Polishook</surname><given-names>J.</given-names></name><name><surname>Onishi</surname><given-names>R.</given-names></name><name><surname>Salowe</surname><given-names>S.</given-names></name><name><surname>Wiltsie</surname><given-names>J.</given-names></name><name><surname>Allocco</surname><given-names>J.</given-names></name><name><surname>Sigmund</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Discovery of kibdelomycin, a potent new class of bacterial type ii topoisomerase inhibitor by chemical-genetic profiling in <italic>Staphylococcus aureus</italic></article-title><source>Chem. Biol.</source><year>2011</year><volume>18</volume><fpage>955</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2011.06.011</pub-id><pub-id pub-id-type="pmid">21867911</pub-id></element-citation></ref><ref id="B51-biomedicines-08-00405"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.B.</given-names></name></person-group><article-title>Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type ii topoisomerase</article-title><source>Bioorg. Med. Chem.</source><year>2016</year><volume>24</volume><fpage>6291</fpage><lpage>6297</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2016.04.043</pub-id><pub-id pub-id-type="pmid">27143131</pub-id></element-citation></ref><ref id="B52-biomedicines-08-00405"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>G.D.</given-names></name></person-group><article-title>Back to the future: A new &#x02018;old&#x02019; lead for tuberculosis</article-title><source>EMBO Mol. Med.</source><year>2012</year><volume>4</volume><fpage>1029</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1002/emmm.201201811</pub-id><pub-id pub-id-type="pmid">22987753</pub-id></element-citation></ref><ref id="B53-biomedicines-08-00405"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Gerth</surname><given-names>K.</given-names></name><name><surname>Muller</surname><given-names>R.</given-names></name><name><surname>Wall</surname><given-names>D.</given-names></name></person-group><article-title>Myxobacterium-produced antibiotic ta (myxovirescin) inhibits type ii signal peptidase</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>2014</fpage><lpage>2021</lpage><pub-id pub-id-type="doi">10.1128/AAC.06148-11</pub-id><pub-id pub-id-type="pmid">22232277</pub-id></element-citation></ref><ref id="B54-biomedicines-08-00405"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonejuie</surname><given-names>P.</given-names></name><name><surname>Burkart</surname><given-names>M.</given-names></name><name><surname>Pogliano</surname><given-names>K.</given-names></name><name><surname>Pogliano</surname><given-names>J.</given-names></name></person-group><article-title>Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>16169</fpage><lpage>16174</lpage><pub-id pub-id-type="doi">10.1073/pnas.1311066110</pub-id><?supplied-pmid 24046367?><pub-id pub-id-type="pmid">24046367</pub-id></element-citation></ref><ref id="B55-biomedicines-08-00405"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>L.L.</given-names></name><name><surname>Schneider</surname><given-names>T.</given-names></name><name><surname>Peoples</surname><given-names>A.J.</given-names></name><name><surname>Spoering</surname><given-names>A.L.</given-names></name><name><surname>Engels</surname><given-names>I.</given-names></name><name><surname>Conlon</surname><given-names>B.P.</given-names></name><name><surname>Mueller</surname><given-names>A.</given-names></name><name><surname>Schaberle</surname><given-names>T.F.</given-names></name><name><surname>Hughes</surname><given-names>D.E.</given-names></name><name><surname>Epstein</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A new antibiotic kills pathogens without detectable resistance</article-title><source>Nature</source><year>2015</year><volume>517</volume><fpage>455</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1038/nature14098</pub-id><?supplied-pmid 25561178?><pub-id pub-id-type="pmid">25561178</pub-id></element-citation></ref><ref id="B56-biomedicines-08-00405"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Therien</surname><given-names>A.G.</given-names></name><name><surname>Huber</surname><given-names>J.L.</given-names></name><name><surname>Wilson</surname><given-names>K.E.</given-names></name><name><surname>Beaulieu</surname><given-names>P.</given-names></name><name><surname>Caron</surname><given-names>A.</given-names></name><name><surname>Claveau</surname><given-names>D.</given-names></name><name><surname>Deschamps</surname><given-names>K.</given-names></name><name><surname>Donald</surname><given-names>R.G.</given-names></name><name><surname>Galgoci</surname><given-names>A.M.</given-names></name><name><surname>Gallant</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Broadening the spectrum of beta-lactam antibiotics through inhibition of signal peptidase type i</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>4662</fpage><lpage>4670</lpage><pub-id pub-id-type="doi">10.1128/AAC.00726-12</pub-id><?supplied-pmid 22710113?><pub-id pub-id-type="pmid">22710113</pub-id></element-citation></ref><ref id="B57-biomedicines-08-00405"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>G.</given-names></name><name><surname>Cheng</surname><given-names>A.T.</given-names></name><name><surname>Peach</surname><given-names>K.C.</given-names></name><name><surname>Bray</surname><given-names>W.M.</given-names></name><name><surname>Bernan</surname><given-names>V.S.</given-names></name><name><surname>Yildiz</surname><given-names>F.H.</given-names></name><name><surname>Linington</surname><given-names>R.G.</given-names></name></person-group><article-title>Image-based 384-well high-throughput screening method for the discovery of skyllamycins a to c as biofilm inhibitors and inducers of biofilm detachment in pseudomonas aeruginosa</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>1092</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1128/AAC.01781-13</pub-id><pub-id pub-id-type="pmid">24295976</pub-id></element-citation></ref><ref id="B58-biomedicines-08-00405"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawksworth</surname><given-names>D.L.</given-names></name><name><surname>L&#x000fc;cking</surname><given-names>R.</given-names></name></person-group><article-title>Fungal diversity revisited: 2.2 to 3.8 million species</article-title><source>Microbiol. Spectr.</source><year>2017</year><volume>5</volume><fpage>79</fpage><lpage>95</lpage></element-citation></ref><ref id="B59-biomedicines-08-00405"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>A.M.</given-names></name><name><surname>Reid-Yu</surname><given-names>S.A.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>King</surname><given-names>D.T.</given-names></name><name><surname>De Pascale</surname><given-names>G.</given-names></name><name><surname>Strynadka</surname><given-names>N.C.</given-names></name><name><surname>Walsh</surname><given-names>T.R.</given-names></name><name><surname>Coombes</surname><given-names>B.K.</given-names></name><name><surname>Wright</surname><given-names>G.D.</given-names></name></person-group><article-title>Aspergillomarasmine a overcomes metallo-beta-lactamase antibiotic resistance</article-title><source>Nature</source><year>2014</year><volume>510</volume><fpage>503</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/nature13445</pub-id><pub-id pub-id-type="pmid">24965651</pub-id></element-citation></ref><ref id="B60-biomedicines-08-00405"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ymele-Leki</surname><given-names>P.</given-names></name><name><surname>Cao</surname><given-names>S.</given-names></name><name><surname>Sharp</surname><given-names>J.</given-names></name><name><surname>Lambert</surname><given-names>K.G.</given-names></name><name><surname>McAdam</surname><given-names>A.J.</given-names></name><name><surname>Husson</surname><given-names>R.N.</given-names></name><name><surname>Tamayo</surname><given-names>G.</given-names></name><name><surname>Clardy</surname><given-names>J.</given-names></name><name><surname>Watnick</surname><given-names>P.I.</given-names></name></person-group><article-title>A high-throughput screen identifies a new natural product with broad-spectrum antibacterial activity</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e31307</elocation-id><pub-id pub-id-type="doi">10.1371/annotation/7efd3085-dd48-4210-9b7a-9ddb1acaa608</pub-id><pub-id pub-id-type="pmid">22359585</pub-id></element-citation></ref><ref id="B61-biomedicines-08-00405"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karaman</surname><given-names>M.</given-names></name><name><surname>Jovin</surname><given-names>E.</given-names></name><name><surname>Malbasa</surname><given-names>R.</given-names></name><name><surname>Matavuly</surname><given-names>M.</given-names></name><name><surname>Popovic</surname><given-names>M.</given-names></name></person-group><article-title>Medicinal and edible lignicolous fungi as natural sources of antioxidative and antibacterial agents</article-title><source>Phytother. Res.</source><year>2010</year><volume>24</volume><fpage>1473</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.1002/ptr.2969</pub-id><pub-id pub-id-type="pmid">20878697</pub-id></element-citation></ref><ref id="B62-biomedicines-08-00405"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Wiese</surname><given-names>J.</given-names></name><name><surname>Labes</surname><given-names>A.</given-names></name><name><surname>Kramer</surname><given-names>A.</given-names></name><name><surname>Schmaljohann</surname><given-names>R.</given-names></name><name><surname>Imhoff</surname><given-names>J.F.</given-names></name></person-group><article-title>Lindgomycin, an unusual antibiotic polyketide from a marine fungus of the lindgomycetaceae</article-title><source>Mar. Drugs</source><year>2015</year><volume>13</volume><fpage>4617</fpage><lpage>4632</lpage><pub-id pub-id-type="doi">10.3390/md13084617</pub-id><pub-id pub-id-type="pmid">26225984</pub-id></element-citation></ref><ref id="B63-biomedicines-08-00405"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>M.Y.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Shao</surname><given-names>C.L.</given-names></name><name><surname>Deng</surname><given-names>D.S.</given-names></name><name><surname>Wang</surname><given-names>C.Y.</given-names></name></person-group><article-title>(+/&#x02212;)-pestalachloride d, an antibacterial racemate of chlorinated benzophenone derivative from a soft coral-derived fungus <italic>Pestalotiopsis</italic> sp.</article-title><source>Mar. Drugs</source><year>2013</year><volume>11</volume><fpage>1050</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.3390/md11041050</pub-id><pub-id pub-id-type="pmid">23538869</pub-id></element-citation></ref><ref id="B64-biomedicines-08-00405"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pruksakorn</surname><given-names>P.</given-names></name><name><surname>Arai</surname><given-names>M.</given-names></name><name><surname>Kotoku</surname><given-names>N.</given-names></name><name><surname>Vilcheze</surname><given-names>C.</given-names></name><name><surname>Baughn</surname><given-names>A.D.</given-names></name><name><surname>Moodley</surname><given-names>P.</given-names></name><name><surname>Jacobs</surname><given-names>W.R.</given-names><suffix>Jr.</suffix></name><name><surname>Kobayashi</surname><given-names>M.</given-names></name></person-group><article-title>Trichoderins, novel aminolipopeptides from a marine sponge-derived <italic>Trichoderma</italic> sp., are active against dormant mycobacteria</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2010</year><volume>20</volume><fpage>3658</fpage><lpage>3663</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2010.04.100</pub-id><?supplied-pmid 20483615?><pub-id pub-id-type="pmid">20483615</pub-id></element-citation></ref><ref id="B65-biomedicines-08-00405"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandra</surname><given-names>H.</given-names></name><name><surname>Bishnoi</surname><given-names>P.</given-names></name><name><surname>Yadav</surname><given-names>A.</given-names></name><name><surname>Patni</surname><given-names>B.</given-names></name><name><surname>Mishra</surname><given-names>A.P.</given-names></name><name><surname>Nautiyal</surname><given-names>A.R.</given-names></name></person-group><article-title>Antimicrobial resistance and the alternative resources with special emphasis on plant-based antimicrobials&#x02014;A review</article-title><source>Plants</source><year>2017</year><volume>6</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.3390/plants6020016</pub-id><?supplied-pmid 28394295?><pub-id pub-id-type="pmid">28394295</pub-id></element-citation></ref><ref id="B66-biomedicines-08-00405"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quideau</surname><given-names>S.</given-names></name><name><surname>Deffieux</surname><given-names>D.</given-names></name><name><surname>Douat-Casassus</surname><given-names>C.</given-names></name><name><surname>Pouysegu</surname><given-names>L.</given-names></name></person-group><article-title>Plant polyphenols: Chemical properties, biological activities, and synthesis</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2011</year><volume>50</volume><fpage>586</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1002/anie.201000044</pub-id><?supplied-pmid 21226137?><pub-id pub-id-type="pmid">21226137</pub-id></element-citation></ref><ref id="B67-biomedicines-08-00405"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>A.L.</given-names></name><name><surname>Edrada-Abel</surname><given-names>R.</given-names></name><name><surname>Quinn</surname><given-names>R.J.</given-names></name></person-group><article-title>The re-emergence of natural products for drug discovery in the genomics era</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>111</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1038/nrd4510</pub-id><pub-id pub-id-type="pmid">25614221</pub-id></element-citation></ref><ref id="B68-biomedicines-08-00405"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radulovic</surname><given-names>N.S.B.</given-names></name><name><surname>Blagojevic</surname><given-names>P.D.</given-names></name><name><surname>Stojanovic-Radic</surname><given-names>Z.Z.</given-names></name><name><surname>Stojanovic</surname><given-names>N.M.</given-names></name></person-group><article-title>Antimicrobial plant metabolites: Structural diversity and mechanism of action</article-title><source>Curr. Med. Chem.</source><year>2013</year><volume>20</volume><fpage>932</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">23210781</pub-id></element-citation></ref><ref id="B69-biomedicines-08-00405"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coban</surname><given-names>I.</given-names></name><name><surname>Toplan</surname><given-names>G.G.</given-names></name><name><surname>Ozbek</surname><given-names>B.</given-names></name><name><surname>Gurer</surname><given-names>C.U.</given-names></name><name><surname>Sariyar</surname><given-names>G.</given-names></name></person-group><article-title>Variation of alkaloid contents and antimicrobial activities of papaver rhoeas l. Growing in turkey and northern cyprus</article-title><source>Pharm. Biol.</source><year>2017</year><volume>55</volume><fpage>1894</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.1080/13880209.2017.1340964</pub-id><pub-id pub-id-type="pmid">28633584</pub-id></element-citation></ref><ref id="B70-biomedicines-08-00405"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nugraha</surname><given-names>A.S.</given-names></name><name><surname>Damayanti</surname><given-names>Y.D.</given-names></name><name><surname>Wangchuk</surname><given-names>P.</given-names></name><name><surname>Keller</surname><given-names>P.A.</given-names></name></person-group><article-title>Anti-infective and anti-cancer properties of the annona species: Their ethnomedicinal uses, alkaloid diversity, and pharmacological activities</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>4419</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24234419</pub-id></element-citation></ref><ref id="B71-biomedicines-08-00405"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Ban</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>H.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Chemical composition and antifungal activity of essential oil from <italic>Cicuta virosa</italic> L. Var. Latisecta celak</article-title><source>Int. J. Food Microbiol.</source><year>2011</year><volume>145</volume><fpage>464</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2011.01.023</pub-id><pub-id pub-id-type="pmid">21320730</pub-id></element-citation></ref><ref id="B72-biomedicines-08-00405"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tariq</surname><given-names>S.</given-names></name><name><surname>Wani</surname><given-names>S.</given-names></name><name><surname>Rasool</surname><given-names>W.</given-names></name><name><surname>Shafi</surname><given-names>K.</given-names></name><name><surname>Bhat</surname><given-names>M.A.</given-names></name><name><surname>Prabhakar</surname><given-names>A.</given-names></name><name><surname>Shalla</surname><given-names>A.H.</given-names></name><name><surname>Rather</surname><given-names>M.A.</given-names></name></person-group><article-title>A comprehensive review of the antibacterial, antifungal and antiviral potential of <italic>Essential oils</italic> and their chemical constituents against drug-resistant microbial pathogens</article-title><source>Microb. Pathog.</source><year>2019</year><volume>134</volume><fpage>103580</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2019.103580</pub-id><pub-id pub-id-type="pmid">31195112</pub-id></element-citation></ref><ref id="B73-biomedicines-08-00405"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name></person-group><article-title>Antimicrobial activities of tea polyphenol on phytopathogens: A review</article-title><source>Molecules</source><year>2019</year><volume>24</volume><elocation-id>816</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24040816</pub-id></element-citation></ref><ref id="B74-biomedicines-08-00405"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouarab Chibane</surname><given-names>L.</given-names></name><name><surname>Degraeve</surname><given-names>P.</given-names></name><name><surname>Ferhout</surname><given-names>H.</given-names></name><name><surname>Bouajila</surname><given-names>J.</given-names></name><name><surname>Oulahal</surname><given-names>N.</given-names></name></person-group><article-title>Plant antimicrobial polyphenols as potential natural food preservatives</article-title><source>J. Sci. Food Agric.</source><year>2019</year><volume>99</volume><fpage>1457</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1002/jsfa.9357</pub-id><?supplied-pmid 30206947?><pub-id pub-id-type="pmid">30206947</pub-id></element-citation></ref><ref id="B75-biomedicines-08-00405"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bostanghadiri</surname><given-names>N.</given-names></name><name><surname>Pormohammad</surname><given-names>A.</given-names></name><name><surname>Chirani</surname><given-names>A.S.</given-names></name><name><surname>Pouriran</surname><given-names>R.</given-names></name><name><surname>Erfanimanesh</surname><given-names>S.</given-names></name><name><surname>Hashemi</surname><given-names>A.</given-names></name></person-group><article-title>Comprehensive review on the antimicrobial potency of the plant polyphenol resveratrol</article-title><source>Biomed. Pharm.</source><year>2017</year><volume>95</volume><fpage>1588</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.09.084</pub-id><?supplied-pmid 28950659?><pub-id pub-id-type="pmid">28950659</pub-id></element-citation></ref><ref id="B76-biomedicines-08-00405"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Martinez</surname><given-names>F.J.</given-names></name><name><surname>Barrajon-Catalan</surname><given-names>E.</given-names></name><name><surname>Encinar</surname><given-names>J.A.</given-names></name><name><surname>Rodriguez-Diaz</surname><given-names>J.C.</given-names></name><name><surname>Micol</surname><given-names>V.</given-names></name></person-group><article-title>Antimicrobial capacity of plant polyphenols against gram-positive bacteria: A comprehensive review</article-title><source>Curr. Med. Chem.</source><year>2018</year><volume>27</volume><fpage>2576</fpage><lpage>2606</lpage><pub-id pub-id-type="doi">10.2174/0929867325666181008115650</pub-id><?supplied-pmid 30295182?><pub-id pub-id-type="pmid">30295182</pub-id></element-citation></ref><ref id="B77-biomedicines-08-00405"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>Studies of the in vitro antibacterial activities of several polyphenols against clinical isolates of methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>12630</fpage><lpage>12639</lpage><pub-id pub-id-type="doi">10.3390/molecules190812630</pub-id><pub-id pub-id-type="pmid">25153875</pub-id></element-citation></ref><ref id="B78-biomedicines-08-00405"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mokhtar</surname><given-names>M.</given-names></name><name><surname>Ginestra</surname><given-names>G.</given-names></name><name><surname>Youcefi</surname><given-names>F.</given-names></name><name><surname>Filocamo</surname><given-names>A.</given-names></name><name><surname>Bisignano</surname><given-names>C.</given-names></name><name><surname>Riazi</surname><given-names>A.</given-names></name></person-group><article-title>Antimicrobial activity of selected polyphenols and capsaicinoids identified in pepper (<italic>Capsicum annuum</italic> L.) and their possible mode of interactio</article-title><source>Curr. Microbiol.</source><year>2017</year><volume>74</volume><fpage>1253</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1007/s00284-017-1310-2</pub-id><pub-id pub-id-type="pmid">28721659</pub-id></element-citation></ref><ref id="B79-biomedicines-08-00405"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caselli</surname><given-names>A.</given-names></name><name><surname>Cirri</surname><given-names>P.</given-names></name><name><surname>Santi</surname><given-names>A.</given-names></name><name><surname>Paoli</surname><given-names>P.</given-names></name></person-group><article-title>Morin: A promising natural drug</article-title><source>Curr. Med. Chem.</source><year>2016</year><volume>23</volume><fpage>774</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.2174/0929867323666160106150821</pub-id><pub-id pub-id-type="pmid">26018232</pub-id></element-citation></ref><ref id="B80-biomedicines-08-00405"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomas-Menor</surname><given-names>L.</given-names></name><name><surname>Barrajon-Catalan</surname><given-names>E.</given-names></name><name><surname>Segura-Carretero</surname><given-names>A.</given-names></name><name><surname>Marti</surname><given-names>N.</given-names></name><name><surname>Saura</surname><given-names>D.</given-names></name><name><surname>Menendez</surname><given-names>J.A.</given-names></name><name><surname>Joven</surname><given-names>J.</given-names></name><name><surname>Micol</surname><given-names>V.</given-names></name></person-group><article-title>The promiscuous and synergic molecular interaction of polyphenols in bactericidal activity: An opportunity to improve the performance of antibiotics?</article-title><source>Phytother. Res.</source><year>2015</year><volume>29</volume><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1002/ptr.5296</pub-id><pub-id pub-id-type="pmid">25625775</pub-id></element-citation></ref><ref id="B81-biomedicines-08-00405"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Takagi</surname><given-names>S.</given-names></name><name><surname>Ando</surname><given-names>T.</given-names></name><name><surname>Yoneyama</surname><given-names>H.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Mizugai</surname><given-names>H.</given-names></name><name><surname>Isogai</surname><given-names>E.</given-names></name></person-group><article-title>Antimicrobial activity of tea catechin against canine oral bacteria and the functional mechanisms</article-title><source>J. Vet. Med. Sci.</source><year>2016</year><volume>78</volume><fpage>1439</fpage><lpage>1445</lpage><pub-id pub-id-type="doi">10.1292/jvms.16-0198</pub-id><pub-id pub-id-type="pmid">27246281</pub-id></element-citation></ref><ref id="B82-biomedicines-08-00405"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cushnie</surname><given-names>T.P.</given-names></name><name><surname>Hamilton</surname><given-names>V.E.</given-names></name><name><surname>Lamb</surname><given-names>A.J.</given-names></name></person-group><article-title>Assessment of the antibacterial activity of selected flavonoids and consideration of discrepancies between previous reports</article-title><source>Microbiol. Res.</source><year>2003</year><volume>158</volume><fpage>281</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1078/0944-5013-00206</pub-id><pub-id pub-id-type="pmid">14717448</pub-id></element-citation></ref><ref id="B83-biomedicines-08-00405"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cushnie</surname><given-names>T.P.</given-names></name><name><surname>Lamb</surname><given-names>A.J.</given-names></name></person-group><article-title>Antimicrobial activity of flavonoids</article-title><source>Int. J. Antimicrob. Agents</source><year>2005</year><volume>26</volume><fpage>343</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2005.09.002</pub-id><pub-id pub-id-type="pmid">16323269</pub-id></element-citation></ref><ref id="B84-biomedicines-08-00405"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Shi</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Zheng</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Peng</surname><given-names>X.</given-names></name><name><surname>Xia</surname><given-names>X.</given-names></name></person-group><article-title>Antimicrobial activity of punicalagin against <italic>Staphylococcus aureus</italic> and its effect on biofilm formation</article-title><source>Foodborne Pathog. Dis.</source><year>2017</year><volume>14</volume><fpage>282</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/fpd.2016.2226</pub-id><?supplied-pmid 28128637?><pub-id pub-id-type="pmid">28128637</pub-id></element-citation></ref><ref id="B85-biomedicines-08-00405"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daglia</surname><given-names>M.</given-names></name></person-group><article-title>Polyphenols as antimicrobial agents</article-title><source>Curr. Opin. Biotechnol.</source><year>2012</year><volume>23</volume><fpage>174</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2011.08.007</pub-id><?supplied-pmid 21925860?><pub-id pub-id-type="pmid">21925860</pub-id></element-citation></ref><ref id="B86-biomedicines-08-00405"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernal</surname><given-names>P.</given-names></name><name><surname>Lemaire</surname><given-names>S.</given-names></name><name><surname>Pinho</surname><given-names>M.G.</given-names></name><name><surname>Mobashery</surname><given-names>S.</given-names></name><name><surname>Hinds</surname><given-names>J.</given-names></name><name><surname>Taylor</surname><given-names>P.W.</given-names></name></person-group><article-title>Insertion of epicatechin gallate into the cytoplasmic membrane of methicillin-resistant <italic>Staphylococcus aureus</italic> disrupts penicillin-binding protein (pbp) 2a-mediated beta-lactam resistance by delocalizing pbp2</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>24055</fpage><lpage>24065</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.114793</pub-id><?supplied-pmid 20516078?><pub-id pub-id-type="pmid">20516078</pub-id></element-citation></ref><ref id="B87-biomedicines-08-00405"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miklasinska-Majdanik</surname><given-names>M.</given-names></name><name><surname>Kepa</surname><given-names>M.</given-names></name><name><surname>Wojtyczka</surname><given-names>R.D.</given-names></name><name><surname>Idzik</surname><given-names>D.</given-names></name><name><surname>Wasik</surname><given-names>T.J.</given-names></name></person-group><article-title>Phenolic compounds diminish antibiotic resistance of <italic>Staphylococcus aureus</italic> clinical strains</article-title><source>Int. J. Environ. Res. Public Health</source><year>2018</year><volume>15</volume><elocation-id>2321</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph15102321</pub-id><?supplied-pmid 30360435?><pub-id pub-id-type="pmid">30360435</pub-id></element-citation></ref><ref id="B88-biomedicines-08-00405"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>R.</given-names></name><name><surname>Xiao</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Peng</surname><given-names>W.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name></person-group><article-title>The combination of catechin and epicatechin callate from fructus crataegi potentiates beta-lactam antibiotics against methicillin-resistant staphylococcus aureus (mrsa) in vitro and in vivo</article-title><source>Int. J. Mol. Sci.</source><year>2013</year><volume>14</volume><fpage>1802</fpage><lpage>1821</lpage><pub-id pub-id-type="doi">10.3390/ijms14011802</pub-id><?supplied-pmid 23325048?><pub-id pub-id-type="pmid">23325048</pub-id></element-citation></ref><ref id="B89-biomedicines-08-00405"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betts</surname><given-names>J.W.</given-names></name><name><surname>Sharili</surname><given-names>A.S.</given-names></name><name><surname>Phee</surname><given-names>L.M.</given-names></name><name><surname>Wareham</surname><given-names>D.W.</given-names></name></person-group><article-title>In vitro activity of epigallocatechin gallate and quercetin alone and in combination versus clinical isolates of methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>J. Nat. Prod.</source><year>2015</year><volume>78</volume><fpage>2145</fpage><lpage>2148</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b00471</pub-id><pub-id pub-id-type="pmid">26267658</pub-id></element-citation></ref><ref id="B90-biomedicines-08-00405"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zwingelstein</surname><given-names>M.</given-names></name><name><surname>Draye</surname><given-names>M.</given-names></name><name><surname>Besombes</surname><given-names>J.L.</given-names></name><name><surname>Piot</surname><given-names>C.</given-names></name><name><surname>Chatel</surname><given-names>G.</given-names></name></person-group><article-title>Viticultural wood waste as a source of polyphenols of interest: Opportunities and perspectives through conventional and emerging extraction methods</article-title><source>Waste Manag.</source><year>2020</year><volume>102</volume><fpage>782</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1016/j.wasman.2019.11.034</pub-id><pub-id pub-id-type="pmid">31812093</pub-id></element-citation></ref><ref id="B91-biomedicines-08-00405"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomas-Menor</surname><given-names>L.</given-names></name><name><surname>Morales-Soto</surname><given-names>A.</given-names></name><name><surname>Barrajon-Catalan</surname><given-names>E.</given-names></name><name><surname>Roldan-Segura</surname><given-names>C.</given-names></name><name><surname>Segura-Carretero</surname><given-names>A.</given-names></name><name><surname>Micol</surname><given-names>V.</given-names></name></person-group><article-title>Correlation between the antibacterial activity and the composition of extracts derived from various spanish cistus species</article-title><source>Food Chem. Toxicol.</source><year>2013</year><volume>55</volume><fpage>313</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2013.01.006</pub-id><pub-id pub-id-type="pmid">23333717</pub-id></element-citation></ref><ref id="B92-biomedicines-08-00405"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubey</surname><given-names>D.</given-names></name><name><surname>Padhy</surname><given-names>R.N.</given-names></name></person-group><article-title>Antibacterial activity of <italic>Lantana camara</italic> L. Against multidrug resistant pathogens from icu patients of a teaching hospital</article-title><source>J. Herb. Med.</source><year>2013</year><volume>3</volume><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.hermed.2012.12.002</pub-id></element-citation></ref><ref id="B93-biomedicines-08-00405"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubey</surname><given-names>D.</given-names></name><name><surname>Sahu</surname><given-names>M.C.</given-names></name><name><surname>Rath</surname><given-names>S.</given-names></name><name><surname>Paty</surname><given-names>B.P.</given-names></name><name><surname>Debata</surname><given-names>N.K.</given-names></name><name><surname>Padhy</surname><given-names>R.N.</given-names></name></person-group><article-title>Antimicrobial activity of medicinal plants used by aborigines of kalahandi, orissa, india against multidrug resistant bacteria</article-title><source>Asian Pac. J. Trop. Biomed.</source><year>2012</year><volume>2</volume><fpage>S846</fpage><lpage>S854</lpage><pub-id pub-id-type="doi">10.1016/S2221-1691(12)60322-0</pub-id></element-citation></ref><ref id="B94-biomedicines-08-00405"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahu</surname><given-names>M.C.</given-names></name><name><surname>Padhy</surname><given-names>R.N.</given-names></name></person-group><article-title>In vitro antibacterial potency of <italic>Butea monosperma</italic> Lam. Against 12 clinically isolated multidrug resistant bacteria</article-title><source>Asian Pac. J. Trop. Dis.</source><year>2013</year><volume>3</volume><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/S2222-1808(13)60044-4</pub-id></element-citation></ref><ref id="B95-biomedicines-08-00405"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>S.</given-names></name><name><surname>Nodwell</surname><given-names>J.R.</given-names></name></person-group><article-title>Actinorhodin is a redox-active antibiotic with a complex mode of action against gram-positive cells</article-title><source>Mol. Microbiol.</source><year>2017</year><volume>106</volume><fpage>597</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1111/mmi.13837</pub-id><?supplied-pmid 28906045?><pub-id pub-id-type="pmid">28906045</pub-id></element-citation></ref><ref id="B96-biomedicines-08-00405"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Jing</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name></person-group><article-title>Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>3445</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05821-1</pub-id><?supplied-pmid 30181560?><pub-id pub-id-type="pmid">30181560</pub-id></element-citation></ref><ref id="B97-biomedicines-08-00405"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pramanik</surname><given-names>A.</given-names></name><name><surname>Stroeher</surname><given-names>U.H.</given-names></name><name><surname>Krejci</surname><given-names>J.</given-names></name><name><surname>Standish</surname><given-names>A.J.</given-names></name><name><surname>Bohn</surname><given-names>E.</given-names></name><name><surname>Paton</surname><given-names>J.C.</given-names></name><name><surname>Autenrieth</surname><given-names>I.B.</given-names></name><name><surname>Braun</surname><given-names>V.</given-names></name></person-group><article-title>Albomycin is an effective antibiotic, as exemplified with <italic>Yersinia enterocolitica</italic> and <italic>Streptococcus pneumoniae</italic></article-title><source>Int. J. Med. Microbiol.</source><year>2007</year><volume>297</volume><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2007.03.002</pub-id><pub-id pub-id-type="pmid">17459767</pub-id></element-citation></ref><ref id="B98-biomedicines-08-00405"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Coffman</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>S.J.</given-names></name></person-group><article-title>Solid-state nmr characterization of amphomycin effects on peptidoglycan and wall teichoic acid biosyntheses in <italic>Staphylococcus aureus</italic></article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>31757</fpage><pub-id pub-id-type="doi">10.1038/srep31757</pub-id><pub-id pub-id-type="pmid">27538449</pub-id></element-citation></ref><ref id="B99-biomedicines-08-00405"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>A.D.</given-names></name><name><surname>Smith</surname><given-names>K.P.</given-names></name><name><surname>Eliopoulos</surname><given-names>G.M.</given-names></name><name><surname>Berg</surname><given-names>A.H.</given-names></name><name><surname>McCoy</surname><given-names>C.</given-names></name><name><surname>Kirby</surname><given-names>J.E.</given-names></name></person-group><article-title>Invitro apramycin activity against multidrug-resistant <italic>Acinetobacter baumannii</italic> and <italic>Pseudomonas aeruginosa</italic></article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2017</year><volume>88</volume><fpage>188</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2017.03.006</pub-id><pub-id pub-id-type="pmid">28341099</pub-id></element-citation></ref><ref id="B100-biomedicines-08-00405"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>P.A.</given-names></name><name><surname>Steed</surname><given-names>D.B.</given-names></name><name><surname>Romesberg</surname><given-names>F.</given-names></name></person-group><article-title>Efforts toward broadening the spectrum of arylomycin antibiotic activity</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2013</year><volume>23</volume><fpage>5654</fpage><lpage>5659</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2013.08.026</pub-id><pub-id pub-id-type="pmid">24012184</pub-id></element-citation></ref><ref id="B101-biomedicines-08-00405"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Dai</surname><given-names>J.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name></person-group><article-title>Identification of two regulatory genes involved in carbomycin biosynthesis in streptomyces thermotolerans</article-title><source>Arch. Microbiol.</source><year>2017</year><volume>199</volume><fpage>1023</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1007/s00203-017-1376-z</pub-id><pub-id pub-id-type="pmid">28389815</pub-id></element-citation></ref><ref id="B102-biomedicines-08-00405"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Z.</given-names></name><name><surname>Tharmalingam</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Jayamani</surname><given-names>E.</given-names></name><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Fuchs</surname><given-names>B.B.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Vilcinskas</surname><given-names>A.</given-names></name><name><surname>Mylonakis</surname><given-names>E.</given-names></name></person-group><article-title>Synergistic efficacy of aedes aegypti antimicrobial peptide cecropin a2 and tetracycline against <italic>Pseudomonas aeruginosa</italic></article-title><source>Antimicrob. Agents</source><year>2017</year><volume>61</volume><fpage>e00617</fpage><lpage>e00686</lpage><pub-id pub-id-type="doi">10.1128/AAC.00686-17</pub-id></element-citation></ref><ref id="B103-biomedicines-08-00405"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustaferro</surname><given-names>C.A.</given-names></name><name><surname>Steckelberg</surname><given-names>J.M.</given-names></name></person-group><article-title>Cephalosporin antimicrobial agents and related compounds</article-title><source>Mayo Clin. Proc.</source><year>1991</year><volume>66</volume><fpage>1064</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1016/S0025-6196(12)61731-5</pub-id><pub-id pub-id-type="pmid">1921490</pub-id></element-citation></ref><ref id="B104-biomedicines-08-00405"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brites</surname><given-names>L.M.</given-names></name><name><surname>Oliveira</surname><given-names>L.M.</given-names></name><name><surname>Barboza</surname><given-names>M.</given-names></name></person-group><article-title>Kinetic study on cephamycin c degradation</article-title><source>Appl. Biochem. Biotechnol.</source><year>2013</year><volume>171</volume><fpage>2121</fpage><lpage>2128</lpage><pub-id pub-id-type="doi">10.1007/s12010-013-0502-x</pub-id><?supplied-pmid 24026415?><pub-id pub-id-type="pmid">24026415</pub-id></element-citation></ref><ref id="B105-biomedicines-08-00405"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>S.</given-names></name><name><surname>Kehrenberg</surname><given-names>C.</given-names></name><name><surname>Doublet</surname><given-names>B.</given-names></name><name><surname>Cloeckaert</surname><given-names>A.</given-names></name></person-group><article-title>Molecular basis of bacterial resistance to chloramphenicol and florfenicol</article-title><source>FEMS Microbiol. Rev.</source><year>2004</year><volume>28</volume><fpage>519</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.femsre.2004.04.001</pub-id><?supplied-pmid 15539072?><pub-id pub-id-type="pmid">15539072</pub-id></element-citation></ref><ref id="B106-biomedicines-08-00405"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>N.E.</given-names></name><name><surname>Nicas</surname><given-names>T.I.</given-names></name></person-group><article-title>Mechanism of action of oritavancin and related glycopeptide antibiotics</article-title><source>FEMS Microbiol. Rev.</source><year>2003</year><volume>26</volume><fpage>511</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2003.tb00628.x</pub-id><?supplied-pmid 12586393?><pub-id pub-id-type="pmid">12586393</pub-id></element-citation></ref><ref id="B107-biomedicines-08-00405"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hakami</surname><given-names>A.Y.</given-names></name><name><surname>Sari</surname><given-names>Y.</given-names></name></person-group><article-title>Beta-lactamase inhibitor, clavulanic acid, attenuates ethanol intake and increases glial glutamate transporters expression in alcohol preferring rats</article-title><source>Neurosci. Lett.</source><year>2017</year><volume>657</volume><fpage>140</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2017.08.013</pub-id><pub-id pub-id-type="pmid">28826758</pub-id></element-citation></ref><ref id="B108-biomedicines-08-00405"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eust&#x000e1;quio</surname><given-names>A.S.</given-names></name><name><surname>Gust</surname><given-names>B.</given-names></name><name><surname>Luft</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>S.-M.</given-names></name><name><surname>Chater</surname><given-names>K.F.</given-names></name><name><surname>Heide</surname><given-names>L.</given-names></name></person-group><article-title>Clorobiocin biosynthesis in streptomyces</article-title><source>Chem. Biol.</source><year>2003</year><volume>10</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(03)00051-6</pub-id><pub-id pub-id-type="pmid">12670542</pub-id></element-citation></ref><ref id="B109-biomedicines-08-00405"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuels</surname><given-names>D.S.</given-names></name><name><surname>Garon</surname><given-names>C.F.</given-names></name></person-group><article-title>Coumermycin a1 inhibits growth and induces relaxation of supercoiled plasmids in borrelia burgdorferi, the lyme disease agent</article-title><source>Antimicrob. Agents Chemother.</source><year>1993</year><volume>37</volume><fpage>46</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1128/AAC.37.1.46</pub-id><pub-id pub-id-type="pmid">8381639</pub-id></element-citation></ref><ref id="B110-biomedicines-08-00405"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedorko</surname><given-names>J.</given-names></name><name><surname>Katz</surname><given-names>S.</given-names></name><name><surname>Allnoch</surname><given-names>H.</given-names></name></person-group><article-title>In vitro activity of coumermycin a</article-title><source>Appl. Microbiol.</source><year>1969</year><volume>18</volume><fpage>869</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1128/AEM.18.5.869-873.1969</pub-id><pub-id pub-id-type="pmid">4391844</pub-id></element-citation></ref><ref id="B111-biomedicines-08-00405"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cercenado</surname><given-names>E.</given-names></name></person-group><article-title>Espectro antimicrobiano de dalbavancina. Mecanismo de acci&#x000f3;n y actividad in vitro frente a microorganismos gram positivos</article-title><source>Enferm. Infecc. Y Microbiol. Cl&#x000ed;n.</source><year>2017</year><volume>35</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/S0213-005X(17)30029-0</pub-id></element-citation></ref><ref id="B112-biomedicines-08-00405"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidary</surname><given-names>M.</given-names></name><name><surname>Khosravi</surname><given-names>A.D.</given-names></name><name><surname>Khoshnood</surname><given-names>S.</given-names></name><name><surname>Nasiri</surname><given-names>M.J.</given-names></name><name><surname>Soleimani</surname><given-names>S.</given-names></name><name><surname>Goudarzi</surname><given-names>M.</given-names></name></person-group><article-title>Daptomycin</article-title><source>J. Antimicrob. Chemother.</source><year>2018</year><volume>73</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx349</pub-id><pub-id pub-id-type="pmid">29059358</pub-id></element-citation></ref><ref id="B113-biomedicines-08-00405"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C.</given-names></name><name><surname>Deng</surname><given-names>J.</given-names></name><name><surname>Man</surname><given-names>Y.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name></person-group><article-title>Green tea extracts epigallocatechin-3-gallate for different treatments</article-title><source>BioMed Res. Int.</source><year>2017</year><volume>2017</volume><fpage>5615647</fpage><pub-id pub-id-type="doi">10.1155/2017/5615647</pub-id><pub-id pub-id-type="pmid">28884125</pub-id></element-citation></ref><ref id="B114-biomedicines-08-00405"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Ge</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>R.D.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name></person-group><article-title>New erythromycin derivatives enhance beta-lactam antibiotics against methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Lett. Appl. Microbiol.</source><year>2015</year><volume>60</volume><fpage>352</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1111/lam.12378</pub-id><?supplied-pmid 25588530?><pub-id pub-id-type="pmid">25588530</pub-id></element-citation></ref><ref id="B115-biomedicines-08-00405"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falagas</surname><given-names>M.E.</given-names></name><name><surname>Vouloumanou</surname><given-names>E.K.</given-names></name><name><surname>Samonis</surname><given-names>G.</given-names></name><name><surname>Vardakas</surname><given-names>K.Z.</given-names></name></person-group><article-title>Fosfomycin</article-title><source>Clin. Microbiol. Rev.</source><year>2016</year><volume>29</volume><fpage>321</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1128/CMR.00068-15</pub-id><?supplied-pmid 26960938?><pub-id pub-id-type="pmid">26960938</pub-id></element-citation></ref><ref id="B116-biomedicines-08-00405"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curbete</surname><given-names>M.M.</given-names></name><name><surname>Salgado</surname><given-names>H.R.</given-names></name></person-group><article-title>A critical review of the properties of fusidic acid and analytical methods for its determination</article-title><source>Crit. Rev. Anal. Chem.</source><year>2016</year><volume>46</volume><fpage>352</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1080/10408347.2015.1084225</pub-id><?supplied-pmid 26337404?><pub-id pub-id-type="pmid">26337404</pub-id></element-citation></ref><ref id="B117-biomedicines-08-00405"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wargo</surname><given-names>K.A.</given-names></name><name><surname>Edwards</surname><given-names>J.D.</given-names></name></person-group><article-title>Aminoglycoside-induced nephrotoxicity</article-title><source>J. Pharm. Pr.</source><year>2014</year><volume>27</volume><fpage>573</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1177/0897190014546836</pub-id><?supplied-pmid 25199523?><pub-id pub-id-type="pmid">25199523</pub-id></element-citation></ref><ref id="B118-biomedicines-08-00405"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>M.</given-names></name><name><surname>Rautenbach</surname><given-names>M.</given-names></name><name><surname>Vosloo</surname><given-names>J.A.</given-names></name><name><surname>Siersma</surname><given-names>T.</given-names></name><name><surname>Aisenbrey</surname><given-names>C.H.</given-names></name><name><surname>Zaitseva</surname><given-names>E.</given-names></name><name><surname>Laubscher</surname><given-names>W.E.</given-names></name><name><surname>Rensburg</surname><given-names>W.</given-names></name><name><surname>Behrends</surname><given-names>J.C.</given-names></name><name><surname>Bechinger</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The multifaceted antibacterial mechanisms of the pioneering peptide antibiotics tyrocidine and gramicidin s</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e00802-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.00802-18</pub-id><pub-id pub-id-type="pmid">30301848</pub-id></element-citation></ref><ref id="B119-biomedicines-08-00405"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Xie</surname><given-names>Z.</given-names></name><name><surname>Ling</surname><given-names>G.</given-names></name><name><surname>Kuang</surname><given-names>Y.Q.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Identification and characterization of the first cathelicidin from sea snakes with potent antimicrobial and anti-inflammatory activity and special mechanism</article-title><source>J. Biol. Chem.</source><year>2015</year><volume>290</volume><fpage>16633</fpage><lpage>16652</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.642645</pub-id><pub-id pub-id-type="pmid">26013823</pub-id></element-citation></ref><ref id="B120-biomedicines-08-00405"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerrero</surname><given-names>M.C.</given-names></name><name><surname>Modolell</surname><given-names>J.</given-names></name></person-group><article-title>Hygromycin a, a novel inhibitor of ribosomal peptidyltransferase</article-title><source>Eur. J. Biochem.</source><year>1980</year><volume>107</volume><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1980.tb06044.x</pub-id><pub-id pub-id-type="pmid">6156832</pub-id></element-citation></ref><ref id="B121-biomedicines-08-00405"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arsic</surname><given-names>B.</given-names></name><name><surname>Barber</surname><given-names>J.</given-names></name><name><surname>Cikos</surname><given-names>A.</given-names></name><name><surname>Mladenovic</surname><given-names>M.</given-names></name><name><surname>Stankovic</surname><given-names>N.</given-names></name><name><surname>Novak</surname><given-names>P.</given-names></name></person-group><article-title>16-membered macrolide antibiotics: A review</article-title><source>Int. J. Antimicrob. Agents</source><year>2018</year><volume>51</volume><fpage>283</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2017.05.020</pub-id><pub-id pub-id-type="pmid">28668674</pub-id></element-citation></ref><ref id="B122-biomedicines-08-00405"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoerr</surname><given-names>V.</given-names></name><name><surname>Duggan</surname><given-names>G.E.</given-names></name><name><surname>Zbytnuik</surname><given-names>L.</given-names></name><name><surname>Poon</surname><given-names>K.K.</given-names></name><name><surname>Grosse</surname><given-names>C.</given-names></name><name><surname>Neugebauer</surname><given-names>U.</given-names></name><name><surname>Methling</surname><given-names>K.</given-names></name><name><surname>Loffler</surname><given-names>B.</given-names></name><name><surname>Vogel</surname><given-names>H.J.</given-names></name></person-group><article-title>Characterization and prediction of the mechanism of action of antibiotics through nmr metabolomics</article-title><source>BMC Microbiol.</source><year>2016</year><volume>16</volume><elocation-id>82</elocation-id><pub-id pub-id-type="doi">10.1186/s12866-016-0696-5</pub-id><pub-id pub-id-type="pmid">27159970</pub-id></element-citation></ref><ref id="B123-biomedicines-08-00405"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beretta</surname><given-names>G.</given-names></name></person-group><article-title>Novel producer of the antibiotic kirromycin belonging to the genus actinoplanes</article-title><source>J. Antibiot.</source><year>1993</year><volume>46</volume><fpage>1175</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.7164/antibiotics.46.1175</pub-id></element-citation></ref><ref id="B124-biomedicines-08-00405"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>H.</given-names></name><name><surname>Chinali</surname><given-names>G.</given-names></name><name><surname>Parmeggiani</surname><given-names>A.</given-names></name></person-group><article-title>Kirromycin, an inhibitor of protein biosynthesis that acts on elongation factor tu</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1974</year><volume>71</volume><fpage>4910</fpage><lpage>4914</lpage><pub-id pub-id-type="doi">10.1073/pnas.71.12.4910</pub-id><?supplied-pmid 4373734?><pub-id pub-id-type="pmid">4373734</pub-id></element-citation></ref><ref id="B125-biomedicines-08-00405"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spizek</surname><given-names>J.</given-names></name><name><surname>Rezanka</surname><given-names>T.</given-names></name></person-group><article-title>Lincomycin, clindamycin and their applications</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2004</year><volume>64</volume><fpage>455</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1007/s00253-003-1545-7</pub-id><?supplied-pmid 14762701?><pub-id pub-id-type="pmid">14762701</pub-id></element-citation></ref><ref id="B126-biomedicines-08-00405"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurabachew</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>S.H.</given-names></name><name><surname>Krastel</surname><given-names>P.</given-names></name><name><surname>Schmitt</surname><given-names>E.K.</given-names></name><name><surname>Suresh</surname><given-names>B.L.</given-names></name><name><surname>Goh</surname><given-names>A.</given-names></name><name><surname>Knox</surname><given-names>J.E.</given-names></name><name><surname>Ma</surname><given-names>N.L.</given-names></name><name><surname>Jiricek</surname><given-names>J.</given-names></name><name><surname>Beer</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Lipiarmycin targets rna polymerase and has good activity against multidrug-resistant strains of mycobacterium tuberculosis</article-title><source>J. Antimicrob. Chemother.</source><year>2008</year><volume>62</volume><fpage>713</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1093/jac/dkn269</pub-id><?supplied-pmid 18587134?><pub-id pub-id-type="pmid">18587134</pub-id></element-citation></ref><ref id="B127-biomedicines-08-00405"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebets</surname><given-names>Y.</given-names></name><name><surname>Lupoli</surname><given-names>T.</given-names></name><name><surname>Qiao</surname><given-names>Y.</given-names></name><name><surname>Schirner</surname><given-names>K.</given-names></name><name><surname>Villet</surname><given-names>R.</given-names></name><name><surname>Hooper</surname><given-names>D.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name><name><surname>Walker</surname><given-names>S.</given-names></name></person-group><article-title>Moenomycin resistance mutations in <italic>Staphylococcus aureus</italic> reduce peptidoglycan chain length and cause aberrant cell division</article-title><source>ACS Chem. Biol.</source><year>2014</year><volume>9</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1021/cb4006744</pub-id><pub-id pub-id-type="pmid">24255971</pub-id></element-citation></ref><ref id="B128-biomedicines-08-00405"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name></person-group><article-title>Mucroporin, the first cationic host defense peptide from the venom of <italic>Lychas mucronatus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2008</year><volume>52</volume><fpage>3967</fpage><lpage>3972</lpage><pub-id pub-id-type="doi">10.1128/AAC.00542-08</pub-id><pub-id pub-id-type="pmid">18779362</pub-id></element-citation></ref><ref id="B129-biomedicines-08-00405"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchard</surname><given-names>C.</given-names></name><name><surname>Brooks</surname><given-names>L.</given-names></name><name><surname>Beckley</surname><given-names>A.</given-names></name><name><surname>Colquhoun</surname><given-names>J.</given-names></name><name><surname>Dewhurst</surname><given-names>S.</given-names></name><name><surname>Dunman</surname><given-names>P.M.</given-names></name></person-group><article-title>Neomycin sulfate improves the antimicrobial activity of mupirocin-based antibacterial ointments</article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>862</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1128/AAC.02083-15</pub-id><pub-id pub-id-type="pmid">26596945</pub-id></element-citation></ref><ref id="B130-biomedicines-08-00405"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>J.F.</given-names></name><name><surname>Henriques</surname><given-names>I.S.</given-names></name><name><surname>Correia</surname><given-names>A.</given-names></name><name><surname>Santos</surname><given-names>E.B.H.</given-names></name><name><surname>Esteves</surname><given-names>V.I.</given-names></name></person-group><article-title>Antibacterial activity of oxytetracycline photoproducts in marine aquaculture&#x02019;s water</article-title><source>Environ. Pollut.</source><year>2017</year><volume>220</volume><fpage>644</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/j.envpol.2016.10.021</pub-id><pub-id pub-id-type="pmid">27769773</pub-id></element-citation></ref><ref id="B131-biomedicines-08-00405"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>A.J.</given-names></name></person-group><article-title>The penicillins</article-title><source>Mayo Clin. Proc.</source><year>1999</year><volume>74</volume><fpage>290</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.4065/74.3.290</pub-id><pub-id pub-id-type="pmid">10090000</pub-id></element-citation></ref><ref id="B132-biomedicines-08-00405"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paukner</surname><given-names>S.</given-names></name><name><surname>Riedl</surname><given-names>R.</given-names></name></person-group><article-title>Pleuromutilins: Potent drugs for resistant bugs-mode of action and resistance</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2017</year><volume>7</volume><fpage>a027110</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a027110</pub-id><pub-id pub-id-type="pmid">27742734</pub-id></element-citation></ref><ref id="B133-biomedicines-08-00405"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trimble</surname><given-names>M.J.</given-names></name><name><surname>Mlynarcik</surname><given-names>P.</given-names></name><name><surname>Kolar</surname><given-names>M.</given-names></name><name><surname>Hancock</surname><given-names>R.E.</given-names></name></person-group><article-title>Polymyxin: Alternative mechanisms of action and resistance</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2016</year><volume>6</volume><fpage>a025288</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a025288</pub-id><pub-id pub-id-type="pmid">27503996</pub-id></element-citation></ref><ref id="B134-biomedicines-08-00405"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>E.C.</given-names></name><name><surname>Curtis</surname><given-names>N.</given-names></name><name><surname>Cranswick</surname><given-names>N.</given-names></name><name><surname>Gwee</surname><given-names>A.</given-names></name></person-group><article-title>Pristinamycin: Old drug, new tricks?</article-title><source>J. Antimicrob. Chemother.</source><year>2014</year><volume>69</volume><fpage>2319</fpage><lpage>2325</lpage><pub-id pub-id-type="doi">10.1093/jac/dku167</pub-id><?supplied-pmid 24891428?><pub-id pub-id-type="pmid">24891428</pub-id></element-citation></ref><ref id="B135-biomedicines-08-00405"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Chaudry</surname><given-names>M.T.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Xiao</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>W.</given-names></name></person-group><article-title>Bacteriostatic effect of quercetin as an antibiotic alternative in vivo and its antibacterial mechanism in vitro</article-title><source>J. Food. Prot.</source><year>2018</year><volume>81</volume><fpage>68</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.4315/0362-028X.JFP-17-214</pub-id><?supplied-pmid 29271686?><pub-id pub-id-type="pmid">29271686</pub-id></element-citation></ref><ref id="B136-biomedicines-08-00405"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Cruz</surname><given-names>M.</given-names></name><name><surname>Gonzalez</surname><given-names>I.</given-names></name><name><surname>Parish</surname><given-names>C.A.</given-names></name><name><surname>Onishi</surname><given-names>R.</given-names></name><name><surname>Tormo</surname><given-names>J.R.</given-names></name><name><surname>Martin</surname><given-names>J.</given-names></name><name><surname>Pelaez</surname><given-names>F.</given-names></name><name><surname>Zink</surname><given-names>D.</given-names></name><name><surname>El Aouad</surname><given-names>N.</given-names></name><name><surname>Reyes</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Production of ramoplanin and ramoplanin analogs by actinomycetes</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>343</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.00343</pub-id><?supplied-pmid 28321210?><pub-id pub-id-type="pmid">28321210</pub-id></element-citation></ref><ref id="B137-biomedicines-08-00405"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floss</surname><given-names>H.G.</given-names></name><name><surname>Yu</surname><given-names>T.W.</given-names></name></person-group><article-title>Rifamycins mode of action, resistance, and biosynthesis</article-title><source>Chem. Rev.</source><year>2005</year><volume>105</volume><fpage>621</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1021/cr030112j</pub-id><pub-id pub-id-type="pmid">15700959</pub-id></element-citation></ref><ref id="B138-biomedicines-08-00405"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nahoum</surname><given-names>V.</given-names></name><name><surname>Spector</surname><given-names>S.</given-names></name><name><surname>Loll</surname><given-names>P.J.</given-names></name></person-group><article-title>Structure of ristocetin a in complex with a bacterial cell-wall mimetic</article-title><source>Acta Cryst. D Biol. Cryst.</source><year>2009</year><volume>65</volume><fpage>832</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1107/S0907444909018344</pub-id></element-citation></ref><ref id="B139-biomedicines-08-00405"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sweeney</surname><given-names>P.</given-names></name><name><surname>Murphy</surname><given-names>C.D.</given-names></name><name><surname>Caffrey</surname><given-names>P.</given-names></name></person-group><article-title>Exploiting the genome sequence of streptomyces nodosus for enhanced antibiotic production</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2016</year><volume>100</volume><fpage>1285</fpage><lpage>1295</lpage><pub-id pub-id-type="doi">10.1007/s00253-015-7060-9</pub-id><pub-id pub-id-type="pmid">26497174</pub-id></element-citation></ref><ref id="B140-biomedicines-08-00405"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L.L.</given-names></name><name><surname>Zhan</surname><given-names>M.Y.</given-names></name><name><surname>Zhuo</surname><given-names>Y.L.</given-names></name><name><surname>Pan</surname><given-names>Y.M.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>X.H.</given-names></name><name><surname>Yang</surname><given-names>P.J.</given-names></name><name><surname>Liu</surname><given-names>H.L.</given-names></name><name><surname>Liang</surname><given-names>Z.H.</given-names></name><name><surname>Huang</surname><given-names>X.D.</given-names></name><etal/></person-group><article-title>Antimicrobial activities of a proline-rich proprotein from <italic>Spodoptera litura</italic></article-title><source>Dev. Comp. Immunol.</source><year>2018</year><volume>87</volume><fpage>137</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.dci.2018.06.011</pub-id><pub-id pub-id-type="pmid">29935286</pub-id></element-citation></ref><ref id="B141-biomedicines-08-00405"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holloway</surname><given-names>W.J.</given-names></name></person-group><article-title>Spectinomyein</article-title><source>Med. Clin. N. Am.</source><year>1982</year><volume>66</volume><fpage>169</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/S0025-7125(16)31450-X</pub-id><pub-id pub-id-type="pmid">6460907</pub-id></element-citation></ref><ref id="B142-biomedicines-08-00405"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>E.</given-names></name><name><surname>Keller</surname><given-names>N.</given-names></name></person-group><article-title>Spiramycin renaissance</article-title><source>J. Antimicrob. Chemother.</source><year>1998</year><volume>42</volume><fpage>572</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1093/jac/42.5.572</pub-id><pub-id pub-id-type="pmid">9848439</pub-id></element-citation></ref><ref id="B143-biomedicines-08-00405"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>H.E.</given-names></name><name><surname>Angulo</surname><given-names>F.J.</given-names></name><name><surname>Granier</surname><given-names>S.A.</given-names></name><name><surname>Scott</surname><given-names>H.M.</given-names></name><name><surname>Loneragan</surname><given-names>G.H.</given-names></name></person-group><article-title>Illustrative examples of probable transfer of resistance determinants from food animals to humans: Streptothricins, glycopeptides, and colistin</article-title><source>F1000Research</source><year>2017</year><volume>6</volume><fpage>1805</fpage><pub-id pub-id-type="doi">10.12688/f1000research.12777.1</pub-id><pub-id pub-id-type="pmid">29188021</pub-id></element-citation></ref><ref id="B144-biomedicines-08-00405"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Martin</surname><given-names>V.</given-names></name><name><surname>Johnson</surname><given-names>A.</given-names></name><name><surname>McEntee</surname><given-names>L.</given-names></name><name><surname>Farrington</surname><given-names>N.</given-names></name><name><surname>Padmore</surname><given-names>K.</given-names></name><name><surname>Cojutti</surname><given-names>P.</given-names></name><name><surname>Pea</surname><given-names>F.</given-names></name><name><surname>Neely</surname><given-names>M.N.</given-names></name><name><surname>Hope</surname><given-names>W.W.</given-names></name></person-group><article-title>Pharmacodynamics of teicoplanin against mrsa</article-title><source>J. Antimicrob. Chemother.</source><year>2017</year><volume>72</volume><fpage>3382</fpage><lpage>3389</lpage><pub-id pub-id-type="doi">10.1093/jac/dkx289</pub-id><?supplied-pmid 28962026?><pub-id pub-id-type="pmid">28962026</pub-id></element-citation></ref><ref id="B145-biomedicines-08-00405"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>F.</given-names></name><name><surname>Starosta</surname><given-names>A.L.</given-names></name><name><surname>Arenz</surname><given-names>S.</given-names></name><name><surname>Sohmen</surname><given-names>D.</given-names></name><name><surname>D&#x000f6;nh&#x000f6;fer</surname><given-names>A.</given-names></name><name><surname>Wilson</surname><given-names>D.N.</given-names></name></person-group><article-title>Tetracycline antibiotics and resistance mechanisms</article-title><source>Biol. Chem.</source><year>2014</year><volume>395</volume><fpage>559</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1515/hsz-2013-0292</pub-id><?supplied-pmid 24497223?><pub-id pub-id-type="pmid">24497223</pub-id></element-citation></ref><ref id="B146-biomedicines-08-00405"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp-Wallace</surname><given-names>K.M.</given-names></name><name><surname>Endimiani</surname><given-names>A.</given-names></name><name><surname>Taracila</surname><given-names>M.A.</given-names></name><name><surname>Bonomo</surname><given-names>R.A.</given-names></name></person-group><article-title>Carbapenems: Past, present, and future</article-title><source>Antimicrob. Agents Chemother.</source><year>2011</year><volume>55</volume><fpage>4943</fpage><lpage>4960</lpage><pub-id pub-id-type="doi">10.1128/AAC.00296-11</pub-id><?supplied-pmid 21859938?><pub-id pub-id-type="pmid">21859938</pub-id></element-citation></ref><ref id="B147-biomedicines-08-00405"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolaou</surname><given-names>K.C.</given-names></name></person-group><article-title>How thiostrepton was made in the laboratory</article-title><source>Angew. Chem. Int. Ed. Engl.</source><year>2012</year><volume>51</volume><fpage>12414</fpage><lpage>12436</lpage><pub-id pub-id-type="doi">10.1002/anie.201205576</pub-id><?supplied-pmid 23208736?><pub-id pub-id-type="pmid">23208736</pub-id></element-citation></ref><ref id="B148-biomedicines-08-00405"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bothra</surname><given-names>M.</given-names></name><name><surname>Lodha</surname><given-names>R.</given-names></name><name><surname>Kabra</surname><given-names>S.K.</given-names></name></person-group><article-title>Tobramycin for the treatment of bacterial pneumonia in children</article-title><source>Expert Opin. Pharm.</source><year>2012</year><volume>13</volume><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1517/14656566.2012.656090</pub-id></element-citation></ref><ref id="B149-biomedicines-08-00405"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>K.</given-names></name><name><surname>Ichikawa</surname><given-names>S.</given-names></name></person-group><article-title>Tunicamycin: Chemical synthesis and biosynthesis</article-title><source>J. Antibiot.</source><year>2019</year><volume>72</volume><fpage>924</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1038/s41429-019-0200-1</pub-id></element-citation></ref><ref id="B150-biomedicines-08-00405"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Ahmad</surname><given-names>I.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>Z.</given-names></name></person-group><article-title>Pharmacokinetic-pharmacodynamic modeling of tylosin against <italic>Streptococcus suis</italic> in pigs</article-title><source>BMC Vet. Res.</source><year>2018</year><volume>14</volume><elocation-id>319</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-018-1645-3</pub-id><pub-id pub-id-type="pmid">30355326</pub-id></element-citation></ref><ref id="B151-biomedicines-08-00405"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holm</surname><given-names>M.</given-names></name><name><surname>Borg</surname><given-names>A.</given-names></name><name><surname>Ehrenberg</surname><given-names>M.</given-names></name><name><surname>Sanyal</surname><given-names>S.</given-names></name></person-group><article-title>Molecular mechanism of viomycin inhibition of peptide elongation in bacteria</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>978</fpage><lpage>983</lpage><pub-id pub-id-type="doi">10.1073/pnas.1517541113</pub-id><pub-id pub-id-type="pmid">26755601</pub-id></element-citation></ref><ref id="B152-biomedicines-08-00405"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischoff</surname><given-names>K.M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Rich</surname><given-names>J.O.</given-names></name></person-group><article-title>Fate of virginiamycin through the fuel ethanol production process</article-title><source>World J. Microbiol. Biotechnol.</source><year>2016</year><volume>32</volume><fpage>76</fpage><pub-id pub-id-type="doi">10.1007/s11274-016-2026-3</pub-id><pub-id pub-id-type="pmid">27038946</pub-id></element-citation></ref><ref id="B153-biomedicines-08-00405"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T.H.</given-names></name><name><surname>Hall</surname><given-names>K.N.</given-names></name><name><surname>Aguilar</surname><given-names>M.I.</given-names></name></person-group><article-title>Antimicrobial peptide structure and mechanism of action: A focus on the role of membrane structure</article-title><source>Curr. Top. Med. Chem.</source><year>2016</year><volume>16</volume><fpage>25</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.2174/1568026615666150703121700</pub-id><pub-id pub-id-type="pmid">26139112</pub-id></element-citation></ref><ref id="B154-biomedicines-08-00405"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>D.</given-names></name><name><surname>Ghosh</surname><given-names>D.</given-names></name><name><surname>Bhattacharya</surname><given-names>S.</given-names></name><name><surname>Sarkar</surname><given-names>S.</given-names></name><name><surname>Karmakar</surname><given-names>P.</given-names></name><name><surname>Koley</surname><given-names>H.</given-names></name><name><surname>Gachhui</surname><given-names>R.</given-names></name></person-group><article-title>Antibacterial activity of polyphenolic fraction of kombucha against <italic>Vibrio cholerae</italic>: Targeting cell membrane</article-title><source>Lett. Appl. Microbiol.</source><year>2018</year><volume>66</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1111/lam.12829</pub-id><pub-id pub-id-type="pmid">29193174</pub-id></element-citation></ref><ref id="B155-biomedicines-08-00405"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakarla</surname><given-names>P.</given-names></name><name><surname>Floyd</surname><given-names>J.</given-names></name><name><surname>Mukherjee</surname><given-names>M.</given-names></name><name><surname>Devireddy</surname><given-names>A.R.</given-names></name><name><surname>Inupakutika</surname><given-names>M.A.</given-names></name><name><surname>Ranweera</surname><given-names>I.</given-names></name><name><surname>Kc</surname><given-names>R.</given-names></name><name><surname>Shrestha</surname><given-names>U.</given-names></name><name><surname>Cheeti</surname><given-names>U.R.</given-names></name><name><surname>Willmon</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>Inhibition of the multidrug efflux pump lmrs from <italic>Staphylococcus aureus</italic> by cumin spice <italic>Cuminum cyminum</italic></article-title><source>Arch. Microbiol.</source><year>2017</year><volume>199</volume><fpage>465</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1007/s00203-016-1314-5</pub-id><?supplied-pmid 27830269?><pub-id pub-id-type="pmid">27830269</pub-id></element-citation></ref><ref id="B156-biomedicines-08-00405"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skariyachan</surname><given-names>S.</given-names></name><name><surname>Sridhar</surname><given-names>V.S.</given-names></name><name><surname>Packirisamy</surname><given-names>S.</given-names></name><name><surname>Kumargowda</surname><given-names>S.T.</given-names></name><name><surname>Challapilli</surname><given-names>S.B.</given-names></name></person-group><article-title>Recent perspectives on the molecular basis of biofilm formation by <italic>Pseudomonas aeruginosa</italic> and approaches for treatment and biofilm dispersal</article-title><source>Folia Microbiol.</source><year>2018</year><volume>63</volume><fpage>413</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1007/s12223-018-0585-4</pub-id><?supplied-pmid 29352409?><pub-id pub-id-type="pmid">29352409</pub-id></element-citation></ref><ref id="B157-biomedicines-08-00405"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inui</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>D.C.</given-names></name><name><surname>Franzblau</surname><given-names>S.G.</given-names></name><name><surname>Pauli</surname><given-names>G.F.</given-names></name></person-group><article-title>Counter-current chromatography based analysis of synergy in an anti-tuberculosis ethnobotanical</article-title><source>J. Chromatogr. A</source><year>2007</year><volume>1151</volume><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.chroma.2007.01.127</pub-id><pub-id pub-id-type="pmid">17316661</pub-id></element-citation></ref><ref id="B158-biomedicines-08-00405"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheesman</surname><given-names>J.M.</given-names></name><name><surname>Ilanko</surname><given-names>A.</given-names></name><name><surname>Blonk</surname><given-names>B.</given-names></name><name><surname>Cock</surname><given-names>I.E.</given-names></name></person-group><article-title>Developing new antimicrobial therapies: Are synergistic combinations of plant extracts/compounds with conventional antibiotics the solution?</article-title><source>Pharm. Rev.</source><year>2017</year><volume>11</volume><fpage>57</fpage><lpage>72</lpage></element-citation></ref><ref id="B159-biomedicines-08-00405"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>B.C.</given-names></name><name><surname>Ip</surname><given-names>M.</given-names></name><name><surname>Lau</surname><given-names>C.B.</given-names></name><name><surname>Lui</surname><given-names>S.L.</given-names></name><name><surname>Jolivalt</surname><given-names>C.</given-names></name><name><surname>Ganem-Elbaz</surname><given-names>C.</given-names></name><name><surname>Litaudon</surname><given-names>M.</given-names></name><name><surname>Reiner</surname><given-names>N.E.</given-names></name><name><surname>Gong</surname><given-names>H.</given-names></name><name><surname>See</surname><given-names>R.H.</given-names></name><etal/></person-group><article-title>Synergistic effects of baicalein with ciprofloxacin against nora over-expressed methicillin-resistant <italic>Staphylococcus aureus</italic> (mrsa) and inhibition of mrsa pyruvate kinase</article-title><source>J. Ethnopharmacol.</source><year>2011</year><volume>137</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.06.039</pub-id><pub-id pub-id-type="pmid">21782012</pub-id></element-citation></ref><ref id="B160-biomedicines-08-00405"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalia</surname><given-names>N.P.</given-names></name><name><surname>Mahajan</surname><given-names>P.</given-names></name><name><surname>Mehra</surname><given-names>R.</given-names></name><name><surname>Nargotra</surname><given-names>A.</given-names></name><name><surname>Sharma</surname><given-names>J.P.</given-names></name><name><surname>Koul</surname><given-names>S.</given-names></name><name><surname>Khan</surname><given-names>I.A.</given-names></name></person-group><article-title>Capsaicin, a novel inhibitor of the nora efflux pump, reduces the intracellular invasion of <italic>Staphylococcus aureus</italic></article-title><source>J. Antimicrob. Chemother.</source><year>2012</year><volume>67</volume><fpage>2401</fpage><lpage>2408</lpage><pub-id pub-id-type="doi">10.1093/jac/dks232</pub-id><pub-id pub-id-type="pmid">22807321</pub-id></element-citation></ref><ref id="B161-biomedicines-08-00405"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponnusamy</surname><given-names>K.</given-names></name><name><surname>Ramasamy</surname><given-names>M.</given-names></name><name><surname>Savarimuthu</surname><given-names>I.</given-names></name><name><surname>Paulraj</surname><given-names>M.G.</given-names></name></person-group><article-title>Indirubin potentiates ciprofloxacin activity in the nora efflux pump of <italic>Staphylococcus aureus</italic></article-title><source>Scand. J. Infect. Dis.</source><year>2010</year><volume>42</volume><fpage>500</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.3109/00365541003713630</pub-id><pub-id pub-id-type="pmid">20380543</pub-id></element-citation></ref><ref id="B162-biomedicines-08-00405"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holler</surname><given-names>J.G.</given-names></name><name><surname>Christensen</surname><given-names>S.B.</given-names></name><name><surname>Slotved</surname><given-names>H.C.</given-names></name><name><surname>Rasmussen</surname><given-names>H.B.</given-names></name><name><surname>Guzman</surname><given-names>A.</given-names></name><name><surname>Olsen</surname><given-names>C.E.</given-names></name><name><surname>Petersen</surname><given-names>B.</given-names></name><name><surname>Molgaard</surname><given-names>P.</given-names></name></person-group><article-title>Novel inhibitory activity of the <italic>Staphylococcus aureus</italic> nora efflux pump by a kaempferol rhamnoside isolated from <italic>Persea lingue</italic> nees</article-title><source>J. Antimicrob. Chemother.</source><year>2012</year><volume>67</volume><fpage>1138</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1093/jac/dks005</pub-id><pub-id pub-id-type="pmid">22311936</pub-id></element-citation></ref><ref id="B163-biomedicines-08-00405"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiu</surname><given-names>W.K.</given-names></name><name><surname>Malkinson</surname><given-names>J.P.</given-names></name><name><surname>Rahman</surname><given-names>M.M.</given-names></name><name><surname>Curry</surname><given-names>J.</given-names></name><name><surname>Stapleton</surname><given-names>P.</given-names></name><name><surname>Gunaratnam</surname><given-names>M.</given-names></name><name><surname>Neidle</surname><given-names>S.</given-names></name><name><surname>Mushtaq</surname><given-names>S.</given-names></name><name><surname>Warner</surname><given-names>M.</given-names></name><name><surname>Livermore</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>A new plant-derived antibacterial is an inhibitor of efflux pumps in <italic>Staphylococcus aureus</italic></article-title><source>Int. J. Antimicrob. Agents</source><year>2013</year><volume>42</volume><fpage>513</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2013.08.007</pub-id><pub-id pub-id-type="pmid">24119569</pub-id></element-citation></ref><ref id="B164-biomedicines-08-00405"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bame</surname><given-names>J.R.</given-names></name><name><surname>Graf</surname><given-names>T.N.</given-names></name><name><surname>Junio</surname><given-names>H.A.</given-names></name><name><surname>Bussey</surname><given-names>R.O.</given-names><suffix>III</suffix></name><name><surname>Jarmusch</surname><given-names>S.A.</given-names></name><name><surname>El-Elimat</surname><given-names>T.</given-names></name><name><surname>Falkinham</surname><given-names>J.O.</given-names><suffix>III</suffix></name><name><surname>Oberlies</surname><given-names>N.H.</given-names></name><name><surname>Cech</surname><given-names>R.A.</given-names></name><name><surname>Cech</surname><given-names>N.B.</given-names></name></person-group><article-title>Sarothrin from <italic>Alkanna orientalis</italic> is an antimicrobial agent and efflux pump inhibitor</article-title><source>Planta Med.</source><year>2013</year><volume>79</volume><fpage>327</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1055/s-0032-1328259</pub-id><?supplied-pmid 23468310?><pub-id pub-id-type="pmid">23468310</pub-id></element-citation></ref><ref id="B165-biomedicines-08-00405"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>S.K.</given-names></name><name><surname>Pahwa</surname><given-names>S.</given-names></name><name><surname>Nandanwar</surname><given-names>H.</given-names></name><name><surname>Jachak</surname><given-names>S.M.</given-names></name></person-group><article-title>Phenylpropanoids of <italic>Alpinia galanga</italic> as efflux pump inhibitors in <italic>Mycobacterium smegmatis</italic> mc(2) 155</article-title><source>Fitoterapia</source><year>2012</year><volume>83</volume><fpage>1248</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1016/j.fitote.2012.06.008</pub-id><?supplied-pmid 22735598?><pub-id pub-id-type="pmid">22735598</pub-id></element-citation></ref><ref id="B166-biomedicines-08-00405"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwivedi</surname><given-names>G.R.</given-names></name><name><surname>Tyagi</surname><given-names>R.</given-names></name><name><surname>Sanchita</surname><given-names/></name><name><surname>Tripathi</surname><given-names>S.</given-names></name><name><surname>Pati</surname><given-names>S.</given-names></name><name><surname>Srivastava</surname><given-names>S.K.</given-names></name><name><surname>Darokar</surname><given-names>M.P.</given-names></name><name><surname>Sharma</surname><given-names>A.</given-names></name></person-group><article-title>Antibiotics potentiating potential of catharanthine against superbug <italic>Pseudomonas aeruginosa</italic></article-title><source>J. Biomol. Struct. Dyn.</source><year>2018</year><volume>36</volume><fpage>4270</fpage><lpage>4284</lpage><pub-id pub-id-type="doi">10.1080/07391102.2017.1413424</pub-id><?supplied-pmid 29210342?><pub-id pub-id-type="pmid">29210342</pub-id></element-citation></ref><ref id="B167-biomedicines-08-00405"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisuria</surname><given-names>V.B.</given-names></name><name><surname>Hosseinidoust</surname><given-names>Z.</given-names></name><name><surname>Tufenkji</surname><given-names>N.</given-names></name></person-group><article-title>Polyphenolic extract from maple syrup potentiates antibiotic susceptibility and reduces biofilm formation of pathogenic bacteria</article-title><source>Appl. Environ. Microbiol.</source><year>2015</year><volume>81</volume><fpage>3782</fpage><lpage>3792</lpage><pub-id pub-id-type="doi">10.1128/AEM.00239-15</pub-id><pub-id pub-id-type="pmid">25819960</pub-id></element-citation></ref><ref id="B168-biomedicines-08-00405"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bag</surname><given-names>A.</given-names></name><name><surname>Chattopadhyay</surname><given-names>R.R.</given-names></name></person-group><article-title>Efflux-pump inhibitory activity of a gallotannin from <italic>Terminalia chebula</italic> fruit against multidrug-resistant uropathogenic <italic>Escherichia coli</italic></article-title><source>Nat. Prod. Res.</source><year>2014</year><volume>28</volume><fpage>1280</fpage><lpage>1283</lpage><pub-id pub-id-type="doi">10.1080/14786419.2014.895729</pub-id><pub-id pub-id-type="pmid">24620744</pub-id></element-citation></ref><ref id="B169-biomedicines-08-00405"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwivedi</surname><given-names>G.R.</given-names></name><name><surname>Maurya</surname><given-names>A.</given-names></name><name><surname>Yadav</surname><given-names>D.K.</given-names></name><name><surname>Khan</surname><given-names>F.</given-names></name><name><surname>Darokar</surname><given-names>M.P.</given-names></name><name><surname>Srivastava</surname><given-names>S.K.</given-names></name></person-group><article-title>Drug resistance reversal potential of ursolic acid derivatives against nalidixic acid- and multidrug-resistant <italic>Escherichia coli</italic></article-title><source>Chem. Biol. Drug Des.</source><year>2015</year><volume>86</volume><fpage>272</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1111/cbdd.12491</pub-id><pub-id pub-id-type="pmid">25476148</pub-id></element-citation></ref><ref id="B170-biomedicines-08-00405"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurya</surname><given-names>A.</given-names></name><name><surname>Dwivedi</surname><given-names>G.R.</given-names></name><name><surname>Darokar</surname><given-names>M.P.</given-names></name><name><surname>Srivastava</surname><given-names>S.K.</given-names></name></person-group><article-title>Antibacterial and synergy of clavine alkaloid lysergol and its derivatives against nalidixic acid-resistant <italic>Escherichia coli</italic></article-title><source>Chem. Biol. Drug Des.</source><year>2013</year><volume>81</volume><fpage>484</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1111/cbdd.12103</pub-id><pub-id pub-id-type="pmid">23290001</pub-id></element-citation></ref><ref id="B171-biomedicines-08-00405"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aghayan</surname><given-names>S.S.</given-names></name><name><surname>Mogadam</surname><given-names>H.K.</given-names></name><name><surname>Fazli</surname><given-names>M.</given-names></name><name><surname>Darban-Sarokhalil</surname><given-names>D.</given-names></name><name><surname>Khoramrooz</surname><given-names>S.S.</given-names></name><name><surname>Jabalameli</surname><given-names>F.</given-names></name><name><surname>Yaslianifard</surname><given-names>S.</given-names></name><name><surname>Mirzaii</surname><given-names>M.</given-names></name></person-group><article-title>The effects of berberine and palmatine on efflux pumps inhibition with different gene patterns in <italic>Pseudomonas aeruginosa</italic> isolated from burn infections</article-title><source>Avicenna J. Med. Biotechnol.</source><year>2017</year><volume>9</volume><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">28090273</pub-id></element-citation></ref><ref id="B172-biomedicines-08-00405"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adwan</surname><given-names>G.</given-names></name><name><surname>Abu-Shanab</surname><given-names>B.</given-names></name><name><surname>Adwan</surname><given-names>K.</given-names></name></person-group><article-title>Antibacterial activities of some plant extracts alone and in combination with different antimicrobials against multidrug-resistant <italic>Pseudomonas aeruginosa</italic> strains</article-title><source>Asian Pac. J. Trop. Biomed.</source><year>2010</year><volume>3</volume><fpage>266</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/S1995-7645(10)60064-8</pub-id></element-citation></ref><ref id="B173-biomedicines-08-00405"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shriram</surname><given-names>V.</given-names></name><name><surname>Khare</surname><given-names>T.</given-names></name><name><surname>Bhagwat</surname><given-names>R.</given-names></name><name><surname>Shukla</surname><given-names>R.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name></person-group><article-title>Inhibiting bacterial drug efflux pumps via phyto-therapeutics to combat threatening antimicrobial resistance</article-title><source>Front. Microbiol.</source><year>2018</year><volume>9</volume><fpage>2990</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02990</pub-id><pub-id pub-id-type="pmid">30619113</pub-id></element-citation></ref><ref id="B174-biomedicines-08-00405"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudano Roccaro</surname><given-names>A.</given-names></name><name><surname>Blanco</surname><given-names>A.R.</given-names></name><name><surname>Giuliano</surname><given-names>F.</given-names></name><name><surname>Rusciano</surname><given-names>D.</given-names></name><name><surname>Enea</surname><given-names>V.</given-names></name></person-group><article-title>Epigallocatechin-gallate enhances the activity of tetracycline in staphylococci by inhibiting its efflux from bacterial cells</article-title><source>Antimicrob. Agents Chemother.</source><year>2004</year><volume>48</volume><fpage>1968</fpage><lpage>1973</lpage><pub-id pub-id-type="doi">10.1128/AAC.48.6.1968-1973.2004</pub-id><?supplied-pmid 15155186?><pub-id pub-id-type="pmid">15155186</pub-id></element-citation></ref><ref id="B175-biomedicines-08-00405"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>V.</given-names></name><name><surname>Luis</surname><given-names>A.</given-names></name><name><surname>Oleastro</surname><given-names>M.</given-names></name><name><surname>Domingues</surname><given-names>F.</given-names></name><name><surname>Ferreira</surname><given-names>S.</given-names></name></person-group><article-title>Polyphenols as resistance modulators in <italic>Arcobacter butzleri</italic></article-title><source>Folia Microbiol.</source><year>2019</year><volume>64</volume><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1007/s12223-019-00678-3</pub-id><?supplied-pmid 30637574?><pub-id pub-id-type="pmid">30637574</pub-id></element-citation></ref><ref id="B176-biomedicines-08-00405"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazly Bazzaz</surname><given-names>B.S.</given-names></name><name><surname>Sarabandi</surname><given-names>S.</given-names></name><name><surname>Khameneh</surname><given-names>B.</given-names></name><name><surname>Hosseinzadeh</surname><given-names>H.</given-names></name></person-group><article-title>Effect of catechins, green tea extract and methylxanthines in combination with gentamicin against <italic>Staphylococcus aureus</italic> and <italic>Pseudomonas aeruginosa</italic>: -combination therapy against resistant bacteria</article-title><source>J. Pharmacopunct.</source><year>2016</year><volume>19</volume><fpage>312</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.3831/KPI.2016.19.032</pub-id><?supplied-pmid 28097041?><pub-id pub-id-type="pmid">28097041</pub-id></element-citation></ref><ref id="B177-biomedicines-08-00405"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palacios</surname><given-names>L.</given-names></name><name><surname>Rosado</surname><given-names>H.</given-names></name><name><surname>Micol</surname><given-names>V.</given-names></name><name><surname>Rosato</surname><given-names>A.E.</given-names></name><name><surname>Bernal</surname><given-names>P.</given-names></name><name><surname>Arroyo</surname><given-names>R.</given-names></name><name><surname>Grounds</surname><given-names>H.</given-names></name><name><surname>Anderson</surname><given-names>J.C.</given-names></name><name><surname>Stabler</surname><given-names>R.A.</given-names></name><name><surname>Taylor</surname><given-names>P.W.</given-names></name></person-group><article-title>Staphylococcal phenotypes induced by naturally occurring and synthetic membrane-interactive polyphenolic beta-lactam resistance modifiers</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e93830</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0093830</pub-id><?supplied-pmid 24699700?><pub-id pub-id-type="pmid">24699700</pub-id></element-citation></ref><ref id="B178-biomedicines-08-00405"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>P.D.</given-names></name><name><surname>Shah</surname><given-names>S.</given-names></name><name><surname>Anderson</surname><given-names>J.C.</given-names></name><name><surname>Hara</surname><given-names>Y.</given-names></name><name><surname>Hamilton-Miller</surname><given-names>J.M.</given-names></name><name><surname>Taylor</surname><given-names>P.W.</given-names></name></person-group><article-title>Modulation of beta-lactam resistance in <italic>Staphylococcus aureus</italic> by catechins and gallates</article-title><source>Int. J. Antimicrob. Agents</source><year>2004</year><volume>23</volume><fpage>462</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2003.09.027</pub-id><pub-id pub-id-type="pmid">15120724</pub-id></element-citation></ref><ref id="B179-biomedicines-08-00405"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stapleton</surname><given-names>P.D.</given-names></name><name><surname>Shah</surname><given-names>S.</given-names></name><name><surname>Hara</surname><given-names>Y.</given-names></name><name><surname>Taylor</surname><given-names>P.W.</given-names></name></person-group><article-title>Potentiation of catechin gallate-mediated sensitization of <italic>Staphylococcus aureus</italic> to oxacillin by nongalloylated catechins</article-title><source>Antimicrob. Agents Chemother.</source><year>2006</year><volume>50</volume><fpage>752</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1128/AAC.50.2.752-755.2006</pub-id><pub-id pub-id-type="pmid">16436737</pub-id></element-citation></ref><ref id="B180-biomedicines-08-00405"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santiago</surname><given-names>C.</given-names></name><name><surname>Pang</surname><given-names>E.L.</given-names></name><name><surname>Lim</surname><given-names>K.H.</given-names></name><name><surname>Loh</surname><given-names>H.S.</given-names></name><name><surname>Ting</surname><given-names>K.N.</given-names></name></person-group><article-title>Inhibition of penicillin-binding protein 2a (pbp2a) in methicillin resistant <italic>Staphylococcus aureus</italic> (mrsa) by combination of ampicillin and a bioactive fraction from <italic>Duabanga grandiflora</italic></article-title><source>BMC Complement. Altern. Med.</source><year>2015</year><volume>15</volume><elocation-id>178</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-015-0699-z</pub-id><pub-id pub-id-type="pmid">26060128</pub-id></element-citation></ref><ref id="B181-biomedicines-08-00405"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>R.</given-names></name><name><surname>Islam</surname><given-names>B.</given-names></name><name><surname>Akram</surname><given-names>M.</given-names></name><name><surname>Shakil</surname><given-names>S.</given-names></name><name><surname>Ahmad</surname><given-names>A.</given-names></name><name><surname>Ali</surname><given-names>S.M.</given-names></name><name><surname>Siddiqui</surname><given-names>M.</given-names></name><name><surname>Khan</surname><given-names>A.U.</given-names></name></person-group><article-title>Antimicrobial activity of five herbal extracts against multi drug resistant (mdr) strains of bacteria and fungus of clinical origin</article-title><source>Molecules</source><year>2009</year><volume>14</volume><fpage>586</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.3390/molecules14020586</pub-id><pub-id pub-id-type="pmid">19214149</pub-id></element-citation></ref><ref id="B182-biomedicines-08-00405"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chovanova</surname><given-names>R.</given-names></name><name><surname>Mikulasova</surname><given-names>M.</given-names></name><name><surname>Vaverkova</surname><given-names>S.</given-names></name></person-group><article-title>In vitro antibacterial and antibiotic resistance modifying effect of bioactive plant extracts on methicillin-resistant <italic>Staphylococcus epidermidis</italic></article-title><source>Int. J. Microbiol.</source><year>2013</year><volume>2013</volume><fpage>760969</fpage><pub-id pub-id-type="doi">10.1155/2013/760969</pub-id><pub-id pub-id-type="pmid">24222768</pub-id></element-citation></ref><ref id="B183-biomedicines-08-00405"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>C.W.</given-names></name><name><surname>Mah</surname><given-names>T.F.</given-names></name></person-group><article-title>Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria</article-title><source>FEMS Microbiol. Rev.</source><year>2017</year><volume>41</volume><fpage>276</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1093/femsre/fux010</pub-id><pub-id pub-id-type="pmid">28369412</pub-id></element-citation></ref><ref id="B184-biomedicines-08-00405"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasamiravaka</surname><given-names>T.</given-names></name><name><surname>Labtani</surname><given-names>Q.</given-names></name><name><surname>Duez</surname><given-names>P.</given-names></name><name><surname>El Jaziri</surname><given-names>M.</given-names></name></person-group><article-title>The formation of biofilms by <italic>Pseudomonas aeruginosa</italic>: A review of the natural and synthetic compounds interfering with control mechanisms</article-title><source>BioMed Res. Int.</source><year>2015</year><volume>2015</volume><fpage>759348</fpage><pub-id pub-id-type="doi">10.1155/2015/759348</pub-id><?supplied-pmid 25866808?><pub-id pub-id-type="pmid">25866808</pub-id></element-citation></ref><ref id="B185-biomedicines-08-00405"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkawash</surname><given-names>M.A.</given-names></name><name><surname>Soothill</surname><given-names>J.S.</given-names></name><name><surname>Schiller</surname><given-names>N.L.</given-names></name></person-group><article-title>Alginate lyase enhances antibiotic killing of mucoid <italic>Pseudomonas aeruginosa</italic> in biofilms</article-title><source>APMIS</source><year>2006</year><volume>114</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0463.2006.apm_356.x</pub-id><pub-id pub-id-type="pmid">16519750</pub-id></element-citation></ref><ref id="B186-biomedicines-08-00405"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>D.</given-names></name><name><surname>Zuo</surname><given-names>R.</given-names></name><name><surname>Gonzalez Barrios</surname><given-names>A.F.</given-names></name><name><surname>Bedzyk</surname><given-names>L.A.</given-names></name><name><surname>Eldridge</surname><given-names>G.R.</given-names></name><name><surname>Pasmore</surname><given-names>M.E.</given-names></name><name><surname>Wood</surname><given-names>T.K.</given-names></name></person-group><article-title>Differential gene expression for investigation of <italic>Escherichia coli</italic> biofilm inhibition by plant extract ursolic acid</article-title><source>Appl. Environ. Microbiol.</source><year>2005</year><volume>71</volume><fpage>4022</fpage><lpage>4034</lpage><pub-id pub-id-type="doi">10.1128/AEM.71.7.4022-4034.2005</pub-id><?supplied-pmid 16000817?><pub-id pub-id-type="pmid">16000817</pub-id></element-citation></ref><ref id="B187-biomedicines-08-00405"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Park</surname><given-names>H.D.</given-names></name></person-group><article-title>Ginger extract inhibits biofilm formation by <italic>Pseudomonas aeruginosa</italic> pa14</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e76106</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0076106</pub-id><?supplied-pmid 24086697?><pub-id pub-id-type="pmid">24086697</pub-id></element-citation></ref><ref id="B188-biomedicines-08-00405"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulrey</surname><given-names>R.K.</given-names></name><name><surname>Barksdale</surname><given-names>S.M.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>van Hoek</surname><given-names>M.L.</given-names></name></person-group><article-title>Cranberry proanthocyanidins have anti biofilm properties against <italic>Pseudomonas aeruginosa</italic></article-title><source>BMC Complement. Altern. Med.</source><year>2014</year><volume>14</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/1472-6882-14-499</pub-id><?supplied-pmid 25511463?><pub-id pub-id-type="pmid">24383621</pub-id></element-citation></ref><ref id="B189-biomedicines-08-00405"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carneiro</surname><given-names>V.A.</given-names></name><name><surname>Santos</surname><given-names>H.S.</given-names></name><name><surname>Arruda</surname><given-names>F.V.</given-names></name><name><surname>Bandeira</surname><given-names>P.N.</given-names></name><name><surname>Albuquerque</surname><given-names>M.R.</given-names></name><name><surname>Pereira</surname><given-names>M.O.</given-names></name><name><surname>Henriques</surname><given-names>M.</given-names></name><name><surname>Cavada</surname><given-names>B.S.</given-names></name><name><surname>Teixeira</surname><given-names>E.H.</given-names></name></person-group><article-title>Casbane diterpene as a promising natural antimicrobial agent against biofilm-associated infections</article-title><source>Molecules</source><year>2010</year><volume>16</volume><fpage>190</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.3390/molecules16010190</pub-id><?supplied-pmid 21193844?><pub-id pub-id-type="pmid">21193844</pub-id></element-citation></ref><ref id="B190-biomedicines-08-00405"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skindersoe</surname><given-names>M.E.</given-names></name><name><surname>Ettinger-Epstein</surname><given-names>P.</given-names></name><name><surname>Rasmussen</surname><given-names>T.B.</given-names></name><name><surname>Bjarnsholt</surname><given-names>T.</given-names></name><name><surname>de Nys</surname><given-names>R.</given-names></name><name><surname>Givskov</surname><given-names>M.</given-names></name></person-group><article-title>Quorum sensing antagonism from marine organisms</article-title><source>Mar. Biotechnol.</source><year>2008</year><volume>10</volume><fpage>56</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s10126-007-9036-y</pub-id></element-citation></ref><ref id="B191-biomedicines-08-00405"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Kaufmann</surname><given-names>G.F.</given-names></name><name><surname>Bowen</surname><given-names>J.P.</given-names></name><name><surname>Arbiser</surname><given-names>J.L.</given-names></name><name><surname>Janda</surname><given-names>K.D.</given-names></name></person-group><article-title>Solenopsin a, a venom alkaloid from the fire ant <italic>Solenopsis invicta</italic>, inhibits quorum-sensing signaling in <italic>Pseudomonas aeruginosa</italic></article-title><source>J. Infect. Dis.</source><year>2008</year><volume>198</volume><fpage>1198</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1086/591916</pub-id><pub-id pub-id-type="pmid">18713055</pub-id></element-citation></ref><ref id="B192-biomedicines-08-00405"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandeputte</surname><given-names>O.M.</given-names></name><name><surname>Kiendrebeogo</surname><given-names>M.</given-names></name><name><surname>Rajaonson</surname><given-names>S.</given-names></name><name><surname>Diallo</surname><given-names>B.</given-names></name><name><surname>Mol</surname><given-names>A.</given-names></name><name><surname>El Jaziri</surname><given-names>M.</given-names></name><name><surname>Baucher</surname><given-names>M.</given-names></name></person-group><article-title>Identification of catechin as one of the flavonoids from <italic>Combretum albiflorum</italic> bark extract that reduces the production of quorum-sensing-controlled virulence factors in <italic>Pseudomonas aeruginosa</italic> pao1</article-title><source>Appl. Environ. Microbiol.</source><year>2010</year><volume>76</volume><fpage>243</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1128/AEM.01059-09</pub-id><pub-id pub-id-type="pmid">19854927</pub-id></element-citation></ref><ref id="B193-biomedicines-08-00405"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandeputte</surname><given-names>O.M.</given-names></name><name><surname>Kiendrebeogo</surname><given-names>M.</given-names></name><name><surname>Rasamiravaka</surname><given-names>T.</given-names></name><name><surname>Stevigny</surname><given-names>C.</given-names></name><name><surname>Duez</surname><given-names>P.</given-names></name><name><surname>Rajaonson</surname><given-names>S.</given-names></name><name><surname>Diallo</surname><given-names>B.</given-names></name><name><surname>Mol</surname><given-names>A.</given-names></name><name><surname>Baucher</surname><given-names>M.</given-names></name><name><surname>El Jaziri</surname><given-names>M.</given-names></name></person-group><article-title>The flavanone naringenin reduces the production of quorum sensing-controlled virulence factors in <italic>Pseudomonas aeruginosa</italic> pao1</article-title><source>Microbiology</source><year>2011</year><volume>157</volume><fpage>2120</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1099/mic.0.049338-0</pub-id><pub-id pub-id-type="pmid">21546585</pub-id></element-citation></ref><ref id="B194-biomedicines-08-00405"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakobsen</surname><given-names>T.H.</given-names></name><name><surname>van Gennip</surname><given-names>M.</given-names></name><name><surname>Phipps</surname><given-names>R.K.</given-names></name><name><surname>Shanmugham</surname><given-names>M.S.</given-names></name><name><surname>Christensen</surname><given-names>L.D.</given-names></name><name><surname>Alhede</surname><given-names>M.</given-names></name><name><surname>Skindersoe</surname><given-names>M.E.</given-names></name><name><surname>Rasmussen</surname><given-names>T.B.</given-names></name><name><surname>Friedrich</surname><given-names>K.</given-names></name><name><surname>Uthe</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing</article-title><source>Antimicrob. Agents Chemother.</source><year>2012</year><volume>56</volume><fpage>2314</fpage><lpage>2325</lpage><pub-id pub-id-type="doi">10.1128/AAC.05919-11</pub-id><?supplied-pmid 22314537?><pub-id pub-id-type="pmid">22314537</pub-id></element-citation></ref><ref id="B195-biomedicines-08-00405"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>T.S.</given-names></name><name><surname>Bais</surname><given-names>H.P.</given-names></name><name><surname>Deziel</surname><given-names>E.</given-names></name><name><surname>Schweizer</surname><given-names>H.P.</given-names></name><name><surname>Rahme</surname><given-names>L.G.</given-names></name><name><surname>Fall</surname><given-names>R.</given-names></name><name><surname>Vivanco</surname><given-names>J.M.</given-names></name></person-group><article-title><italic>Pseudomonas aeruginosa</italic>-plant root interactions. Pathogenicity, biofilm formation, and root exudation</article-title><source>Plant. Physiol.</source><year>2004</year><volume>134</volume><fpage>320</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1104/pp.103.027888</pub-id><?supplied-pmid 14701912?><pub-id pub-id-type="pmid">14701912</pub-id></element-citation></ref><ref id="B196-biomedicines-08-00405"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Gong</surname><given-names>Q.</given-names></name></person-group><article-title>Eugenol inhibits quorum sensing at sub-inhibitory concentrations</article-title><source>Biotechnol. Lett.</source><year>2013</year><volume>35</volume><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1007/s10529-012-1126-x</pub-id><pub-id pub-id-type="pmid">23264268</pub-id></element-citation></ref><ref id="B197-biomedicines-08-00405"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girennavar</surname><given-names>B.</given-names></name><name><surname>Cepeda</surname><given-names>M.L.</given-names></name><name><surname>Soni</surname><given-names>K.A.</given-names></name><name><surname>Vikram</surname><given-names>A.</given-names></name><name><surname>Jesudhasan</surname><given-names>P.</given-names></name><name><surname>Jayaprakasha</surname><given-names>G.K.</given-names></name><name><surname>Pillai</surname><given-names>S.D.</given-names></name><name><surname>Patil</surname><given-names>B.S.</given-names></name></person-group><article-title>Grapefruit juice and its furocoumarins inhibits autoinducer signaling and biofilm formation in bacteria</article-title><source>Int. J. Food Microbiol.</source><year>2008</year><volume>125</volume><fpage>204</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2008.03.028</pub-id><?supplied-pmid 18504060?><pub-id pub-id-type="pmid">18504060</pub-id></element-citation></ref><ref id="B198-biomedicines-08-00405"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Yin</surname><given-names>B.</given-names></name><name><surname>Qian</surname><given-names>L.</given-names></name><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name></person-group><article-title>Screening for novel quorum-sensing inhibitors to interfere with the formation of <italic>Pseudomonas aeruginosa</italic> biofilm</article-title><source>J. Med. Microbiol.</source><year>2011</year><volume>60</volume><fpage>1827</fpage><lpage>1834</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.024166-0</pub-id><pub-id pub-id-type="pmid">21852522</pub-id></element-citation></ref><ref id="B199-biomedicines-08-00405"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Z.</given-names></name><name><surname>Qian</surname><given-names>L.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Tan</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name></person-group><article-title>Virtual screening for novel quorum sensing inhibitors to eradicate biofilm formation of <italic>Pseudomonas aeruginosa</italic></article-title><source>Appl. Microbiol. Biotechnol.</source><year>2008</year><volume>79</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1007/s00253-008-1406-5</pub-id><pub-id pub-id-type="pmid">18330563</pub-id></element-citation></ref><ref id="B200-biomedicines-08-00405"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vadhana</surname><given-names>P.</given-names></name><name><surname>Singh</surname><given-names>B.R.</given-names></name><name><surname>Bharadwaj</surname><given-names>M.</given-names></name><name><surname>Singh</surname><given-names>S.V.</given-names></name></person-group><article-title>Emergence of herbal antimicrobial drug resistance in clinical bacterial isolates</article-title><source>Pharm. Anal. Acta</source><year>2015</year><volume>6</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4172/2153-2435.1000434</pub-id></element-citation></ref><ref id="B201-biomedicines-08-00405"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnke</surname><given-names>P.H.</given-names></name><name><surname>Becker</surname><given-names>S.T.</given-names></name><name><surname>Podschun</surname><given-names>R.</given-names></name><name><surname>Sivananthan</surname><given-names>S.</given-names></name><name><surname>Springer</surname><given-names>I.N.</given-names></name><name><surname>Russo</surname><given-names>P.A.</given-names></name><name><surname>Wiltfang</surname><given-names>J.</given-names></name><name><surname>Fickenscher</surname><given-names>H.</given-names></name><name><surname>Sherry</surname><given-names>E.</given-names></name></person-group><article-title>The battle against multi-resistant strains: Renaissance of antimicrobial essential oils as a promising force to fight hospital-acquired infections</article-title><source>J. Cranio Maxillofac Surg.</source><year>2009</year><volume>37</volume><fpage>392</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.jcms.2009.03.017</pub-id></element-citation></ref><ref id="B202-biomedicines-08-00405"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pisoschi</surname><given-names>A.M.</given-names></name><name><surname>Pop</surname><given-names>A.</given-names></name><name><surname>Georgescu</surname><given-names>C.</given-names></name><name><surname>Turcus</surname><given-names>V.</given-names></name><name><surname>Olah</surname><given-names>N.K.</given-names></name><name><surname>Mathe</surname><given-names>E.</given-names></name></person-group><article-title>An overview of natural antimicrobials role in food</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>143</volume><fpage>922</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.11.095</pub-id><pub-id pub-id-type="pmid">29227932</pub-id></element-citation></ref><ref id="B203-biomedicines-08-00405"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>B.R.</given-names></name><name><surname>Singh</surname><given-names>V.</given-names></name><name><surname>Ebibeni</surname><given-names>N.</given-names></name><name><surname>Singh</surname><given-names>R.K.</given-names></name></person-group><article-title>Antimicrobial and herbal drug resistance in enteric bacteria isolated from faecal droppings of common house lizard/gecko (<italic>Hemidactylus frenatus</italic>)</article-title><source>Int. J. Microbiol.</source><year>2013</year><volume>2013</volume><fpage>340848</fpage><pub-id pub-id-type="doi">10.1155/2013/340848</pub-id><pub-id pub-id-type="pmid">24223595</pub-id></element-citation></ref><ref id="B204-biomedicines-08-00405"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>P.D.</given-names></name><name><surname>Birdi</surname><given-names>T.J.</given-names></name></person-group><article-title>Development of botanicals to combat antibiotic resistance</article-title><source>J. Ayurveda Integr. Med.</source><year>2017</year><volume>8</volume><fpage>266</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.jaim.2017.05.004</pub-id><?supplied-pmid 28869082?><pub-id pub-id-type="pmid">28869082</pub-id></element-citation></ref><ref id="B205-biomedicines-08-00405"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>San Millan</surname><given-names>A.</given-names></name><name><surname>MacLean</surname><given-names>R.C.</given-names></name></person-group><article-title>Fitness costs of plasmids: A limit to plasmid transmission</article-title><source>Microbiol. Spectr.</source><year>2017</year><volume>5</volume><fpage>65</fpage><lpage>79</lpage></element-citation></ref><ref id="B206-biomedicines-08-00405"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dur&#x000e3;o</surname><given-names>P.</given-names></name><name><surname>Balbont&#x000ed;n</surname><given-names>R.</given-names></name><name><surname>Gordo</surname><given-names>I.</given-names></name></person-group><article-title>Evolutionary mechanisms shaping the maintenance of antibiotic resistance</article-title><source>Trends Microbiol.</source><year>2018</year><volume>26</volume><fpage>677</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.01.005</pub-id><?supplied-pmid 29439838?><pub-id pub-id-type="pmid">29439838</pub-id></element-citation></ref><ref id="B207-biomedicines-08-00405"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melnyk</surname><given-names>A.H.</given-names></name><name><surname>Wong</surname><given-names>A.</given-names></name><name><surname>Kassen</surname><given-names>R.</given-names></name></person-group><article-title>The fitness costs of antibiotic resistance mutations</article-title><source>Evol. Appl.</source><year>2015</year><volume>8</volume><fpage>273</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1111/eva.12196</pub-id><pub-id pub-id-type="pmid">25861385</pub-id></element-citation></ref><ref id="B208-biomedicines-08-00405"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sang</surname><given-names>Y.</given-names></name><name><surname>Blecha</surname><given-names>F.</given-names></name></person-group><article-title>Antimicrobial peptides and bacteriocins: Alternatives to traditional antibiotics</article-title><source>Anim. Health Res. Rev.</source><year>2008</year><volume>9</volume><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1017/S1466252308001497</pub-id><pub-id pub-id-type="pmid">18983725</pub-id></element-citation></ref><ref id="B209-biomedicines-08-00405"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hintz</surname><given-names>T.</given-names></name><name><surname>Matthews</surname><given-names>K.K.</given-names></name><name><surname>Di</surname><given-names>R.</given-names></name></person-group><article-title>The use of plant antimicrobial compounds for food preservation</article-title><source>BioMed Res. Int.</source><year>2015</year><volume>2015</volume><fpage>246264</fpage><pub-id pub-id-type="doi">10.1155/2015/246264</pub-id><pub-id pub-id-type="pmid">26539472</pub-id></element-citation></ref><ref id="B210-biomedicines-08-00405"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuiness</surname><given-names>W.A.</given-names></name><name><surname>Malachowa</surname><given-names>N.</given-names></name><name><surname>DeLeo</surname><given-names>F.R.</given-names></name></person-group><article-title>Vancomycin resistance in <italic>Staphylococcus aureus</italic></article-title><source>Yale J. Biol. Med.</source><year>2017</year><volume>90</volume><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">28656013</pub-id></element-citation></ref><ref id="B211-biomedicines-08-00405"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nannini</surname><given-names>E.</given-names></name><name><surname>Murray</surname><given-names>B.E.</given-names></name><name><surname>Arias</surname><given-names>C.A.</given-names></name></person-group><article-title>Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Curr. Opin. Pharm.</source><year>2010</year><volume>10</volume><fpage>516</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2010.06.006</pub-id></element-citation></ref><ref id="B212-biomedicines-08-00405"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>L.</given-names></name><name><surname>Iwamoto</surname><given-names>A.</given-names></name><name><surname>Lian</surname><given-names>J.Q.</given-names></name><name><surname>Neoh</surname><given-names>H.M.</given-names></name><name><surname>Maruyama</surname><given-names>T.</given-names></name><name><surname>Horikawa</surname><given-names>Y.</given-names></name><name><surname>Hiramatsu</surname><given-names>K.</given-names></name></person-group><article-title>Novel mechanism of antibiotic resistance originating in vancomycin-intermediate <italic>Staphylococcus aureus</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2006</year><volume>50</volume><fpage>428</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1128/AAC.50.2.428-438.2006</pub-id><pub-id pub-id-type="pmid">16436693</pub-id></element-citation></ref><ref id="B213-biomedicines-08-00405"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baltz</surname><given-names>R.H.</given-names></name></person-group><article-title>Genetic manipulation of secondary metabolite biosynthesis for improved production in <italic>Streptomyces</italic> and other actinomycetes</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2016</year><volume>43</volume><fpage>343</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1007/s10295-015-1682-x</pub-id><pub-id pub-id-type="pmid">26364200</pub-id></element-citation></ref><ref id="B214-biomedicines-08-00405"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>C.W.</given-names></name><name><surname>Connaty</surname><given-names>A.D.</given-names></name><name><surname>Skinnider</surname><given-names>M.A.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Grunwald</surname><given-names>A.</given-names></name><name><surname>Wyatt</surname><given-names>M.A.</given-names></name><name><surname>Kerr</surname><given-names>R.G.</given-names></name><name><surname>Magarvey</surname><given-names>N.A.</given-names></name></person-group><article-title>Informatic search strategies to discover analogues and variants of natural product archetypes</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2016</year><volume>43</volume><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1007/s10295-015-1675-9</pub-id><?supplied-pmid 26350080?><pub-id pub-id-type="pmid">26350080</pub-id></element-citation></ref><ref id="B215-biomedicines-08-00405"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medema</surname><given-names>M.H.</given-names></name><name><surname>Fischbach</surname><given-names>M.A.</given-names></name></person-group><article-title>Computational approaches to natural product discovery</article-title><source>Nat. Chem. Biol.</source><year>2015</year><volume>11</volume><fpage>639</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1884</pub-id><pub-id pub-id-type="pmid">26284671</pub-id></element-citation></ref><ref id="B216-biomedicines-08-00405"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>M.</given-names></name><name><surname>Hover</surname><given-names>B.M.</given-names></name><name><surname>Brady</surname><given-names>S.F.</given-names></name></person-group><article-title>Culture-independent discovery of natural products from soil metagenomes</article-title><source>J. Ind. Microbiol. Biotechnol.</source><year>2016</year><volume>43</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1007/s10295-015-1706-6</pub-id><?supplied-pmid 26586404?><pub-id pub-id-type="pmid">26586404</pub-id></element-citation></ref><ref id="B217-biomedicines-08-00405"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zakeri</surname><given-names>B.</given-names></name><name><surname>Lu</surname><given-names>T.K.</given-names></name></person-group><article-title>Synthetic biology of antimicrobial discovery</article-title><source>ACS Synth. Biol.</source><year>2013</year><volume>2</volume><fpage>358</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1021/sb300101g</pub-id><?supplied-pmid 23654251?><pub-id pub-id-type="pmid">23654251</pub-id></element-citation></ref><ref id="B218-biomedicines-08-00405"><label>218.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>G.M.</given-names></name><name><surname>Lim-Wilby</surname><given-names>M.</given-names></name></person-group><source>Molecular Modeling of Proteins</source><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2008</year><volume>Volume 443</volume></element-citation></ref><ref id="B219-biomedicines-08-00405"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saikia</surname><given-names>S.</given-names></name><name><surname>Bordoloi</surname><given-names>M.</given-names></name></person-group><article-title>Molecular docking: Challenges, advances and its use in drug discovery perspective</article-title><source>Curr. Drug Targets</source><year>2019</year><volume>20</volume><fpage>501</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.2174/1389450119666181022153016</pub-id><?supplied-pmid 30360733?><pub-id pub-id-type="pmid">30360733</pub-id></element-citation></ref><ref id="B220-biomedicines-08-00405"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gertsch</surname><given-names>J.</given-names></name></person-group><article-title>Botanical drugs, synergy, and network pharmacology: Forth and back to intelligent mixtures</article-title><source>Planta Med.</source><year>2011</year><volume>77</volume><fpage>1086</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1055/s-0030-1270904</pub-id><?supplied-pmid 21412698?><pub-id pub-id-type="pmid">21412698</pub-id></element-citation></ref><ref id="B221-biomedicines-08-00405"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>B.S.</given-names></name><name><surname>Carter</surname><given-names>G.T.</given-names></name><name><surname>Bronstrup</surname><given-names>M.</given-names></name></person-group><article-title>Editorial: Are natural products the solution to antimicrobial resistance?</article-title><source>Nat. Prod. Rep.</source><year>2017</year><volume>34</volume><fpage>685</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1039/C7NP90026K</pub-id><?supplied-pmid 28671218?><pub-id pub-id-type="pmid">28671218</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="biomedicines-08-00405-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Leading causes of death in the world in 2016 (blue bars) and prognosis for antimicrobial resistance (AMR) related deaths in 2050 (red bar).</p></caption><graphic xlink:href="biomedicines-08-00405-g001"/></fig><fig id="biomedicines-08-00405-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Approximate dates of discovery of new classes of antibiotics and identification of bacterial resistance.</p></caption><graphic xlink:href="biomedicines-08-00405-g002"/></fig><fig id="biomedicines-08-00405-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The number of research articles available in PubMed by searching &#x0201c;Natural Antimicrobial&#x0201d; from 1998 to 2018. The red arrow represents a growing trend.</p></caption><graphic xlink:href="biomedicines-08-00405-g003"/></fig><fig id="biomedicines-08-00405-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Main known molecular targets of antimicrobial NPs described in this review.</p></caption><graphic xlink:href="biomedicines-08-00405-g004"/></fig><fig id="biomedicines-08-00405-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Antimicrobial resistance mechanisms and acquisition mechanisms in bacteria.</p></caption><graphic xlink:href="biomedicines-08-00405-g005"/></fig><table-wrap id="biomedicines-08-00405-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">biomedicines-08-00405-t001_Table 1</object-id><label>Table 1</label><caption><p>Alphabetically ordered natural products (NPs) with their properties and capabilities. Grey shaded cells mean effectiveness against AMR bacteria. Asterisk (*) means no antimicrobial activity alone.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Natural Product</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Productor Organism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Organism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Activity Against</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Use</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinorhodin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Streptomyces coelicolor</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including multidrug-resistant <italic>S. aureus</italic></td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">ROS production inside bacterial cells</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B95-biomedicines-08-00405" ref-type="bibr">95</xref>] </td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Albomycin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Streptomyces sp. ATCC 700974</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-negative and Gram-positive, including MRSA</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Seryl t-RNA synthetase inhibition</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B96-biomedicines-08-00405" ref-type="bibr">96</xref>,<xref rid="B97-biomedicines-08-00405" ref-type="bibr">97</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Amphomycin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Streptomyces canus</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including MRSA, VRE and MDR <italic>S. pneumoniae</italic></td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of peptidoglycan and wall teichoic acid biosyntheses</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B98-biomedicines-08-00405" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Apramycin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Streptoalloteicus hindustanus</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-negative, including MDR <italic>A. baumannii</italic> and <italic>P. areuginosa</italic></td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Veterinary</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B99-biomedicines-08-00405" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Arlomycins</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Streptomyces</italic> sp. T&#x000fc; 6075</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of type I bacterial signal peptidase</td><td align="center" valign="middle" rowspan="1" colspan="1">In research for medical use</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B100-biomedicines-08-00405" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Aspergillomarasmine A *</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>A. versicolor</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Fungus</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Sensitivizes carbapenem-resistant bacteria</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of bacterial metallo-&#x003b2;-lactamases</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">In research for medical use</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B59-biomedicines-08-00405" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Carbomycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces halstedii</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and <italic>Mycoplasma</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B101-biomedicines-08-00405" ref-type="bibr">101</xref>] </td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Cathelicidin-BF</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Bungarus fasciatus</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Reptile</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Mainly Gram-negative, including MDR strains</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Damage in microbial cytoplasmic membrane</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B41-biomedicines-08-00405" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CaTx-II</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>C. adamanteus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Reptile</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Membrane pore formation and cell wall disintegration</td><td align="center" valign="middle" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B42-biomedicines-08-00405" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cecropin A</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Aedes aegypti</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Insect</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Disruption of the cytoplasmic membrane</td><td align="center" valign="middle" rowspan="1" colspan="1">In research for medical use</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B102-biomedicines-08-00405" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cephalosporin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Cephalosporium acremonium</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Fungus</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of cell wall synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B103-biomedicines-08-00405" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cephamycin C</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces clavuligerus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of cell wall synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine and veterinary</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B104-biomedicines-08-00405" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chloramphenicol</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces venezuelae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine and veterinary</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B105-biomedicines-08-00405" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Chloroeremomycin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Amycolatopsis orientalis</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including VRE</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of bacterial cell wall formation</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B106-biomedicines-08-00405" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Clavulanic acid *</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>S. clavuligerus</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Sensitivizes &#x003b2;-lactam-resistant bacteria</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">&#x003b2;-lactamase inhibitor</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine and veterinary</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B107-biomedicines-08-00405" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clorobiocin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Strteptomyces roseochromogenes</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibitors of DNA gyrase</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B108-biomedicines-08-00405" ref-type="bibr">108</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Coumermycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces rishiriensis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Mainly Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of DNA gyrase</td><td align="center" valign="middle" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B109-biomedicines-08-00405" ref-type="bibr">109</xref>,<xref rid="B110-biomedicines-08-00405" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Dalbavancin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Nonomuraea sp.</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including MRSA</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of cell wall synthesis</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B111-biomedicines-08-00405" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Daptomycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces roseosporus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein, DNA and RNA synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B112-biomedicines-08-00405" ref-type="bibr">112</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Epigallocatechin gallate</td><td align="center" valign="middle" rowspan="1" colspan="1">Abundant in <italic>Camellia sinensis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Plant</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Damage in microbial cytoplasmic membrane</td><td align="center" valign="middle" rowspan="1" colspan="1">In research for medical use</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B81-biomedicines-08-00405" ref-type="bibr">81</xref>,<xref rid="B113-biomedicines-08-00405" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Erythromycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Saccharopolyspora erythraea</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B114-biomedicines-08-00405" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fosfomycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces wedmorensis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of cell wall synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B115-biomedicines-08-00405" ref-type="bibr">115</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Fusidic acid</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Fusidium coccineus</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Fungus</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including MRSA</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B116-biomedicines-08-00405" ref-type="bibr">116</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gentamicin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Micromonospora purpurea</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B117-biomedicines-08-00405" ref-type="bibr">117</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gramicidin S</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>B. subtilis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Bacillales</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Delocalizes peripheral membrane proteins involved in cell division and cell envelope synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B118-biomedicines-08-00405" ref-type="bibr">118</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hc-CATH</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Hydrophis cyanocinctus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Reptile</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Damage in microbial cytoplasmic membrane</td><td align="center" valign="middle" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B119-biomedicines-08-00405" ref-type="bibr">119</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hygromycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces hygroscopicus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Veterinary and research</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B120-biomedicines-08-00405" ref-type="bibr">120</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Josamycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces narbonensis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive, certain Gram-negative and <italic>mycoplasma</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B121-biomedicines-08-00405" ref-type="bibr">121</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kanamycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces kanamyceticus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Mainly Gram-negative and certain Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B122-biomedicines-08-00405" ref-type="bibr">122</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Kirromycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces collinus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Anaerobes, <italic>neisseriae</italic> and <italic>streptococci</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B123-biomedicines-08-00405" ref-type="bibr">123</xref>,<xref rid="B124-biomedicines-08-00405" ref-type="bibr">124</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lincomycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces lincolnensis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B125-biomedicines-08-00405" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Lipiaramycin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Dactosporangium aurantiacum</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive and <italic>Mycobacterium</italic>, including MDR strains</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of early transcription</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B126-biomedicines-08-00405" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Melittin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>A. mellifera</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Insect</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive and Gram-negative, including MDR strains</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Damage in microbial cytoplasmic membrane</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B39-biomedicines-08-00405" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Mirandamycin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Endophytic fungus isolated from the twig of <italic>Neomirandea angularis</italic></td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Fungus</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-negative and Gram-positive, including MRSA</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of bacterial quinol oxidase/ROS production</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">In research for medical use</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B60-biomedicines-08-00405" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Moenomycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces ghanaensis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of cell wall synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Veterinary</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B127-biomedicines-08-00405" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Morin</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Moraceae</italic> family</td><td align="center" valign="middle" rowspan="1" colspan="1">Plant</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of adhesion to host tissue and DNA helicase</td><td align="center" valign="middle" rowspan="1" colspan="1">Food technology</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B79-biomedicines-08-00405" ref-type="bibr">79</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Mucroporin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Lychas mucronatus</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Arachnid</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive and Gram-negative, including MDR strains</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Damage in microbial cytoplasmic membrane</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B128-biomedicines-08-00405" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neomycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. fradiae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of ribonuclease P</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B129-biomedicines-08-00405" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Orthoformimycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. griseus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">In research for medical use</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B49-biomedicines-08-00405" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Oxytetracycline</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces rimosus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Aquaculture</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B130-biomedicines-08-00405" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Penicillins</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Penicillium crysogenum</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Fungus</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of cell wall synthesis and activation of the endogenous autolytic system</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B131-biomedicines-08-00405" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Pleuromutalin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Clitopilus scyphoides</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Fungus</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive, Gram-negative and <italic>Mycoplasma</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of translation</td><td align="center" valign="middle" rowspan="1" colspan="1">Veterinary</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B132-biomedicines-08-00405" ref-type="bibr">132</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Polymyxin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Paenibacillus polymyxa</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Bacillales</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Mainly Gram-negative (including MDR) and certain Gram-positive</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Disruption of the cytoplasmic membrane</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B133-biomedicines-08-00405" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Pristinamycin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Streptomyces pristinaespiralis</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including MRSA</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B134-biomedicines-08-00405" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Punicalagin</td><td align="center" valign="middle" rowspan="1" colspan="1">Abundant in <italic>Punica granatum</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Plant</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Damage in microbial cytoplasmic membrane</td><td align="center" valign="middle" rowspan="1" colspan="1">Food technology</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B80-biomedicines-08-00405" ref-type="bibr">80</xref>,<xref rid="B84-biomedicines-08-00405" ref-type="bibr">84</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Quercetin</td><td align="center" valign="middle" rowspan="1" colspan="1">Ubiquitous in plants</td><td align="center" valign="middle" rowspan="1" colspan="1">Plant</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Damage in the structure of the bacterial cell wall and cell membrane</td><td align="center" valign="middle" rowspan="1" colspan="1">In research for medical use</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B135-biomedicines-08-00405" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Ramoplanin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1"><italic>Actinoplanes sp.</italic> ATCC 33076</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including MDR strains</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of cell wall synthesis</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B136-biomedicines-08-00405" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Resveratrol</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Abundant in grapes, berries and legumes</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Plant</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive and Gram-negative, including MDR strains</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of motility, adhesion, quorum sensing, biofilm formation, flagellar gene expression and hemolytic activity</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B75-biomedicines-08-00405" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rifamycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Amycolatopsis mediterranei</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and certain Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of DNA-dependent RNA synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B137-biomedicines-08-00405" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Ristocetin A</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>A. orientalis</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including MRSA</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of cell wall synthesis</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B138-biomedicines-08-00405" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Royalisin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Apis melifera</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Insect</td><td align="center" valign="middle" rowspan="1" colspan="1">Mainly gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Damage in the structure of the bacterial cell wall and cell membrane</td><td align="center" valign="middle" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B37-biomedicines-08-00405" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Skyllamycins</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces sp. KY 11784</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of biofilm formation</td><td align="center" valign="middle" rowspan="1" colspan="1">In research for medical use</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B139-biomedicines-08-00405" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SlLebocin1</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Spodoptera litura</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Insect</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Damage in microbial cytoplasmic membrane or cell division inhibition</td><td align="center" valign="middle" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B140-biomedicines-08-00405" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spectinomycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces spectabilis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B141-biomedicines-08-00405" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Spiramycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces ambofaciens</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B142-biomedicines-08-00405" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Streptothricin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces (multiple species)</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Veterinary and plant production</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B143-biomedicines-08-00405" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Teicoplanin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Actinoplanes teichomyceticus</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including MRSA</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of bacterial cell wall synthesis</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B144-biomedicines-08-00405" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Teixobactin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Eleftheria terrae</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Betaproteobacteria</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including MRSA</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Causes digestion of the cell wall by autolysins</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B55-biomedicines-08-00405" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tetracycline</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces rimosus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B145-biomedicines-08-00405" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Thienamycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces cattleya</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of bacterial cell wall synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Derivates used in medicine</td><td align="center" valign="middle" rowspan="1" colspan="1"> [<xref rid="B146-biomedicines-08-00405" ref-type="bibr">146</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Thiostrepton</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces azureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Veterinary and research</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B147-biomedicines-08-00405" ref-type="bibr">147</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tobramycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptoalloteicus hindustanus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis and membrane destabilization</td><td align="center" valign="middle" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B148-biomedicines-08-00405" ref-type="bibr">148</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tunicamycin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>Streptomyces chartreusis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of peptidoglycan and lipopolysaccharide synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B149-biomedicines-08-00405" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tylosin</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic>S. fradiae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" rowspan="1" colspan="1">Gram-positive and <italic>Mycoplasma</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" rowspan="1" colspan="1">Veterinary</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B150-biomedicines-08-00405" ref-type="bibr">150</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Vancomycin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>S. orientalis</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-positive, including MRSA</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of bacterial cell wall synthesis</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B45-biomedicines-08-00405" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Vejovine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>V. mexicanus</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Arachnid</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Gram-negative, including MDR</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Damage in microbial cytoplasmic membrane</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Research</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B44-biomedicines-08-00405" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Viomycin</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">
<italic>Streptomyces sp. 11861</italic>
</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">MDR <italic>Mycobacterium</italic></td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">Medicine</td><td align="center" valign="middle" style="background:#BFBFBF" rowspan="1" colspan="1">[<xref rid="B151-biomedicines-08-00405" ref-type="bibr">151</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Virginiamycin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptomyces virginiae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Actinomycete</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gram-positive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibition of protein synthesis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Agriculture and industry</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B152-biomedicines-08-00405" ref-type="bibr">152</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>